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Abstract	
	 	
Colorectal	cancer	(CRC)	is	the	second	most	common	cause	of	cancer	related	deaths	
in	the	UK.	Whilst	identification	of	molecular	events	that	contribute	to	the	initiation	
and	progression	of	CRC	have	facilitated	the	development	of	predictive	biomarker-
driven	therapeutics,	their	success	in	the	clinic	has	been	restricted	by	the	lack	of	
anticipated	responses.	Furthermore,	not	all	genetic	signatures	of	a	tumour	have	
been	linked	to	related	drug	targets,	highlighting	the	need	for	novel	development	of	
compounds	and	better	therapeutic	rationales	for	the	treatment	of	patient	subsets.	
The	limited	success	of	targeted	therapies,	both	within	the	clinic	and	drug	discovery	
pipeline,	has	been	attributed	to	a	lack	of	effective	preclinical	models	that	are	
capable	of	capturing	the	complexity	of	deregulated	signalling	networks.	The	
development	of	functional	readouts	that	better	represent	tumour	complexity,	is	
therefore	imperative	to	confirm	the	effects	of	hypothesis-driven	therapeutics.			
	
This	thesis	therefore	aimed	to	investigate	whether	3D	CRC	organoids	,	which	
show	a	degree	of	greater	complexity	compared	to	preceding	in	vitro	models,	could	
be	applied	as	suitable	readouts	for	stratified	medicine	programmes	and	novel	
compounds	within	the	drug	discovery	setting.	To	achieve	this,	a	panel	of	3D	patient-
derived	CRC	organoids	cultures	were	generated.	Suitable	methodologies	were	
established	to	facilitate	organoids	towards	quantifiable,	robust	assay	formats.	This	
platform	enabled	the	study	of	organoids	within	an	in	vitro	clinical	trial	setting,	based	
upon	treatments	administered	within	the	ongoing	FOCUS	4	stratified	medicine	trial,	
exploring	organoids’	capacity	to	predict	responses	to	targeted	therapeutics.	
Organoids	were	differentially	sensitive	to	therapies,	irrespective	of	their	genotypic	
background.	It	will	be	interesting	to	see	whether	prediction-response	correlations	
observed	in	this	study	are	typical	of	those	seen	in	patients	and	whether	functional	
readouts	will	be	required	to	support	stratified	medicine	approaches.	Quantitative	
image-based	analysis	was	also	found	to	identify	signatures	of	organoid	responses	
against	novel	Wnt	signalling	inhibitors,	suggesting	that	organoids	may	constitute	a	
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platform	that	can	be	used	to	study	the	effects	of	targeting	a	prospective	cancer	stem	
cell	(CSC)	population.	Taken	together,	the	findings	in	this	thesis	highlight	the	utility	
of	patient	derived	organoid	models	as	a	functional	model	to	evaluate	novel	
therapeutic	strategies,	potentially	generating	clinically	relevant	hypotheses.		
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1. 	Introduction	
1.1 Anatomy	and	function	of	the	intestine	
	
The	mammalian	lower	gastrointestinal	tract	is	comprised	of	both	the	small	and	large	
intestine.	The	small	intestine	emerges	from	the	pyloric	sphincter	of	the	stomach	and	
is	divided	into	the	duodenum,	jejunum	and	ileum.	This	tube-like	structure	is	
composed	of	a	range	of	cell	types,	which	facilitate	some	key	roles	including	
enzymatic	digestion	and	absorption	of	nutrients.	The	large	intestine	extends	from	
the	caecum,	through	the	ascending	colon,	transverse	colon,	descending	colon,	
sigmoid	colon,	to	the	rectum,	which	then	opens	to	the	anus.	The	large	intestine	
mainly	functions	in	maintaining	fluid	and	electrolyte	balance	by	absorption	of	water	
from	food	material.	It	also	is	the	primary	site	for	degradation	of	complex	
carbohydrates	and	nutrients	by	the	gut	microbiota.		The	intestine	is	highly	plastic,	
undergoing	continuous	self-renewal	to	facilitate	its	functions	within	such	a	harsh	
environment.	The	luminal	surface	of	the	large	intestine	is	composed	of	a	single	
epithelial	cell	layer	that	invaginates	into	the	underlying	submucosa,	forming	crypt	
structures.	Beneath	the	epithelial	sheet	are	stromal	fibroblasts	and	a	surrounding	
vasculature.	The	smooth	muscle	layer	resides	further	below	and	is	responsible	for	
generating	the	peristaltic	movement	required	to	move	food	through	the	intestine.	
	
1.2 Intestinal	epithelium	homeostasis	
1.2.1 Cell	compartments	within	the	large	intestine	
	
At	a	cellular	level,	the	large	intestine	is	composed	of	a	main	epithelial	cell	layer,	
which	form	the	basis	of	individual	crypt	structures.	At	the	base	of	the	colonic	crypt	
reside	a	progeny	of	multipotent	stem	cells	capable	of	differentiating	into	multiple	
epithelial	lineages	including	enterocytes,	endocrine	cells	and	goblet	cells	(Pinto	and	
Clevers	2005;	Ashley	2013a;	Barker	2014a).	As	cells	from	the	base	of	the	crypt	
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migrate	towards	the	lumen	of	the	intestine,	they	undergo	differentiation	into	
distinct	cell	progenies,	which	perform	critical	functions	involved	in	intestinal	
homeostasis.	Cells	continue	to	migrate	until	they	are	eventually	shed	into	the	lumen	
at	the	apex	of	the	crypt,	resulting	in	a	process	that	rapidly	regenerates	the	colonic	
epithelium,	depicted	in	Figure	1.1(Barker	2014).	The	population	of	intestinal	stem	
cells	(ISCs)	at	the	base	of	the	crypts	facilitate	a	continual	turnover	of	cells,	generating	
daughter	cells	capable	of	differentiating	into	any	of	the	epithelial	lineages	within	the	
intestine.	Differentiated	cells	have	several	functions	within	the	intestine.	The	
absorptive	enterocytes	align	each	individual	crypt	and	are	critical	for	nutrient	uptake	
as	food	moves	through	the	intestinal	tube.		Goblet	cells,	identified	through	their	
expression	of	Mucin	2,	provide	lubrication	to	lesser	the	impact	of	mechanical	stress	
from	peristalsis	of	food	through	the	gut.	Furthermore,	endocrine	cells	play	a	role	
secreting	various	hormones	that	maintain	gut	homeostasis	(Pinto	and	Clevers	2005).	
The	entire	intestinal	epithelium	is	renewed	between	every	3-5	days	and	is	tightly	
regulated	to	maintain	tissue	homeostasis.	
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Figure	1.1	Schematic	of	a	single	crypt	within	the	large	intestine	
Schematic	diagram	a	single	colonic	crypt	showing	the	range	of	cell	types.	The	base	of	the	crypt	is	
composed	of	a	stem	cell	niche,	whereby	stem	cells	are	able	to	self	renew	and	differentiate	into	
various	lineages	whilst	migrating	to	the	tip	of	the	crypt.	Crypt	proliferation	is	generally	maintained	by	
high	levels	of	Wnt	Signalling,	and	cell	differentiation	occurs	primarily	due	to	increased	levels	of	Notch	
signalling	when	closest	to	the	lumen.		
	
	
	
Notch 
Signalling 
Wnt 
Signalling 
Transit 
Amplifying cells 
Stem Cells 
Goblet cells 
Myofibroblasts 
Enterocytes 
Enteroendocrine 
cell 
	 4	
	
1.2.2 Colorectal	stem	cell	maintenance	
	
The	adult	stem	cells	are	defined	as	a	population	of	pluripotent	cells	capable	of	self-
renewal	and	differentiation	that	carry	out	functions	of	vital	importance	for	tissue	
homeostasis	and	maintenance	(Ashley	2013a).		Within	the	intestine,	the	rapid	
renewal	of	the	tissue	occurs	as	a	result	of	continual	migration	of	intestinal	stem	cells	
towards	the	intestinal	lumen	along	the	crypt-villus	axis	(Fre	et	al.	2005).	
As	such,	a	number	of	protective	mechanisms	are	in	place	to	prevent	neoplastic	
growth	within	a	rapidly	renewing	environment.	Such	mechanisms	include	the	
induction	of	quiescence	to	repair	damaged	DNA	of	rapidly	proliferating	cells,	and	the	
ability	to	undergo	programmed	cell	death	by	apoptosis	to	maintain	stem	cell	
integrity	(Blanpain	et	al	2011;	Barker	2014a).			
	
The	foundation	of	the	current	understanding	of	intestinal	stem	cells	is	based	upon	
studies	in	the	murine	small	intestine,	which	can	also	be	applied	to	the	colonic	
epithelium	in	humans.	Early	studies	demonstrated	that	the	self-renewing	
component	of	the	intestine	is	located	at	the	base	of	the	crypt,	in	the	‘+4	region’	
suggesting	that	the	migration	of	epithelial	cells	towards	the	intestinal	lumen	
originated	from	the	crypt	(Pinto	and	Clevers	2005).	This	evidence	was	furthered	
using	DNA	labelling	of	stem	cells	using	3[H]-thymidine,	whilst	labelling	newly	
synthesised	DNA	strands	with	a	different	marker	(bromodeoxyuridine),	enabling	a	
segregation	of	the	two	markers	to	further	study	stem	cell	dynamics.	Recent	evidence	
suggests	that	stem	cell	identity	within	the	intestine	is	more	plastic	than	previously	
thought,	with	the	possibility	that	crypt	based	columnar	cells	(CBC)	can	function	as	
stem	cells		(Barker	2014a).	It	has	therefore	been	postulated	that	the	crypt	base	
contains	both	active	cells	(The	CBC	cells)	as	well	as	more	quiescent	stem	cells	(+4	
cells)	that	function	as	a	reserve	in	response	to	injury	(Barker	2014a).	Subsequently,	a	
number	of	markers	have	been	postulated	as	possible	indicators	of	intestinal	stem	
cells.	Lineage	tracing	experiments	have	demonstrated	that	leucine	rich	repeat	
containing	G	protein	coupled	receptor	5(Lgr5)+	cells	in	the	crypt	had	the	capacity	to	
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form	all	different	epithelial	lineages	over	a	2	month	period	in	the	mouse	(Barker	et	
al.	2007a),	as	well	as	within	in	vitro	experiments	(Sato	et	al.	2009)	(discussed	further	
in	section	1.8).	Furthermore,	engraftments	of	single	Lgr5+	cells	have	been	shown	to	
successfully	repair	the	colonic	epithelium	(Yui	et	al.	2012).	Analysis	of	gene	
expression	profiles	of	intestinal	epithelial	cells	expressing	high	and	low	levels	of	Lgr5	
has	further	identified	markers	such	as	Ascl2,	a	Wnt	signalling	target	(van	der	Flier	et	
al.	2009).	Subsequent	studies	have	concluded	that	Ascl2	,	alongside	ß-catenin/Tcf,	is	
able	to	activate	genes	related	to	cell	stemness,	and	thus	initiate	transcription	that	is	
responsive	to	Wnt	signalling		(Schuijers	et	al.	2015).	
1.2.3 Signalling	pathways	implicated	within	intestinal	homeostasis	
	
A	range	of	intricate	networks,	which	interplay	to	control	cellular	proliferation,	
migration,	and	apoptosis,	closely	regulate	the	overall	structure	and	function	of	the	
dynamic	intestinal	tissue.	This	is	mediated	by	a	gradient	of	signalling	pathways	that	
control	gene	expression	to	control	the	fate	of	a	well-defined	epithelial	hierarchy	and	
maintain	stem	cell	homeostasis,	some	of	which	are	discussed	here.	
1.2.3.1 Wnt	signalling	pathway	
	
The	canonical	(ß-catenin	dependent)	Wnt	signalling	pathway	plays	a	major	role	
during	mammalian	development,	mediating	effects	on	an	array	of	target	genes	
involved	in	proliferation,	cell	adhesion	and	migration.		
	
In	the	absence	of	a	Wnt	ligand,	the	canonical	Wnt	signalling	pathway	remains	in	an	
‘off-state’	whereby	cytoplasmic	β-	catenin	is	marked	by	a	destruction	complex	
composed	of	multiple	proteins,	including	axis	inhibitor	(Axin)	scaffolding	protein,	the	
tumour	suppressor	Adenomatous	polyposis	coli	(APC),	and	the	serine/threonine	
kinases	CK1	and	Glycogen	Synthase	Kinase-3	(GSK3).	The	destruction	complex	acts	to	
phosphorylate	ß-catenin	on	serine	and	threonine	residues	leading	to	ubiquitination	
and	protesomal	degradation.	Activation	of	canonical	Wnt	signalling,	as	a	result	of	
Wnt	ligand	binding	to	Frizzled	and	lipoprotein	receptor-related	protein	5/6	(LRP5/6)	
co-receptors,	mediates	the	interaction	between	Dishevelled	(Dsh)	and	Axin	at	the	
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cell	surface,	preventing	the	formation	of	the	ß-catenin	destruction	complex.	
Consequently,	free	pools	of	cytoplasmic	β-catenin	accumulate	and	translocate	to	the	
nucleus	(Kim	et	al.	2008)	subsequently	displacing	Groucho,	a	transcriptional	
repressor,		and	binds	to	T-cell	specific	transcription	factor	of	Lymphoid	enhancer-
binding	factor	1	(TCF/LEF)	family	of	transcription	factors,	facilitating	the	transcription	
of	Wnt	target	genes	(Barker	2014a).	Wnt	signalling	is	further	potentiated	by	the	
R(oof	plate	specific)-spondin	protein	family,	which,	upon	binding	with	their	receptor	
leucine-rich	G	protein	coupled	receptor	4/5/6	(LGR4/5/6)	or	Lgr5	receptor,	active	in	
adult	stem	cells	in	the	base	of	crypts,	enhance	the	Wnt	ligand	signal.	This	effect	is	
mediated	by	the	inhibition	of	zinc	and	ring	finger	3	(Znrf3)	and	ring	finger	43	(Rnf43)	
transmembrane	ubiquitin	ligases,	which	target	Fzd/Lrp	receptors	for	degradation	
(Barker	et	al.	2013;	Koo	et	al.	2012;	de	Lau	et	al.	2011a).	The	R-spondins	therefore	
elicit	their	effect	by	inhibiting	the	removal	of	Fzd	and	Lrp	receptors	from	the	cell	
surface,	thus	mediating	β-catenin	stabilization	(de	Lau	et	al.	2014)	As	a	result,	this	
amplifies	the	Wnt	responses		(Barker	et	al.	2013),	enhancing	gene	transcription.	A	
number	of	Wnt	target	genes	are	associated	with	cell	proliferation,	migration	and	
adhesion	and	include,	but	are	not	restricted	to,	c-myc,	Cyclin	D1,	CD44	and	Axin	2	
(Krausova	and	Korinek	2014).				
	
Wnt	signalling	(Figure	1.2)	has	a	diverse	role	throughout	development	and	
homeostasis	and	is	therefore	tightly	regulated	at	variety	of	stages	to	maintain	
physiology.	At	a	cellular	level,	downregulation	of	Wnt	signalling	can	occur	through	
multiple	feedback	loops	which,	upon	ß-catenin	transcription,	mediate	the	
upregulation	of	Axin2	to	re-establish	the	formation	of	the	ß-catenin	destruction	
complex.	Furthermore,	the	destruction	complex	is	also	directly	regulated	as	
required;	Axin	,	for	example,	is	one	of	the	concentration-limiting	components	of	the	
destruction	complex	and	is	in	turn	tightly	regulated	by	tankyrases	1/2,	members	of	
the	poly	ADP	ribosylation	enzymes	family	that	attenuate	Wnt	signalling	by	mediating	
Axin	stabilisation	(Wu	et	al.	2016;	de	Sousa	and	Vermeulen	2016;	de	Sousa	et	al.	
2011).		
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In	the	intestine,	Wnt	signalling	has	long	been	recognised	as	a	master	regulator	of	the	
turnover	of	stem	cell	generation	(Schuijers	and	Clevers	2012;	Pinto	and	Clevers	
2005)	and	has	been	shown	to	be	a	key	mediator	of	proliferation	and	intestinal	
homeostasis.	Within	the	intestinal	crypt,	a	gradient	of	expression	of	Wnt	agonists	
and	antagonists	mediate	tight	regulation	of	this	pathway,	with	highest	relative	Wnt	
levels	prominent	in	the	base	of	crypts	(Schuijers	and	Clevers	2012).	A	number	of	
studies	have	demonstrated	the	implications	of	Wnt	signalling	in	crypt	development	
and	function.	Firstly,	conditional	homozygous	deletion	of	ß-catenin	in	the	intestine	
has	been	shown	to	result	in	an	increase	in	apoptotic	events	and	crypt	ablation	in	a	
transgenic	mouse	line	(Ireland	et	al.	2004).	In	concordance	with	this,	Fevr	et	al	
demonstrated	that	ß-catenin	loss	results	in	a	rapid	absence	of	proliferating	cells,	a	
loss	of	crypt	formation,	and	strikingly,	an	induction	of	terminal	differentiation	in	ISCs	
(Fevr	et	al.	2007).	Furthermore,	overexpression	of	DIckkopf1	(Dkk1),	a	Wnt	
antagonist,	causes	progressive	degeneration	of	crypt	architectures	(Kuhnert	et	al.	
2004),	and	alters	crypt-villus	structure	within	small	intestine	of	mice	(Pinto	et	al.	
2003).		Conversely,	injection	of	human	R-spondin	1	(hRSpo1)	has	been	shown	to	
result	in	an	aberrant	activation	of	the	Wnt	pathway,	and	an	overall	increase	in	the	
number	of	Lgr5+	stem	cells	in	mice	(Kim	et	al.	2005).	Taken	together,	such	studies	
emphasise	the	importance	of	the	Wnt	signalling	network	in	the	ISC	compartment,	
and	in	maintenance	of	homeostasis.		
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Figure	1.2	The	Canonical	Wnt	signalling	pathway	
The	Wnt	signalling	pathway	is	typically	represented	in	a	‘off’	and	‘on’	state.	In	the	absence	of	Wnt	ligand,	a	destruction	complex	formed	of	multiple	proteins	including	Axin	
and	APC,	glycogen	synthase	kinase	3	and	casein	kinase	1,	all	of	which	mediate	the	degradation	of	ß-catenin	by	ubiquitination,	preventing	translocation	into	the	nucleus.	In	
the	presence	of	Wnt	ligand,	the	destruction	complex	is	recruited	to	the	receptor-ligand	complex,	enabling	the	accumulation	of	ß-catenin	within	the	cytoplasm.	This	in	turn	
mediates	downstream	activation	of	target	gene	expression.		
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1.2.3.2 The	Notch	signalling	pathway	
	
Notch	signalling	is	activated	in	response	to	cell-cell	contact;	an	extracellular	domain	
binds	to	a	Jagged	or	Delta	ligands	that	reside	on	a	opposing	cell	surfaces,	as	depicted	
in	Figure	1.3.	The	interaction	of	Notch	ligands	with	the	Notch	receptor	induces	
proteolytic	cleavage	at	the	extracellular	domain,	mediated	by	the	tumour	necrosis	
factor-α-converting	enzyme	(TACE).	Following	this	interaction,	the	transmembrane	
receptor	domain	of	Notch	(NICD)	is	cleaved	by	a	presenilin-γ	secretase	complex,	
which	mediates	the	translocation	of	the	intracellular	receptor	domain	to	the	nucleus	
(Qiao	and	Wong	2009).	Notch	signalling	effectors	regulate	the	transcription	factor	
CSL	that	control	gene	expression	of	Notch	target	genes.	Target	genes	of	Notch	
signalling	have	various	functions	such	as	cell	proliferation	and	differentiation	(Badalà	
et	al.	2011)		
	
Notch	signalling	plays	a	pivotal	role	in	the	coordination	of	differentiation	events	
within	intestinal	epithelial	cells,	and	is	therefore	critical	in	maintaining	intestinal	
development	and	homeostasis,	and	equally	a	role	in	the	transformation	of	epithelial	
cells	towards	a	more	malignant	phenotype	(Ashley	2013a).	Both	Notch1	and	Jagged-
1	are	expressed	at	high	levels	in	transit	amplifying	cells	of	the	colon	(Badalà	et	al.	
2011).	The	loss	of	notch	signalling	in	mouse	intestinal	stem	cells	promotes	the	
differentiation	of	stem	cells	towards	a	goblet	or	enteroendocrine	cell	lineages	(van	
Es	et	al.	2010)	as	opposed	to	absorptive	cells.	Conversely,	induced	Notch	signalling	
activation	has	been	shown	to	reduce	differentiation	and	increase	proliferation	of	
progenitor	cells	(Fre	et	al.	2005).	Using	inducible	tissue-specific	Notch-mutant	mice,	
studies	have	further	demonstrated	the	role	of	Notch	signalling	in	crypt	
differentiation	and	proliferation,	whereby	loss	of	Notch	receptors	result	in	loss	of	
cell	cycle	progression	of	crypt	progenitor	cells	(Riccio	et	al.	2008)	.	Culture	of	
intestinal	stem	cells	has	also	demonstrated	that	extracellular	application	of	Notch	
ligands	to	culture	conditions	directs	stem	cells	towards	a	more	differentiated	
phenotype	(Yin	et	al.	2013).	Some	studies	have	also	highlighted	the	interplay	
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between	Notch	and	Wnt	signalling	within	the	intestine,	particularly	in	the	ISC	
population.	Recently,	it	has	been	shown,	by	utility	of	Notch	blocking	antibodies,	that	
Notch	signalling	has	the	ability	to	diminish	outputs	of	Wnt	signalling,	thus	also	
contributing	to	stem	cell	activity	(Tian	et	al.	2015).		
1.2.3.3 TGFβ	/	BMP	signalling	pathway	
	
The	Transforming	Growth	Factor	Beta	(TGFβ)	family	of	proteins	are	involved	in	an	
array	of	cell	signalling	events.	Upon	ligand	binding	to	membrane-bound	receptors	
(Type	I	and	Type	II)	the	type	II	receptor	dimerises	with	type	I,	and	then	
phosphorylates	the	cytoplasmic	domain	of	type	I.	This	phosphorylated	domain	in	
turn	recruits	Smad2/Smad3	cytosolic	proteins	and	mediates	their	phosphorylation.	
The	Bone	Morphogenic	Protein	(BMP)	signalling	pathway	forms	a	large	subgroup	of	
the	TGFβ		family,	and	typically	results	in	the	recruitment	and	phosphorylation	of	
Smad1,	Smad	5	and	Smad	8	(Yeung	et	al.	2011).	The	dissociation	and	activation	of	
recruited	Smads	enable	a	complex	formation	with	Smad	4.	This	in	turn	mediates	the	
translocation	of	the	complex	to	the	nucleus,	enabling	the	interaction	with	co-
activators	and	co-repressors	of	transcription,	enabling	the	expression	of	TGFβ	
related	genes	upon	binding,	as	represented	in	Figure	1.3.	Target	genes	are	involved	
in	the	inhibition	of	growth	and	proliferation,	highlighting	a	definitive	role	in	the	
intestine	(Ashley	2013b).		
	
BMP	signalling	is	predominantly	active	at	the	surface	of	the	colon	lumen	as	opposed	
to	the	stem	cell	rich	compartments	at	the	base	of	crypts.	The	BMP	pathway	has	a	
definitive	role	in	the	establishment	of	the	crypt	axis	in	the	intestine	as	well	as	
maintaining	the	proliferative	environment	to	restrict	intestinal	hyperproliferation.	
Mechanistically,	the	direct	inhibition	of	Wnt-driven	ß-catenin	dependent	signalling	
by	functional	BMP	signalling	ensures	the	terminal	differentiation	of	intestinal	cell	
lineages,	particularly	the	maturation	of	secretory	lineages	(Auclair	et	al.	2007).		
Inhibition	of	BMP	signalling,	using	agents	such	has	Noggin	has	previously	been	
shown	to	result	in	the	formation	of	ectopic	crypts	(Batts	et	al.	2006).	BMP	inhibition	
has	also	been	linked	to	an	expanding	stem	and	progenitor	cell	population	in	the	
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intestine,	eventually	resulting	in	intestinal	polyposis	(He	et	al.	2004).	An	interplay	
between	BMP	and	Wnt	signalling	has	also	been	postulated,	with	some	studies	having	
shown	that	Wnt	signalling	is	suppressed	by	BMP	to	further	control	self	renewal	of	
ISCs	(Yeung	et	al.	2011;	He	et	al.	2004).		Recent	in	vitro	studies	with	Lgr5+	ISCs	
cultured	with	BMP	showed	an	overall	suppression	in	a	stem	cell	marker	signature,	
suggesting	that	functional	BMP	signalling	limit	self-renewal	of	a	pool	of	stem	cells	in	
the	crypt,	and	in	turn	prevents	hyperproliferation	(Qi	et	al.	2017).		
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Figure	1.3	Schematic	of	Notch	and	TGFß/BMP	Signaling	
Homeostasis	of	the	large	intestine	relies	on	Notch	and	TGFß/BMP	signalling,	which	play	a	role	in	the	expression	of	genes	associated	with	specific	functions	such	as	
proliferation	and	differentiation.		
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1.2.3.4 Mitogen-Activated	Protein	Kinase	Pathways	(MAPK/ERK)	signalling	
pathway	
	
The	canonical	MAPK/ERK	pathway,	as	depicted	in	Figure	1.4,	is	activated	by	receptor	
tyrosine	kinases,	such	as	EGFR,	that	mediate	a	downstream	signalling	cascade	
(Burotto	et	al.	2015).	Upon	stimulation,	downstream	RAS	proteins,	including	HRAS,	
NRAS	and	KRAS,	are	localised	to	the	membrane,	which	in	turn	triggers	the	growth-
factor	receptor	binding	protein	2	(GRB2),	activating	Sevenless	homolog	(SOS),	both	
of	which	mediate	the	activation	of	RAS.	RAS	proteins	belong	to	a	family	of	
guanosine-5’-triphosphate	binding	proteins	(GTPases)	and	are	thus	activated	by	
dissociation	of	guanosine	diphosphate	to	guanosine	triphosphate-bound	RAS	
(Santarpia	et	al.	2012).	This	mediates	a	number	of	downstream	effects,	including	
recruitment	of	RAF	protein	isoforms	(ARAF,BRAF	and	CRAF)	to	the	cell	membrane,	
and	activation	of	function	(Dhillon	et	al.	2007).	RAF	in	turn	activates	Mitogen	
activated	kinase	1/2	(Mek	1/2)	which	then	activate	extracellular	signal-related	kinase	
1/2	(ERK	1/2).	Upon	activation,	ERK1/ERK2	phosphorylate	a	number	of	cellular	and	
nuclear	substrates	whereby	cell	cycle	regulators	are	targeted;	including	cyclin	D,	as	
well	as	target	genes	involved	in	apoptosis	including	Bim	(Mebratu	and	Tesfaigzi	
2009)	which	mediate	a	broad	range	of	cellular	responses	such	stimulation	of	
proliferation,	differentiation	survival	and	apoptosis	(Santarpia	et	al.	2012;	Burotto	et	
al.	2015).		
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Figure	1.4	Schematic	of	EGFR/RAF/MEK/ERK	signalling	
Activation	of	receptor	Tyrosine	Kinases	(RTKs)	such	as	EGFR	lead	to	recruitment	of	GRB2,	and	SOS,	the	
guanine	nucleotide	exchange	factor.	This	in	turn	activates	Ras,	mediating	the	phosphorylation	and	
activation	of	Raf.	This	initiates	the	phosphorylation	of	MEK1/2,	with	subsequently	phosphorylates	ERK	
1/2.	Activated	ERK1/2	is	translocated	to	the	nucleus,	which	leads	to	the	activation	of	transcription	
factors	involved	in	cell	cycle	regulation,	proliferation	and	cell	survival.		
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1.2.3.5 Phosphoinositide	3-kinases	(PI3Ks)	Signalling	
	
Phosphoinositide	3-kinases	(PI3Ks)	are	a	family	of	lipid	kinases	composed	of	
regulatory	subunits	and	a	catalytic	subunit,	which	exist	in	several	isoforms	and	are	
tightly	regulated	in	the	normal	cell	(Engelman	2009).	PI3K	activation	occurs	as	a	
result	of	receptor	tyrosine	kinases,	G-protein	coupled	receptors	and	interaction	with	
Ras	(Zhao	and	Vogt	2008).		
	
Once	activated,	PI3Ks	initiate	the	phosphorylation	of	the	3’	hydroxyl	group	of	
phosphatidylinositol	4,5	bisphosphate	(PIP2)	to	phosphatidylinositol	3,4,5-
triphosphate	(PIP3)	on	the	plasma	membrane.		Signalling	can	be	terminated	at	this	
point	by	the	phosphatase	PTEN	(phosphatase	and	TENsin	homolog	deleted	on	
chromosome	10),	which	facilitates	the	hydrolysis	of	PIP3	to	PiP2	(Zhao	and	Vogt	
2008).	Upon	accumulation	of	PIP3,	AKT	is	recruited	to	the	membrane,	whereby	
phosphoinositide-dependent	protein	kinase	1	(PDK1)	phosphorylates	within	the	
activation	loop	of	AKT	(threonine	308),	and	mechanistic	target	of	rapamycin	complex	
2	(mTORC2)	phosphorylates	a	hydrophobic	motif	of	AKT	(serine	473)	facilitating	AKT	
activation.	Following	activation,	AKT	mediates	the	phosphorylation	of	several	
proteins,	which,	in	turn	regulate	several	cell	processes	including	proliferation,	cell	
survival	and	protein	synthesis	(Engelman	2009).	
	
1.3 Colorectal	cancer	
	
Colorectal	cancer	is	the	third	most	common	cancer,	and	the	second	most	common	
cause	of	cancer	related	deaths	in	the	UK	(CRUK,	2014).	The	incidence	of	CRC	is	
particularly	high	due	to	the	challenging	environment	of	the	tissue.	The	high	rate	of	
cell	division	required	to	facilitate	the	rapid	turnover	of	cells	within	the	crypts	provide	
a	potential	source	of	DNA	replication	errors,	making	oncogenic	transformations	
more	likely	(Ashley	et	al.	2013).	Furthermore,	colorectal	tissue	is	directly	exposed	to	
carcinogens	from	ingested	food,	and	thus	provides	multiple	factors	for	carcinogenic	
occurrences	to	take	place.		
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CRC	is	classically	divided	into	sporadic	and	hereditary	conditions.	Sporadic	CRC	
development	has	been	proposed	as	a	process	whereby	modulation	in	the	
aforementioned	signalling	pathways,	as	well	as	accumulative	genetic	abnormalities	
in	oncogenes	or	tumour	suppressor	genes,	can	drive	the	transition	from	normal	
epithelial	tissue	to	a	benign	adenoma,	to	a	carcinoma	which	has	the	potential	to	
metastasise	into	other	tissues	within	the	body	(Gervaz	et	al.	2004;	Smith	et	al.	2002),	
with	proposed	mechanisms	discussed	in	section	1.3.2.	The	incidence	of	sporadic	
bowel	cancer	is	largely	attributed	to	external	factors,	such	as	diet,	smoking	and	
increased	alcohol	consumption,	with	recent	studies	also	investigating	the	role	of	the	
gut	microbiota	in	the	initiation	and	possible	influence	on	carcinogenic	processes	
(Drewes	et	al.	2016).		
	
Hereditary	conditions	have	also	been	found	to	contribute	to	the	incidence	of	CRC,	
namely	through	familial	adenomatous	polyposis	(FAP),	a	hereditary	condition	which	
leads	to	the	development	of	polyps	with	potential	to	form	benign	lesions	and	
adenocarcinomas	(Bodmer	et	al.	1987).	
	
1.3.1 TNM	and	Dukes	staging	of	colorectal	cancer	
	
Histopathological	assessment	of	patient	tumour	samples	enables	disease	staging,	
ideally	from	surgical	resection	specimens	according	to	the	Tumour	Node	Metastasis	
(TNM)	system.	This	is	a	revised	modification	of	the	previously	established	Dukes’	
staging	and	is	of	prognostic	significance,	as	highlighted	in	Figure	1.5	and	Table	1.1	
(Greene	2004).	This	enables	an	assessment	of	degree	of	the	degree	of	invasion	of	a	
primary	tumour,	as	designated	by	Tumour	T	stage	T1-T4,	a	pathological	assessment	
of	tumour	cell	presence	in	regional	lymph	nodes	(N	stage	N0-2),	and	finally,	a	
classification	for	metastases	distant	from	the	primary	malignancy	‘M’	‘M’	(x,0,1)	to	
indicate	local	or	further	metastasis.		
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Figure	1.5	Gross	anatomy	of	the	large	intestine	showing	representative	grading	for	tumour	
invasion.	
(A)	Gross	anatomy	of	the	large	intestine,	from	the	caecum	to	the	rectum.	Surgically	resected	
specimens	from	the	Wales	Cancer	Bank	come	from	throughout	this	region.	(B)	Diagram	representing	
‘TNM’	staging	of	colorectal	cancer;	early	stages	show	tumour	invasion	into	the	inner	lining	of	the	
colon,	whilst	later	stages	show	invasion	which	can	spread	to	adjacent	lymph	nodes	and	potentially	
metastasise	into	other	regions	of	the	body.		
	
(A) 
(B) 
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Table	1.1	TNM/	Dukes’	classification	of	colorectal	cancer.	
Table	describing	tumour	stages	for	classification	of	disease	progression.	
TNM Classification Dukes’ 
Classification 
Stage 0 Carcinoma in situ 
Stage I Tumour invasion of the submucosa of the 
bowel only (T1, N0, M0) 
A 
Tumour invasion of the muscle layer of the 
bowel wall, muscularis propria (T2, N0,M0) 
 
B1 
Stage II Tumour invasion, into the outer lining of the 
bowel wall (T3, N0, M0) 
B2 
Tumour invaded through the outer lining of the 
bowel wall (T4, N0, M0) 
 
B2 
Stage III 1-3 lymph nodes contain cancer cells (T1-2, 
N1, M0) 
 
C1 
4 or more lymph nodes containing cancer cells  
(T1-2, N2, M0) 
 
C1 
1-3 lymph nodes contain cancer cells  (T3-4, 
N1, M0) 
 
C2 
4 or more lymph nodes containing cancer cells 
(T3-4, N2, M0) 
 
C2 
Stage IV Known metastasis in the patient (T1-4, N1-2, 
M1) 
 
D 
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1.3.2 The	genetic	progression	of	colorectal	cancer	development	
	
Given	the	intricate	plethora	of	aforementioned	signalling	pathways	involved	in	
maintaining	intestinal	homeostasis,	it	is	unsurprising	that	modulation	of	such	
pathways	as	a	result	of	mutations	in	key	tumour	suppressors	and	oncogenes	have	
the	potential	to	initiate	and	drive	CRC	progression.	The	understanding	of	molecular	
events	that	are	key	to	tumour	initiation	and	progression	not	only	underpin	the	
understanding	of	tumourigenesis,	but	are	also	of	vital	relevance	to	the	development	
of	novel	targeted	therapies.	
	
Sporadic	CRC	development	has	been	proposed	as	a	process	whereby	modulation	in	
homeostatic	signalling	pathways,	as	well	as	accumulative	genetic	abnormalities	in	
oncogenes	or	tumour	suppressor	genes,	drive	the	transition	from	normal	epithelial	
tissue	to	a	benign	adenoma,	to	a	carcinoma	which	has	the	potential	to	metastasise	
into	other	tissues,	as	depicted	in	Figure	1.6	(Gervaz	et	al.	2004;	Smith	et	al.	2002).	
The	development	of	CRC	has	long	been	established	as	a	multi-step	process,	whereby	
mutations	are	acquired	and	accumulated,	driving	tumour	progression	from	a	
dysplastic	epithelium,	to	benign	adenoma	and	adenocarcinoma,	which	then	has	the	
potential	to	metastasise	into	other	tissues.	This	‘classic’	genetic	model	of	CRC	
progression	was	proposed	over	20	years	ago	in	a	landmark	study	by	Fearon	and	
Vogelstein,	where	they	carried	out	a	comprehensive	analysis	of	histopathological	
and	genetic	data	in	late	stage	tumours	compared	to	early	stage	tumours	to	
understand	mutations	that	initiate	and	play	a	role	in	CRC	development	(Fearon	and	
Vogelstein	1990).	It	was	observed	that	many	genetic	alterations	occurred	at	a	higher	
frequency	in	late	stage	tumours.	The	authors	hypothesised	that	the	adenomatous	
polyposis	coli	(APC)	gene	was	the	initiating	mutation	in	the	formation	of	benign	
lesions,	leading	the	acquisition	of	activating	mutations	in	kirsten	rat	sarcoma	viral	
oncogene	homolog	(KRAS),	allelic	loss	of	18q	locus	and	p53	loss,	all	of	which	were	
critical	drivers	of	tumour	progression	due	to	genetically	unstable	cells	(Fearon	and	
Vogelstein	1990;	Pinto	and	Clevers	2005;	Gervaz	et	al.	2004).	Despite	such	
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alterations	having	been	observed	in	the	advanced	tumours,	this	work	came	with	the	
caveat	that	such	specific	genetic	alterations	were	not	observed	in	all	tumours	and	
that	it	was	more	likely	that	the	accumulative	mutations,	rather	than	their	order	of	
acquisition	lead	to	advanced	tumour	formation	(Fearon	and	Vogelstein	1990).	
Further	to	these	remarks,	Smith	et	al	(Smith	et	al.	2002)	noted	that	mutations	in	all	
genes		APC,	KRAS	and	P53	occurred	in	only	6.6%	of	tumours	of	a	cohort	of	over	100	
CRC	patients,		suggesting	that	alternative	genetic	pathways	occur	in	CRC	progression.		
	
The	loss	of	the	tumour	suppressor	APC	is	well	established	as	a	key	driver	for	CRC	
progression.	An	activating	mutation	in	APC	was	firstly	associated	with	patients	
suffering	from	familial	adenomatous	polyposis	(FAP),	a	hereditary	condition	which	
leads	to	multiple	polyp	development	(Bodmer	et	al.	1987).	Both	germline	and	
somatic	APC	mutations	result	in	aberrant	signalling	which	allow	the	formation	of	
benign	lesions,	which	can	potentially	initiate	tumour	progression.	APC	regulates	the	
degradation	of	β-catenin	and	is	hence	a	critical	component	of	the	Wnt-signalling	
cascade.	Mutations	therefore	result	in	a	constitutive	activation	of	canonical	Wnt	
signalling	which	causes	an	activation	of	transcription	of	downstream	signals,	
primarily	involved	in	enhanced	cell	proliferation.	Inactivation	of	APC	in	the	murine	
intestinal	epithelium	has	previously	been	implicated	in	a	rapid	relocalisation	of	ß-
catenin	to	the	nucleus	in	histological	samples,	suggestive	of	Wnt	signalling	induction,	
resulting	in	cellular	changes	such	as	an	expansion	of	a	progenitor	cell	population	in	
the	crypt	and	a	failure	of	cells	to	migrate	and	differentiate	(Sansom	et	al.	2004).		
	
Activating	mutations	in	RAS	often	follows	in	colorectal	cancer	progression.	Early	
studies	that	grouped	adenomas	according	to	volume	noted	that	mutations	in	KRAS	
or	NRAS	were	prevalent	in	larger	adenomas	(Vogelstein	et	al.	1988)	suggesting	that	
RAS	mutations	facilitate	tumour	progression	towards	malignancy.	DNA	sequencing	
studies	have	further	confirmed	the	role	of	mutated	RAS	in	colorectal	cancer,	
particularly	KRAS	activating	mutations,	which	constitute	approximately	40%	of	
colorectal	cancers,	the	majority	in	codon	12	(Cancer	Genome	Atlas	Network	2012).	
As	discussed	further	in	section	1.5,	KRAS	is	a	downstream	mediator	of	the	MAP/ERK	
pathway,	constituting	a	role	in	a	major	signalling	cascade	that	is	integrated	with	
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multiple	pathways,	and	thus	constitutes	a	large	role	in	control	of	cell	proliferation	
and	cell	survival.			
	
The	transition	from	adenoma	to	carcinoma	is	further	driven	by	loss	of	the	long	arm	
of	chromosome	18,	then	the	tumour	suppressor	p53,	which,	in	the	normal	cell	
mediates	cell	cycle	suppression	or	induces	apoptosis	in	response	to	stress	or	damage	
(Colussi	et	al.	2013)	.	The	later	stages	of	colorectal	tumourigenesis	are	frequently	
classified	by	p53	loss	of	function,	and	approximately	75%	of	CRC	contain	p53	
mutations	(Cancer	Genome	Atlas	Network	2012).	Such	mutations	result	in	the	
stimulation	of	high	proliferative	activity	due	to	failed	function	in	cell	cycle	control.	
Frequently,	a	molecular	event	which	co-occurs	is	the	LOH	of	chromosome	18q,	
where	the	genes	Smad2,	Smad4	and	DCC	are	located	(Colussi	et	al.	2013).	
	
A	comparison	of	normal	and	tumour	tissue	by	deep	sequencing	has	further	
emphasised	the	complexity	of	events	that	drive	the	formation	of	colorectal	
tumourigenesis,	by	demonstrating	the	plethora	of	genes	involved	in	tumour	
progression	(Wood	et	al.	2007;	Cancer	Genome	Atlas	Network	2012).	It	has	been	
noted	in	such	studies	that	other	changes	are	likely	to	occur	during	this	classic	
progression	model,	and	further	studies	have	demonstrated	the	implication	of	an	
array	of	signalling	cascades	that	also	influence	CRC	progression,	including	the	PI3K	
pathway,	further	discussed	in	section	1.2.3.5.	The	recent	‘Big	Bang’	theory,	
postulates	that	tumour	growth	results	from	the	expansion	of	an	initial	population	of	
cells	containing	mutations	such	as	APC	and	KRAS,	with	heterogeneous	subclones	
continuously	accumulating	within	the	tumour,	resulting	in	intratumoral	
heterogeneity	(Sottoriva	et	al.	2015).	Such	studies	highlight	the	complex	genomic	
landscape	of	CRC,	which	ultimately	plays	a	role	in	explaining	the	difficulty	in	
identifying	therapeutics	for	CRC.		
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Figure	1.6	Schematic	of	tumour	initiation	and	progression	in	the	intestine.	
Classical	model	of	tumour	progression	proposed	by	Fearon	and	Volgstein,	depicting	accumulating	mutations	that	lead	to	the	transition	of	the	normal	epithelium	to	
carcinoma	formation.	
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1.4 Current	therapeutic	strategies	for	CRC	
	
Therapeutic	strategies	for	CRC	primarily	involve	surgical	resection	of	both	tumour	
and	metastasis,	in	conjunction	with	radiotherapy	and/or	chemotherapy	in	the	
neoadjuvant	(prior	surgery)	setting	to	shrink	the	tumour,	or	in	the	adjuvant	setting	
(following	surgery).		For	rectal	cancer	patients	specifically,	the	administration	of	
chemotherapy	alongside	radiotherapy	is	frequently	used	as	a	therapeutic	strategy.		
	
5-Fluoruracil	(5-FU)	was	introduced	as	a	chemotherapeutic	agent	over	40	years	ago	
and	has	remained	the	most	widely	used	treatment	regimen	for	CRC.	5-FU,	when	
metabolised	to	5-fluoro-2’-deoxyuridylate,	acts	as	an	irreversible	thymidylate	
synthase	inhibitor,	disrupting	DNA	and	RNA	synthesis	leading	to	the	initiation	of	
apoptosis	and	cell	death	(Gill	et	al.	2003).	As	a	monotherapy,	5-FU	or	in	recent	
advances	Capecitabine,	a	pro-drug	equivalent,	is	associated	with	an	improved	
disease	free	median	survival	(Longley	et	al.	2003)	rate	in	approximately	10-15%	of	
patients.	5-FU	is	frequently	used	in	combination	to	overcome	these	limited	response	
rates.	Leucovorin,	a	folinic	acid	that	mechanistically	stabilises	bonds	formed	by	
thymidylate	synthase	and	a	metabolite	of	fluorouracil,	has	been	shown	to	improve	
survival	compared	to	5-FU	alone	(12	months	versus	7	months)	(Poon	et	al.	1991)and	
in	prospective	studies	the	addition	to	Leucovorin	to	a	chemotherapeutic	regime	
conferred	response	rates	of	23%	(Gill	et	al.	2003).	
	
Further	advances	have	been	made	to	improve	the	therapeutic	repertoire	of	CRC	
treatment,	including	the	generation	of	oxaliplatin,	which	induces	cross-linking	of	
DNA,	impairing	DNA	synthesis	and	cell	replication	(Longley	et	al.	2003).	Although	
somewhat	active	as	a	single	agent,	oxaliplatin	in	combination	with	5-FU	and	
levouricin,	has	been	shown	to	yield	response	rates	of	20%	in	refractory	disease	
(Andre	et	al.	1998).	Similarly,	irinotecan,	a	topoisomerase	1	inhibitor,	has	been	
reported	to	improve	median	survival	in	patients	receiving	5-
FU/Leucovorin/Irinotecan	compared	to	5-FU/	Leucovorin	alone,	as	well	as	higher	
response	rates	in	387	patients	within	the	randomised	trial	(Douillard	et	al.	2000;	
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Goldberg	et	al.	2005).	Varying	combinations	of	fluorouracil,	irinotecan	and	
oxaliplatin	are	now	well	established	in	the	clinic,	dependent	on	CRC	tumour	stages,	
and	have	been	found	to	increase	median	survival	(Goldberg	et	al.	2005).	
	
However,	despite	the	substantial	improvement	made	to	CRC	treatment	over	the	past	
decade,	chemotherapeutics	are	toxic	and	combination	chemotherapeutics	show	
increased	toxicities,	such	that	treatment	regimes	are	generally	limited	by	the	
damage	inflicted	on	healthy	tissues.	Clinical	trials,	such	as	the	Medical	Research	
Council	(MRC)	COIN	trial,	have	reported	some	reduction	in	toxic	effects	when	
chemotherapeutics	are	administered	intermittently	as	opposed	to	continuous	pre-
defined	intervals	which	are	regular	in	the	clinic.	However,	such	regimens	have	failed	
to	significantly	improve	overall	survival	in	advanced	CRC	(Adams	et	al.	2011)	.	
Another	consideration	for	the	continued	use	of	chemotherapeutic	agents	is	their	
strong	association	with	tumour	resistance,	which	ultimately	leads	to	patient	relapse	
and	tumour	progression.	Studies	investigating	treatments	in	the	adjuvant	setting	
have	thus	far	reported	limited	benefits	of	combinations	at	more	advances	stages	of	
CRC;	the	MOSAIC	trial	for	Stage	III	CRC	patients,	for	example,	showed	that	
Leucovorin,	oxaliplatin	and	5-FU	combination	increased	disease	free	survival	at	3	
years	by	only	7%,	compared	to	5-FU	and	leucovorin	alone	(Binefa	et	al.	2014).	The	
advances	in	chemotherapeutic	therapies	in	the	curative	setting	therefore	need	to	be	
improved.		
	
The	advances	in	the	understanding	of	CRC	and	biomarkers	of	tumour	types	have	
moved	treatment	towards	more	targeted	therapy	to	improve	survival.		The	
epidermal	growth	factor	(EGFR)	for	example,	is	a	receptor	tyrosine	kinase	that	is	an	
emerging	prognostic	biomarker	for	CRC	following	identification	of	EGFR	
amplification	across	CRC	patient	samples	(Resnick	et	al.	2004;	Spano	et	al.	2005).	
Cetuximab	and	Panitumumab	are	two	anti-EGFR	monoclonal	antibody	therapies	that	
inhibit	the	EGFR	transmembrane	glycoprotein,	inhibiting	downstream	signalling.	
Both	agents	have	been	approved	in	the	clinical	setting,	with	the	exception	of	KRAS	
mutant	patients,	which	fail	to	respond	to	EGFR	inhibitor	therapy		(Roock	et	al.	2010).	
As	shown	in	Figure	1.4,	the	EGFR	ligand	lies	upstream	of	RAS;	a	mutation	in	KRAS	
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could	thus	override	any	inhibition	of	upstream	targets	and	maintain	downstream	
signaling.		Despite	vast	advances	in	the	understanding	of	CRC	biology,	treatment	
remains	largely	palliative	and	is	limited	in	overall	impact	upon	long-term	survival.	
Studies	are	still	underway	to	improve	survival	long-term	by	investigating	targeted	
therapies,	as	well	as	scheduling	chemotherapeutic	regimens	appropriately.		
	
1.5 Deregulated	pathways	in	CRC	development	and	associated	targeted	
therapies	for	a	biomarker-driven	clinical	trial.		
1.5.1 FOCUS	4	clinical	trial	as	a	molecularly	stratified	clinical	trial	
	
The	MRC/NIHR,	alongside	Cancer	Research	UK	(CRUK)	have	funded	a	NCRI	CRC	
Clinical	Studies	Group	development,	FOCUS	4	(registered	ISRCT90061546)	as	a	drive	
to	investigate	biomarker-selected	therapies	in	CRC.	This	UK-wide	clinical	trial	is	a	
molecularly	stratified,	multi-arm	programme	(Figure	1.7)	that	aims	to	address	the	
relation	between	tumour	biomarker	profiles	and	selective	therapeutic	intervention	
to	improve	progression	free	survival	in	CRC.		
	
As	depicted	in	Figure	1.7,	this	trial	aims	to	classify	patients	with	progressed	or	
inoperable	metastatic	CRC	according	to	the	molecular	background	of	their	tumour,	
and	treat	accordingly.	Following	16	weeks	of	palliative	chemotherapy,	and	fulfilment	
of	eligibility	criteria,	patients	will	be	categorised	into	sub-groups	(treatment	‘arms’)	
according	to	the	molecular	make-up	of	their	tumour.	Patients	will	be	randomized	to	
receive	treatment	or	placebo	and	their	progression	free	response	to	treatment	will	
be	tested.	The	panel	of	molecular	markers	under	investigation	are	based	on	
biomarkers	that	have	been	previously	identified	or	hypothesised	to	elicit	predictable	
responses	to	targeted	therapies,	particularly	from	previous	data	collected	from	the	
MRC	COntinuous	or	INtermittent	(COIN)	trial,	and	will	be	discussed	in	turn.	The	
adaptive	design	of	the	trial	enables	progressive	changes	to	be	incorporated	during	
the	course	of	the	trial	as	a	result	of	novel	biomarker	identification,	novel	treatments,	
or	the	identification	of	trial	arms	better	fitted	with	alternative	treatments.	Given	the	
complex	mutation	spectrum	in	CRC,	it	would	be	a	fair	assumption	that	patients	could	
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harbour	a	number	of	the	main	molecular	mutations	and	thus	be	categorised	into	
several	arms.	Treatments	are	therefore	tiered	based	on	a	hierarchy	(arms	left	to	
right)	according	to	the	strength	of	prognostic	effect	and	targets	of	agents	used	
(Professor	Tim	Maughan,	personal	communication).	The	trial	version	as	depicted	
below	will	be	discussed	in	the	context	of	this	thesis	(as	discussed	with	members	of	
FOCUS	4	team	and	recent	publications	(Richman	et	al.	2015).	
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Figure	1.7	Outline	of	the	MRC	FOCUS	4	clinical	trial.	
Patients	with	metastatic	CRC,	fit	for	first	line	chemotherapy	will	undergo	biomarker	analysis,	and	will	be	stratified	on	the	basis	of	the	molecular	profile	of	their	tumour	and	
treated	accordingly,	adapted	from	FOCUS	4	master	protocol.	The	MSI/MMR	deficient	arm	(dotted)	is	beyond	the	scope	of	this	thesis	and	is	for	reference	only.	
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1.5.2 Targeting	the	Mitogen-Activated	Protein	Kinase	Pathways	(MAPK/ERK)	
pathway	
	
Mutations	in	numerous	components	within	the	MAPK/ERK	signaling	cascade	
(previously	discussed	in	intestinal	homeostasis	in	section	1.2.3.4)	result	in	altered	
gene	expression	and	constitutive	activation	in	MAPK/ERK	signaling	activity,	and	have	
been	shown	to	be	involved	in	CRC	tumour	progression.	KRAS	mutations	are	found	in	
approximately	40%	of	CRCs	(Cancer	Genome	Atlas	Network	2012),	with	the	majority	
of	such	activating	mutations	occurring	at	codon	12.	MAPK	signaling	is	also	aberrantly	
activated	in	CRCs	following	oncogenic	mutations	in	BRAF,	and	lead	to	a	constitutive	
activation	of	BRAF	kinase	activation,	resulting	in	the	phosphorylation	and	activation	
of	MEK	1/2	(Santarpia	et	al.	2012)	and	therefore	sustained	MAPK	activity.	BRAF	
mutations	are	found	in	approximately	8-12%	of	CRCs,	and	occur	mostly	at	the	V600	
domain	whereby	a	single	amino	acid	is	substituted	to	glutamic	acid	(V600E),	
resulting	in	a	constitutive	kinase	activity	(Corcoran	2015).	Importantly,	KRAS	and	
BRAF	activating	mutations	are	mutually	exclusive,	and	thus	act	as	key	negative	
predictors	for	response	against	monoclonal	antibodies	against	EGFR,	such	as	
cetuximab.	Therapies	that	target	the	MAPK	pathway	have	therefore	been	generated	
in	a	strategy	to	target	RAS	and	RAF	protein,	and	more	recently,	MEK	as	a	
downstream	target	of	both.		
	
At	the	receptor	tyrosine	kinase	level,	the	MAPK	ERK	pathway	can	be	activated	by	
EGFR	activity,	and	aberrantly	activated	by	EGFR	gene	overexpression,	amplification	
as	a	result	of	activating	mutations	as	observed	in	CRCs	(Santarpia	et	al.	2012;	Burotto	
et	al.	2015).	Monoclonal	antibodies	(mAbs)	which	have	been	directed	against	the	
extracellular	domain	of	EGFR	have	been	developed,	and	have	shown	effectiveness	in	
CRC	with	amplification	of	EGFR-mediated	signalling.	Panitumumab	is	a	mAb	
developed	for	use	in	metastatic	CRC	and	has	an	overall		overall	8%	response	rate,	
with	improved	toxicities	compared	to	mAbs	such	as	cetuximab	(Roberts	and	Der	
2007;	Gibson	et	al.	2006).	In	addition	to	EGFR	inhibition,	selective	BRAF	inhibitors	
have	been	developed,	such	as	vemurafenib	and	Dabrafenib	and	have	proved	to	yield	
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high	response	rates	in	BRAF-mutant	melanoma	patients	(Ahronian	et	al.	2015).	
However,	pre-clinical	studies	have	reported	that	CRC	patients	harbouring	the	same	
mutation	do	not	necessarily	respond	to	direct	inhibition	of	BRAF,	indicating	that	this	
strategy	fails	to	sufficiently	inhibit	MAPK	signaling.	Studies	have	suggested	that	
negative	feedback	loops,	driven	by	EGFR-mediated	reactivation,	compensate	for	RAF	
inhibition	in	BRAF-	mutant	CRC	cells,	resulting	in	feedback	reactivation	of	MAPK	
signaling	(Corcoran	et	al.	2012;	Prahallad	et	al.	2012).	Some	evidence	has	also	
suggested	that	BRAF	mutant	CRCs	express	high	levels	of	total	EGFR	compared	to	
melanomas	bearing	the	same	mutation,	suggesting	that	EGFR-dependent	resistance	
would	be	more	prominent	within	BRAF-mutant	CRCs	(Corcoran	2015;	Corcoran	et	al.	
2012).	Furthermore,	inhibition	of	downstream	targets	such	as	MEK1/2	have	been	
shown	suppress	activation	of	ERK	and	thus	improve	overall	targeted	inhibition	of	the	
MAPK	pathway,	inducing	an	improved	outcome	in	numerous	xenograft	models	of	
pancreas,	breast	and	colon,	(Roberts	and	Der	2007;	Davies	et	al.	2007).	However,	
targeting	downstream	KRAS	or	BRAF	activity	using	MEK1/2	inhibitors	in	colorectal	
cancer	cells	has	highlighted	some	instances	of	acquired	resistance	to	therapy,	in	
which	KRAS	or	BRAF	activity	are	amplified	as	a	result	of	treatment	(Little	et	al.	2014).		
	
In	order	to	suppress	feedback	reactivation	of	MAPK	signaling	cascade	and	overcome	
acquired	resistance,	it	has	been	hypothesized	that	sustained	inhibition	of	a	
combination	of	components	within	the	pathway	could	be	an	alternative	approach	to	
therapy.	Combinations	of	RAF/MEK	or	EGFR/RAF	inhibition	have	thus	been	
introduced	in	clinical	trials	and	have	recently	showing	some	response	rates	
(Corcoran	et	al.	2015),	with	newer	trials	introducing	triple	combination	therapy	
against	EGFR,	RAF	and	MEK	.	Within	the	FOCUS	4	clinical	trial	a	treatment	regimen	of	
an	anti	EGFR	antibody	(Panitumumab),	alongside	BRAF	inhibitor	(Dabrafenib)	will	be	
tested	for	efficacy	and	progression	free	survival	with	and	without	a	MEK	1/2	
inhibitor	(Trametinib)	in	patients	harboring	BRAF	V600E	mutations	(BRAF	mutation	
arm).		
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1.5.3 Phosphoinositide	3-kinase	(PI3K	pathway)	
	
Deregulation	of	the	numerous	components	within	the	PI3K	cascade	is	associated	
with	many	malignancies,	and	further	findings	in	the	literature	support	the	
involvement	of	aberrant	PI3K	signalling	in	tumour	progression	(Samuels	and	
Velculescu	2004;	Engelman	2009a).	The	PIK3CA	gene	encodes	the	p110α	catalytic	
subunit	of	PI3K,	and	mutations	occur	at	a	frequency	of	approximately	15%	of	CRCs	
(Cancer	Genome	Atlas	Network	2012).	Further	studies	have	identified	that	80%	of	
mutations	within	PIK3CA	are	frequently	found	within	conserved	hotspots	in	the	
helical	(exon	9)	and	kinase	(exon	20)	domain	of	the	protein,	resulting	in	a	
constitutive	activation	of	the	PI3K-AKT	pathway	that	regulates	proliferation,	
apoptosis	and	metabolism	(Samuels	et	al.	2004;	Samuels	and	Velculescu	2004).	
Further	studies	have	found	that	disruption	of	helical	or	kinase	domain	of	two	
colorectal	cancer	cell	lines	resulted	in	activation	of	the	AKT	pathway,	and	highlighted	
the	role	of	PIK3CA	in	attenuating	apoptotic	events	(Samuels	et	al.	2005).		
	
Currently,	compounds	that	directly	target	elements	of	PI3K	signalling	are	being	
introduced	in	clinical	trial.	BEZ235	(Novartis),	for	example,	is	a	dual	PI3K/	mTOR	
inhibitor	that	has	demonstrated	promising	results	in	tumour	xenografts	and	GEMMs	
(Maira	et	al.	2008;	Raja	et	al.	2015)	.	Given	the	complex	network	involved	for	PI3K	
signalling,	it	is	worth	noting	that	the	complex	landscape	of	mutations	in	CRC	could	
provide	a	mechanism	of	resistance	against	PI3K	targeted	therapies,	whereby	
mutations	or	amplifications	in	downstream	or	linked	pathway	components	could	
induce	compensatory	effects	of	inhibition	(Liu	et	al.	2009).	Emerging	data	from	
retrospective	studies	have	thus	far	shown	beneficial	effects	of	aspirin	administration	
in	patients	harbouring	mutations	in	exon	9	and	20	of	PIK3CA,	improving	overall	
mortality	compared	to	placebo	(Liao	et	al.	2012).	In	vitro	studies	have	somewhat	
confirmed	that	PIK3CA	mutations	play	a	role	in	aspirin	sensitivity;	a	recent	study	
demonstrated	that	aspirin	activity	was	exacerbated	in	CRC	cell	lines	with	PIK3CA	
mutations	(Zumwalt	et	al.	2017)	The	precise	mechanisms	involved	are	thus	far	
unknown,	and	are	therefore	under	exploration	in	the	FOCUS	4	clinical	trial,	whereby	
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PIK3CA	mutant	patients	will	receive	aspirin	following	standard	of	care	treatment	
(Figure	1.7).			
1.5.4 Agents	targeting	the	DNA	damage	response	pathway	
	
The	DNA	damage	response	(DDR)	consists	of	a	plethora	of	complex	signalling	events	
which	facilitate	transient	cell	cycle	arrest,	DNA	repair	or	apoptosis,	in	order	to	
maintain	the	genomic	integrity	of	cells		(Khalil	et	al.	2012).	
	
Ataxia-telangiectasia	mutated	(ATM)	and	ataxia–telangiectasia	and	Rad3	related	
(ATR)	are	central	kinases	that	are	activated	as	a	result	of	replicative	stress	induced	
by	double	strand	breaks	in	DNA	or	stalled	replications	forks.	Upon	activation	of	DNA	
damage,	ATM	directly	stabilises	the	tumour	suppressor	p53,	or	indirectly	via	the	
downstream	mediator	checkpoint	kinase	2	(Chk2).	As	a	result	of	p53	activation,	the	
gene	expression	of	cell	cycle	checkpoint	activators,	such	as	p21,	or	genes	involved	in	
apoptosis	are	induced.	This	ultimately	initiates	G1/S	phases	of	the	cell	cycle	
checkpoint	to	initiate	cell	cycle	arrest,	DNA	repair	and	henceforth	cell	survival	
(Weber	and	Ryan	2015a).	ATR	monitors	replication	fork	progression	and	is	a	principal	
component	of	the	G2/M	cell	cycle.	ATR	mediates	downstream	effects	via	checkpoint	
kinase	1	(Chk1),	which	subsequently	facilitates	the	degradation	of	Cdc25c,	and	
activation	of	Wee1	kinase	activity.	As	a	result,	the	phosphorylation	and	inactivation	
of	the	Cdk2-cyclin	B	complex	results	in	cell-cycle	arrest,	preventing	entry	into	
mitosis.	This	mechanism	enables	the	suppression	of	DNA	replication	progression,	
allowing	time	to	identify	the	source	and	resolve	replicative	stress	(Matheson	et	al.	
2016).		
	
The	deregulation	of	the	G1	checkpoint	is	a	characteristic	of	many	cancer	types,	and	
ultimately	impairs	DNA	damage	repair	prior	to	replication,	resulting	in	the	
accumulation	of	mutations	during	DNA	synthesis.	However,	the	G2/M	checkpoint	is	
retained	in	cancer	cells.	Damage	present	at	G2/M	leads	to	cell	cycle	arrest	such	that	
cancer	cells	are	able	to	repair	DNA	defects	that	would	otherwise	lead	to	catastrophic	
changes	that	drive	apoptosis	(Khalil	et	al.	2012).	Theoretically,	the	selective	ablation	
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of	tumour	cells	can	be	achieved	by	G2/M	checkpoint	inhibition,	since	normal	cells	
with	functional	checkpoints	would	be	unaffected.		The	abrogation	of	the	G2/M	
checkpoint	has	therefore	been	exploited	as	a	potential	therapeutic	option	to	target	
tumour	cells	carrying	specific	defects	in	DNA	repair	or	damage,	driving	cells	to	
undergo	mitosis,	and	essentially	cell	death	by	mitotic	catastrophe	(Matheson	et	al.	
2016).	
	
Pre-clinical	studies	have	shown	promise	in	targeting	components	of	the	DDR	
pathway	that	would	induce	cell	death	selectively	in	tumour	cells.	Wee1	is	expressed	
in	many	tumour	types,	including	colorectal	cancer,	with	a	recent	study	identifying	
Wee1	expression	in	the	nuclei	of	89%	patient	histological	samples	(Egeland	et	al.	
2016),	and	current	studies	underway	to	establish	clinical	significance.	In	vitro	studies	
have	demonstrated	the	efficacy	of	a	potent	and	selective	Wee1	inhibitor,	MK-1775	
in	inducing	DNA	damage	in	G2/M	and	S-phase	cells	(Guertin	et	al.	2013),	as	well	as	
enhancing	cytotoxic	effects	in	colon	cancer	cell	lines	treated	with	a	standard	of	care	
treatment,	5-FU.		A	similar	therapeutic	strategy	is	targeting	ATR;	cancers	with	pre-
existing	ATM	loss	would	theoretically	respond	to	ATR	inhibition	as	both	cell	cycle	
checkpoints	would	be	abrogated,	impacting	downstream	signalling	pathways	such	as	
checkpoint	kinases,	and	lead	to	cell	death.		
	
Many	studies	have	revealed	that	inhibition	of	ATR	increases	the	sensitivity	of	cancer	
cells	to	replication	stress,	thus	inducing	cell	death	and	inhibiting	tumour	growth.	A	
compound	developed	by	Aztrazeneca,	AZD6738,	an	analogue	of	AZ20,	with	
improved	solubility,	has	been	demonstrated	to	induce	substantial	effects	in	vivo	
(Weber	and	Ryan	2015b)	whereby	established	human	LoVo	colorectal	
adenocarcinoma	xenografts	dosed	with	ATR	inhibitor	showed	a	substantial	reduction	
in	tumour	volume	(Foote	et	al.	2013).		Within	the	FOCUS	4	clinical	trial,	targeting	the	
DDR	pathway	will	be	an	approach	within	two	treatment	arms.	Firstly,	patients	
harbouring	ATM	loss,	as	established	from	immunohistochemistry	(IHC)	will	be	
treated	with	AZD6738	(ATR	inhibitor).	Wee1	inhibitors	will	be	administered	to	
patients	harbouring	KRAS/p53	mutations	to	further	establish	links	between	Wee1	
inhibitions	as	a	therapeutic	strategy	for	RAS	mutant	patients	(Figure	1.8).	Within	the	
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FOCUS	4	trial,	it	is	hypothesised	that	treatment	with	Wee1	inhibitor	will	induce	
synthetic	lethality	in	RAS/p53	mutant	tumours	due	to	the	defective	G1	checkpoint	in	
cells,	and	increased	replication	stress	(FOCUS4-C	Protocol,	2017).	p53	is	a	key	
regulator	of	the	G1	checkpoint	and	thus	p53	deficient	cells	are	more	likely	to	be	
susceptible	to	treatment	targeting	the	G2	checkpoint.	The	rationale	for	targeting	
mutant	RAS	is	also	based	on	studies	which	have	demonstrated	the	role	of	Ras	in	
mitotic	progression,	that	could	be	exploited	for	synthetic	lethality	as	a	therapeutic	
treatment	(Luo	et	al.	2009;	FOCUS4-C	2017)	.	
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Figure	1.8	Schematic	of	DNA	damage	response	pathway		
	Representation	of	DNA	damage	response	in	normal,	tumour	cells,	and	as	a	therapeutic	strategy	to	induce	synthetic	lethality.	
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1.5.5 Tumour	heterogeneity	and	patient	stratification	for	treatment	
	
Despite	extensive	therapeutic	strategies	implemented	to	target	tumour	
development,	a	major	reason	for	a	lack	of	response	in	drug	trials	is	as	a	result	of	
inter-	and	intra-	patient	heterogeneity	de	novo	and	acquired	by	tumours.	CRC	overall	
is	a	very	heterogeneous	disease,	occurring	between	tumour	types	as	well	as	within	a	
tumour	mass.	Studies	by	the	Cancer	Genome	Atlas	Network,	for	example,	
successfully	performed	a	genome-scale	analysis	of	over	200	different	CRC	samples	
(Cancer	Genome	Atlas	Network	2012),	with	integrative	analysis	highlighting	markers	
for	more	aggressive	carcinomas.	Evidence	of	correlation	between	gene	expression	
signatures	and	treatments	effective	against	tumour	growth	are	slowly	mounting.	For	
example,	KRAS-mutant	CRCs	have	been	shown	to	have	limited	responses	to	EGFR-
targeting	antibodies,	due	to	downstream	signalling	with	limits	the	effects	of	EGFR	
inhibition	(Linardou	et	al.	2008).	This	has	been	further	highlighted	in	a	consortium	of	
patient-derived	CRC	xenografts	(Julien	et	al.	2012a).	Studies	of	various	molecular	
subtypes	in	vitro	have	been	associated	with	differential	responses	to	
chemotherapeutics	(Sadanandam	et	al.	2013).		
	
The	recognition	of	intra-tumour	heterogeneity	as	a	hallmark	of	CRC	has	resulted	in	a	
paradigm	shift	in	clinical	implications,	with	growing	emphasis	upon	stratifying	
patients	according	to	the	molecular	signature	of	a	tumour,	that	ultimately	defines	
and	appropriate	therapeutic	strategy	and	suitability	to	a	particular	anti-cancer	agent	
(Gervaz	et	al.	2004).	It	is	becoming	increasingly	evident	that	biomarkers	that	predict	
patient	response	to	treatment	will	be	required	for	drugs	to	go	into	late	stage	clinical	
trials	(Puig	et	al.	2013).	However,	genomic-focused	precision	oncology	has	also	been	
recognised	as	a	limited	platform	to	predict	the	outcomes	of	complex	biological	
signaling.	The	presence	or	absence	of	genetic	drivers	often	underestimates	the	
activity	of	corresponding	biological	pathways	(Daniela	et	al.,2017)	and	are	
potentially	unable	to	represent	signalling	feedback	controls,	cross-talk	with	other	
pathways,	as	well	as	tissue-dependent	differences.	Given	that	biomarkers	are	
present	within	a	dynamic	signalling	network,	a	more	comprehensive	approach	to	
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elucidate	mechanisms	are	required	(Alizadeh	et	al.,	2015).	Many	studies	
characterizing	the	genomic,	epigenomic,	proteomic	and	transcriptomic	profiles	of	
tumours	are	becoming	more	prevalent	in	the	literature.	Linking	different	model	
platforms	is	therefore	critical	to	ascertain	a	more	comprehensive	approach	to	
overcome	challenges	of	tumour	heterogeneity	(Daniela	et	al.,2017).	
	
1.6 Novel	targeted	therapies	for	colorectal	cancer	
1.6.1 Cancer	stem	cells	
	
Similarly	to	the	normal	colonic	epithelium,	colorectal	tumours	are	composed	of	a	
heterogeneous	population	of	cells	which	exhibit	various	levels	of	differentiation	and	
self-renewal	capacities,	shown	at	both	histological	and	molecular	levels	(Vermeulen	
et	al.	2008).	The	cancer	stem	cell	(CSC)	hypothesis	maintains	that,	similar	to	tissue-
specific	stem	cells	that	regulate	normal	tissue	homeostasis,	a	sub-population	of	
clonogenic	cancer	cells	with	stem	cell-like	characteristics	are	capable	of	self-renewal	
and	multi-lineage	differentiation,	enabling	tumour	propagation	and	expansion.	An	
increasing	body	of	evidence	supports	the	CSC	hypothesis,	following	observations	
that	only	a	sub-population	of	genetically	identical	cancer	cells	(termed	tumour-
initiating	cells)	have	the	capacity	to	form	tumours	when	transplanted	into	immune	
deficient	mice	(O’Brien	et	al.	2007),	implying	that	not	all	cell	types	are	able	to	
regenerate	another	tumour	bulk.	Considerable	efforts	to	experimentally	identify	CSC	
populations	have	gained	momentum	in	the	literature.		
	
One	of	the	most	prominent	candidates	as	a	colorectal	cancer	stem	cell	marker	is	
CD133.	CD133+	cells	were	firstly	shown	to	enrich	for	tumour-initiating	cells	in	
comparison	to	CD133-	cells	when	incorporated	into	a	mouse	transplantation	assay		
(O’Brien	et	al.	2007;	Lugli	et	al.	2010).	Vermeulen	et	al	suggested	that	CSCs	are	
characterised	by	multiple	markers	that	are	co-expressed	on	cells	with	the	tumour-
initiating	capacity.	Using	single	cell	cloning	experiments,	they	demonstrated	that	
1/16	CD133+	cells	had	the	capacity	to	produce	a	colony,	compared	to	1/250	CD133-	
negative	cells.	An	improved	colony	formation	capacity	was	found	when	cells	
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expressed	both	CD133	and	CD24,	suggesting	a	single	marker	does	not	necessarily	
represent	a	cancer	stem	cell	(Vermeulen	et	al.	2008).	Further	to	this,	dissociation	of	
CRC	tumour	samples	from	both	patient	and	established	xenograft	to	single	cell	
suspension	and	analysis	by	flow	cytometry	enabled	cell	sorting	determined	by	
specific	surface	markers.	It	was	shown	that	successful	engraftment	was	dependent	
on	a	population	of	cells	expressing	high	levels	of	CD44	and	epithelial	cell	adhesion	
molecule	(EpCAM).	Lgr5	and	CD24	have	since	been	identified	as	markers	expressed	
within	ISC,	which	were	overexpressed	in	colorectal	cancers		(Barker	et	al.	2007b;	
Vermeulen	et	al.	2008).	It	is	worth	noting	however	that	a	number	of	caveats	are	still	
raised	in	the	literature	when	using	such	experimentation	models.	Firstly,	dissociation	
and	culture	of	tumour	cells	in	itself	may	alter	cell	surface	marker	expression,	and	
must	therefore	be	interpreted	with	caution	as	a	representation	of	the	in	vivo	
situation	(Clevers	2011)	.	Furthermore,	xenotransplantation	assays,	despite	being	a	
current	gold	standard	for	cancer	stem	cell	identification,	is	not	necessarily	
pathophysiologically	relevant	to	tumour	growth.	Such	assays,	despite	being	carried	
out	in	vivo,	are	unlikely	to	wholly	represent	cells	due	to	an	alteration	in	their	
environment	and	potential	lack	in	appropriate	growth	factors.	Results	may	therefore	
be	an	artefact	of	enhanced	selection	of	a	subpopulation	of	cells	and	not	necessarily	a	
true	representation	of	a	CSC	population	(Visvader	and	Lindeman	2008).		
	
Taking	such	caveats	into	account,	and	given	the	lack	of	the	unequivocal	identity	of	
the	cell-of-origin	of	cancer	within	the	literature,	there	has	been	a	drive	in	recent	
years	to	further	apply	novel	techniques	to	expand	current	understanding	following	
identification	of	markers	(de	Sousa	et	al.	2011).	Conditional	transgenic	techniques	in	
mice	have	enabled	specific	deletion	in	stem	cells,	such	as	APC	deletion	within	Lgr5+	
of	CD133+	stem	cells	in	the	intestine,	which	enabled	Wnt	pathway	activation.	This	in	
turn	enhanced	intestinal	transformation	and	tumour	propagation,	which	was	not	
mirrored	by	the	same	deletion	in	progenitor	or	differentiated	cells	(Barker	et	al.	
2009).	Moreover,	using	fluorescent	‘confetti’	reporter	alleles	for	lineage	tracing	in	
mouse	models	of	tumourigenesis,	it	has	been	demonstrated	that	Lgr5+	cells	marked	
a	subpopulation	of	intestinal	adenoma	cells	capable	of	propagating	adenomas	
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composed	of	cells	organised	in	a	hierarchy,	containing	Lgr5+	positive	cells	as	well	as	
different	cell	types	(Snippert	et	al.	2014).		
	
Under	the	assumption	that	a	population	of	slowly	dividing	CSCs	maintains	tumour	
growth,	from	a	clinical	perspective,	successful	ablation	of	a	tumour	would	require	
the	removal	of	this	cell	population,	as	depicted	in	Figure	1.9.	Chemotherapeutic	
agents	that	target	rapidly	dividing	cells,	in	theory,	are	therefore	more	likely	to	induce	
cytotoxic	effects	upon	bulk	tumour	cells,	enabling	slowly	dividing	CSCs	to	repopulate	
the	tumour	and	confer	relapse	potential.	Studies	have	identified	a	correlation	
between	recurrent	colorectal	tumours	and	a	high	level	of	stem	cell	marker	
expression	(Merlos-Suárez	et	al.	2011).	CSC-mediated	resistance	has	also	been	
increasingly	evident	in	the	literature,	with	many	studies	identifying	CSC	specific	
resistance	mechanisms	such	as	DNA	damage	repair	and	acquisition	of	drug	
transporters	to	efflux	a	cytotoxic	agent	from	the	cell	(Visvader	and	Lindeman	2008).		
	
Targeting	CSCs	is	therefore	becoming	an	attractive	target	for	treatment,	however,	it	
presents	difficulties:	markers	that	exclusively	identify	CSCs	remain	to	be	ascertained,	
and	their	overlap	with	ISC	markers	could	present	as	damage	to	normal	tissue			
(Zeilstra	et	al.	2008).	However,	the	very	fact	that	ISC	and	CSCs	from	the	same	tissue	
of	origin	are	highly	interlinked	in	terms	of	molecular	signals	provides	prospective	
targets	for	therapy.	Pathways	that	maintain	ISC	populations,	such	as	the	Wnt	
signalling	cascade,	are	frequently	activated	in	CSCs	originating	from	the	same	tissue,	
and	Wnt	activity	has	been	shown	to	define	colonic	CSCs	in	vitro	(Vermeulen	et	al.	
2010).	Hence,	alteration	of	Wnt	signalling	dynamics	is	an	attractive	therapeutic	
target	to	eliminate	a	prospective	CSC	population	in	CRC.	
	
	 39	
	
	
	
	
Figure	1.9	The	Cancer	stem	cell	hypothesis	
Targeting	Cancer	stem	cells	(CSCs)	is	becoming	an	attractive	therapeutic	strategy.	Cancer	stem	cells	
could	potentially	repopulate	a	tumour,	therefore	targeting	cancer	stem	cells	could	ablate	tumour	
cells.		
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1.6.2 Targeting	the	Wnt	signalling	pathway	as	a	therapeutic	strategy	for	CRC	
	
Aberrant	Wnt	signalling	is	strongly	associated	with	both	sporadic	and	hereditary	
forms	of	CRC	initiation	and	development.	Wnt	signalling	is	best	regarded	as	a	whole	
network	as	opposed	to	a	strict	linear	cascade,	and	due	to	such	complexity,	
alterations	within	multiple	components	of	the	pathway	can	modulate	Wnt	signalling.	
In	a	recent	study	whereby	a	sample	of	patient	tumours	were	sequenced,	it	was	
found	that	93%	contained	Wnt	signalling	pathway	alterations,	with	a	high	frequency	
harbouring	mutations	in	the	genes	APC	and	CTNNB1	(ß-catenin	encoding).	Despite	
the	subsequent	accumulation	of	multiple	mutations	that	further	drive	CRC	
progression,	Wnt	activation	maintenance	appears	to	be	a	continued	requirement	for	
cell	survival.	Inducible	short	hairpin	RNA	(shRNA)-	mediated	silencing	and	
reactivation	of	APC	within	transgenic	mice	was	recently	shown	to	reverse	intestinal	
hyperproliferation,	even	in	the	presence	of	KRAS	and	p53	mutations,	suggesting	that	
APC	loss	has	a	role	in	tumour	maintenance	(Dow	et	al.	2015;	de	Sousa	and	
Vermeulen	2016).		
	
Furthermore,	the	role	of	Wnt	signalling	and	maintenance	of	CSCs	in	the	intestine	is	
becoming	more	apparent	in	the	literature,	with	a	growing	number	of	studies	
supporting	the	notion	that	CRC	cells	with	stem-like	features	are	characterised	by	
high	Wnt	activity	(de	Sousa	and	Vermeulen	2016).	Using	a	Wnt	reporter	construct	in	
human	CRC	cell	lines,	Vermeulen	et	al.	demonstrated	that	Wnt	signalling	activity	not	
only	marks	a	hierarchical	subset	of	colon	cancer	cells	with	stem-like	characteristics,	
but	is	a	target	pathway	for	further	modulation	by	secreted	factors	within	the	
microenvironment,	suggesting	that	CSCs	retain	some	levels	of	plasticity	(Vermeulen	
et	al.	2010;	de	Sousa	and	Vermeulen	2016).		
	
Inhibition	of	the	Wnt	signalling	pathway	has	therefore	been	postulated	as	a	
prospective	therapeutic	strategy.		The	diversity	of	the	Wnt	pathway	mutation	
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spectrum	means	that	aberrant	Wnt	activation	is	not	necessarily	confined	to	a	single	
mutation,	making	it	difficult	to	bypass	multiple	components	of	the	pathway	that	can	
compensate	for	inhibitory	effects.	Although	mutations	may	be	distinct,	they	
ultimately	lead	to	ß-catenin	led	transcription	of	key	Wnt	related	genes	(de	Sousa	and	
Vermeulen	2016)	and	thus	intervention	can	occur	at	multiple	levels.		
	
Efforts	have	therefore	been	made	in	recent	years	to	target	Wnt	signalling	at	the	
various	levels	within	the	pathway;	from	the	Wnt	ligand,	to	downstream	proteins	that	
influence	Wnt-related	gene	expression	(Novellasdemunt	et	al.	2015).	One	such	class	
of	components	that	have	shown	promise	as	a	valid	inhibitor	of	the	Wnt	signalling	
cascade	are	inhibitors	of	tankyrases	1	(TNKS1)	and/or	TNKS2	activity,	which	have	
been	shown	modulate	the	concentration-limiting	component	of	the	ß-catenin	
destruction	complex,	Axin.	The	TNKS	inhibitor	XAV939,	originally	reported	by	Huang	
et	al,	was	shown	to	inhibit	ß-catenin	mediated	transcription	(Huang	et	al.	2009)	and	
has	been	further	shown	to	promote	Axin	stability,	inhibiting	Wnt	signalling	in	a	ß-
catenin	dependent	manner	in	APC-mutant	CRC	cell	lines	(Wu	et	al.	2016).	Reduced	
growth	is	accompanied	by	reduced	stemness	and	induced	differentiation,	further	
highlighting	the	importance	of	Wnt	signalling	in	CSCs.		Multiple	analogues	of	
tankyrase	inhibitors	have	since	been	reported	in	the	literature;	JW55,	HW67,	JW64,	
G007-LK	and	G244-LM	and	have	reported	to	reduce	the	growth	of	APC	mutant	CRC	
tissue	in	xenograft	models	(Waaler	et	al.,	2012;	Lau	et	al.	2013).		
	
Given	that	the	Wnt	signalling	cascade	has	a	critical	role	in	homeostasis	of	multiple	
organ	systems,	not	limited	to	the	intestine,	side	effects	may	be	anticipated.	
Tankyrase	inhibitors	administered	to	mice	have	also	been	reported	to	induce	
epithelial	degeneration	and	inflammation;	however,	such	side	effects	were	
reversible,	highlighting	the	key	balance	of	Wnt	signalling	activity	(Zhong	et	al.	2015).	
Targeting	such	a	crucial	signalling	cascade	therefore	requires	the	identification	of	
context-specific	therapeutic	windows	that	ensure	minimal	side	effects	while	
maximising	on-target	activity.	Furthermore,	the	transition	of	such	compounds	to	the	
clinic,	relies	on	extensive	pre-clinical	studies	within	relevant	models	to	investigate	
the	effects.		
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1.7 Pre-clinical	models	of	CRC	for	translational	research	
1.7.1 In	vivo	models:	Mouse-	and	Patient	Derived	Xenografts	
	
Pre-clinical	studies	using	xenograft	models	have	successfully	overcome	some	
limitations	presented	by	cell	lines,	providing	an	approach	to	study	tumour	
development	and	interactions	with	surrounding	environment	in	vivo.	Immuno-
deficient	mice	that	are	injected	subcutaneously	with	culture-adapted	tumour	cell	
lines	successfully	generate	tumours	and	have	been	of	therapeutic	value.	However,	
studies	have	also	demonstrated	that	xenografts	rarely	exhibit	clinically	relevant	drug	
profiles	with	patients	with	pathologically	equivalent	tumour	and	hence	do	not	
correlate	with	Phase	II	clinical	trial	outcomes	(Voskoglou-nomikos	et	al.	2003).		
	
Patient	derived	tumour	xenografts	(PDTXs)	are	generated	by	the	implantation	of	
resected	human	tumour	material	into	immuno-compromised	mice,	and	have	proved	
to	show	clinical	relevance	to	primary	tumours.	A	recent	study	demonstrated	the	
potential	of	PDTXs	as	a	valid	preclinical	model	of	CRC,	as	patients	were	treated	
according	to	successful	drug	responses	of	their	xenograft	counterparts.	A	close	
correlation	was	found	between	drug	screens	on	mice	and	clinical	patient	outcome,	in	
terms	of	drug	resistance	and	sensitivity	(Hidalgo	et	al.	2011).	Furthermore,	PDTXs	
have	also	shown	promise	to	retain	tumour	heterogeneity	of	human	colorectal	cancer	
within	molecular	studies,	as	well	as	general	histopathological	features	(Julien	et	al.	
2012b).	The	translational	relevance	of	PDTX	models	have	recently	been	studied	in	
the	context	of	targeted	therapies,	whereby	a	comparison	between	molecular	data	
gathered	from	PDTX	models	and	those	previously	published	for	patient	tumours	in	
the	Cancer	Genome	Atlas	Study	showed	a	similar	trend	in	genomic	alteration	
frequencies	as	well	as	generating	responses	to	cetuximab	(EGFR	inhibitor)	
representative	of	clinical	data	from	patients	which	responses	observed	in	KRAS	wild	
type	models	only	(Nunes	et	al.	2015;	Bertotti	et	al.	2016).		
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Despite	emerging	evidence	that	PDTXs	have	the	potential	to	serve	as	relevant	modes	
that	more	closely	resemble	the	original	tumour	in	comparison	to	established	cell	
lines,	multiple	caveats	need	to	be	considered	(Siolas	and	Hannon	2013).		
	
Firstly,	on	a	practical	level,	establishment	of	PDTX	models	can	vary	from	one	tumour	
to	the	next,	with	variable	rates	of	engraftment,	ranging	from	a	latency	period	of	2	to	
12	months	until	a	tumour	is	established	(Siolas	and	Hannon	2013),	if	at	all,	which	
could	pose	a	problem	in	the	development	of	avatar	models	that	are	designed	to	
mimic	patient	responses.	Furthermore,	the	need	for	rigorous	preclinical	testing	
involves	a	high	number	of	mice	usage	and	associated	costs,	which	in	turn	limits	large	
scale	studies	such	as	multiple	drug	combinations.	Recent	attempts	have	been	made	
towards	moving	PDTX	models	towards	a	high-throughput	screening	platform.	Gao	et	
al	(2015)	reported	the	generation	of	1000	extensively	characterised	PDTX	models	
from	a	range	of	different	cancer	types	and	subsequently	showed	a	relevant	clinical	
translation,	performing	a	‘one	animal	per	model	treatment’	approach	(Gao	et	al.	
2015).	However,	given	that	the	genomic	landscape	is	more	representative	at	a	
population	level	as	opposed	to	a	personalized	medicine	setting,	this	approach	has	
limitations	in	sufficiently	representing	individual	tumour	heterogeneity	(Gao	et	al.	
2015).		
	
As	well	as	logistical	problems,	the	host	mice	need	to	be	immunocompromised	to	
circumvent	xenograft	rejection,	resulting	in	a	loss	of	interaction	between	tumour	
and	immunological	component.	Not	only	does	this	hamper	examining	the	stromal	
effects	upon	a	given	tumour	interactions	(Sachs	and	Clevers	2014),	but	also	excludes	
assessment	of	immunotherapeutic	agents	on	a	given	PDTX	model.	In	terms	of	high	
throughput	screening,	despite	the	relevance	of	PDTX	to	patient	tumours,	such	
models	are	not	yet	able	to	replace	pre	clinical	data	from	in	vitro	studies	(Sachs	and	
Clevers	2014).	Alternative	strategies	would	therefore	need	to	be	explored	to	relieve	
experimental	burden,	such	as	the	use	of	in	vitro	models	to	carry	out	large	scale	
pharmacogenomics	screens	(Byrne	et	al.	2017).		
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1.7.2 2D	Culture	of	primary	tumour	material	
	
The	culture	of	primary	material	from	the	large	intestine	has	proved	challenging	due	
to	the	finite	lifespan	of	colonic	epithelial	cells;	cell	viability	is	often	compromised	as	
isolated	primary	cells	frequently	undergo	apoptosis	as	a	result	of	separation	from	
respective	connective	tissue	and	transfer	to	plastic	(Hofmann	et	al.	2007).	Studies	
have	shown	that	growth	of	primary	cells	from	intact	crypts	and	grown	on	
extracellular-matrix	coated	dishes	is	limited	to	24	hours	in	culture	(Wilhelm	et	al.	
2012).	An	approach	which	has	been	favoured	is	the	short	term	culture	of	tumour	
sections,	such	as	those	described	by	Centenera	et	al.	2012,	showing	the	ex	vivo	
culture	of	human	primary	prostate	tissue	which	can	be	implemented	into	short	term	
assessments	of	drug	sensitivities	(Centenera	et	al.	2012).		However,	primary	2D	
cultures	ultimately	fail	to	accurately	resemble	tissue-specific	features	such	as	cell	
differentiation,	gene	expression	and	cell-to-cell	contact	that	result	in	a	limited	life	
span.		
	
Some	recent	approaches	have	investigated	the	isolation	of	stem-like	cells	from	
primary	tissues,	whereby	cultures	were	propagated	from	primary	tumour	material	in	
suspension,	and	then	transferred	to	an	extracellular	matrix	substitute	(Matrigel).	
Only	in	the	presence	of	matrigel	were	the	cells	able	to	differentiate	(Ashley	et	al.	
2014).	However,	despite	positively	expressing	markers	relevant	to	CRCs,	a	large	
proportion	of	isolated	cells	were	necrotic,	containing	a	number	of	cystic	structures	
that	were	unviable	after	extensive	expansion.		Continuous	cultures	within	these	
systems	are	therefore	yet	to	show	suitability	towards	long-term	studies.	(Ashley	et	
al.	2014).		
1.7.3 Generation	and	culture	of	cell	lines	in	2D	and	3D		
	
The	applications	of	cell-based	assays	using	2D	immortalised	clonal	cell	lines	have	
been	a	mainstay	of	biological	investigation	of	many	cancers,	including	CRC.	
Immortalised	2D	cell	lines	are	traditionally	grown	in	a	monolayer	of	homogeneous	
cells,	whereby	mainly	proliferating	cells	stretch	to	adhere	to	a	flat	surface.	Overall,	
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such	cultures	are	relatively	easy	to	propagate	and	maintain	in	culture.	Furthermore,	
the	array	of	cancer	cell	lines	available	not	only	constitutes	a	resource	that	is	useful	to	
both	delineate	molecular	mechanisms	involved	in	tumourigenesis	and	drug	
screening,	but	have	also	shown	partial	representation	of	genetic	backgrounds	of	
primary	tissue	enabling	screening	on	multiple	cell	types	(Mouradov	et	al.	2014).	Next	
generation	sequencing	methods	have	enabled	extensive	genomic,	epigenetic	and	
transcriptomic	characterisation	of	a	library	of	cancer	cell	lines,	thus	providing	a	
useful	resource	for	biological	and	therapeutic	readouts	(Garnett	and	Mcdermott	
2014).		
	
Nonetheless,	it	has	long	been	recognised	that	2D	cell	lines	are	unable	to	faithfully	
recapitulate	specific	aspects	of	cancer	biology	and	therefore	not	necessarily	a	fully	
relevant	model	system	for	CRC.	Of	the	10%	of	compounds	that	enter	clinical	
development	based	on	pre-clinical	studies	in	2D	cell	lines	and	subsequent	testing	in	
animals,	a	huge	contribution	of	drugs	fail	at	later	phases	and	this	is	largely	attributed	
to	pre-clinical	testing,	whereby	2D	cell	lines	do	not	reflect	clinical	efficacy	(Breslin	
and	O’Driscoll	2013;	Edmondson	et	al.	2014).	Findings	from	2D	culture	conditions	of	
cell	lines	therefore	have	a	limited	translation	to	expected	outcomes	in	vivo,	and	
could	not	only	generate	false	positive	results	that	generate	little	therapeutic	benefit	
for	patients	(Crockford	et	al.	2013)	but	also	miss	potential	promising	candidates	in	
drug	screenings.	
	
The	disparity	between	cell	lines	in	2D	and	counterpart	tumours	a	due	to	a	number	of	
factors.	Firstly,	the	monolayer	culture	of	clonal	cells	fails	to	represent	the	tumour	
environment,	such	that	oxygen	and	nutrients	perfuse	equally,	which	fails	to	capture	
cellular	reprogramming	typically	observed	within	subpopulations	of	tumour	cells	to	
enhance	an	either	hypoxic	or	aerobic	metabolic	profile	(Hanahan	and	Weinberg	
2011).	Morphologically,	cells	grown	in	this	way	are	also	unable	to	establish	cell-to-
cell	contacts,	and	thus	critical	cell	signalling	elements	of	a	tumour.	A	representation	
of	the	heterogeneous	nature	of	CRC	is	also	compromised	in	such	cultures.	The	
generation	of	cell	lines	from	solid	tumours	rarely	generates	a	high	yield	of	viable	cells	
as	they	often	fail	to	adapt	to	the	in	vitro	environment,	and	as	a	result	become	mostly	
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clonal,	and	potentially	lose	the	ability	to	differentiate	into	different	cell	types	(Sachs	
and	Clevers	2014;	Hongisto	et	al.	2013).		As	2D	cell	lines	only	represent	a	subtype	of	
cells,	this	would	result	in	some	bias	and	not	necessarily	a	full	representation	of	how	
the	tumour	bulk	would	respond	to	treatment.	A	large	number	of	cell	lines	would	
therefore	be	required	to	capture	the	genetic	diversity	of	a	single	tumour.		
	
In	order	to	translate	in	vitro	CRC	studies	towards	a	more	relevant	in	vivo	tumour	
situation,	attempts	to	transition	2D	cell	lines	to	a	3D	system	have	been	reported	in	
the	literature.	These	include	suspended	cell	aggregates	or	3D	spheroids	embedded	
within	a	matrix	such	as	laminin-rich	matrigel,	to	promote	relevant	cell	signalling	and	
tissue	architecture.		Such	structures	have	demonstrated	that	distinct	spheroid	
morphologies	are	cell	line	dependent.	A	study	by	Luca	et	al	demonstrated	that	
culturing	an	array	of	2D	CRC	cell	lines	influenced	morphology	of	spheroids,	that	did	
not	necessarily	correlate	with	migratory	or	proliferative	capacity	(Luca	et	al.	2013).	
Some	CRC	lines	have	been	shown	to	form	grape-like	clusters	in	culture,	whereas	
others	have	the	capacity	to	form	polarised	cells	surrounding	a	central	lumen	
representative	of	the	intestinal	in	vivo	architecture.	Such	structures	have	the	
capacity	to	differentiate	into	enterocyte,	enteroendocrine	and	goblet	cell	lineages	
expressing	limited	intestinal	differentiation	markers	such	as	Villin	and	stem	cell	
markers	such	as	CD44	(Yeung	et	al.	2010).	However,	given	that	only	a	subset	of	cell	
lines	can	form	such	structures,	there	are	limitations	as	to	how	many	different	
tumour	types	this	could	indeed	resemble.		
	
Interestingly,	an	overall	differential	response	between	drug	sensitivities	and	gene	
expression	of	the	same	lines	grown	in	2D	and	3D	have	been	reported	in	the	
literature	(Karlsson	et	al.	2012;	Luca	et	al.	2013).	For	both	drug	discovery,	and	
biomarker	driven	therapeutic	pre-clinical	studies,	2D	cell	lines	have	classically	been	
utilised	to	facilitate	high	throughput	drug	assays	due	to	their	ease	of	expansion	
maintenance	in	culture.	The	definitive	in	vitro	model	would	ideally	combine	features	
from	such	systems	to	fully	recapitulate	patient	tumours;	to	maintain	tissue	specific	
structure	whilst	maintaining	relevant	cell	signalling,	have	the	capacity	to	retain	
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several	cell	lineages	as	well	retaining	relevance	in	large	scale	studies	for	preclinical	
data	acquisition.		
1.8 Organoid	culture	as	a	pre-clinical	model	system	
1.8.1 	 Development	of	the	organoid	model	
	
Attempts	to	further	translate	in	vivo	biology	to	3D	in	vitro	culture	from	primary	
material	have	widely	been	reported	in	the	literature	over	a	number	of	decades,	
following	observations	that	2D	cell	lines	are	a	less	than	ideal	surrogate	to	study	
tissue-specific	systems.	The	use	of	floating	collagen	gels	and	hanging	drop	cell	
culture	methods	to	facilitate	3D	structure	formation,	to	name	a	few	examples,	have	
aimed	to	develop	models	more	representative	of	the	in	vivo	situation,	in	the	form	of	
general	‘organoid’	systems,	with	the	most	recent	advances	and	new	definitions	
within	the	field	discussed	here.		
	
An	organoid,	at	simplest,	is	defined	as	a	structure	resembling	the	organ	from	which	it	
is	derived.	More	specifically,	an	organoid	is	considered	as	a	structure	grown	in	3D,	
originating	from	stem	cells,	which	consist	of	organ-specific	cell	types	that	self-
organize	and	are	capable	of	continuous	expansion	in	vitro	(Simian	and	Bissell	2016;	
Clevers	2016).	The	earliest	attempts	at	culturing	intestinal	organoids	from	primary	
material	were	presented	by	Evans	et	al	(1992)	where	they	described	the	generation	
and	growth	of	3D	organoids	from	rat	intestinal	tissue	(Evans	et	al.	1992).	Despite	
providing	a	system	that	was	more	functionally	capable	of	resembling	the	intestine	
compared	to	immortalised	cell	lines,	the	transient	nature	of	the	Intestinal	stem	cells	
resulted	in	cultures	failing	to	survive	beyond	1	month.	The	stem-cell	containing	
organoid	culture	system	was	defined	in	a	landmark	study	by	Toshiro	Sato	and	Hans	
Clevers	(2009),	whereby	a	robust	methodology	was	revealed	to	develop	organoids	
that	not	only	recapitulated	murine	intestinal	crypt	physiology,	but	promoted	the	
successful	expansion	of	a	stem	cell	compartment,	including	Lgr5+	stem	cells,	
propagating	their	renewal	and	long	term	culture	(Sato	et	al.	2009).	Stem-cell	
containing	organoids	differ	hugely	from	their	equivalent	predecessors	cultured	from	
primary	material.	Firstly,	on	a	cellular	level,	they	are	composed	of	both	stem	cells,	
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derived	from	the	tissue	of	origin	that	facilitate	long	term	culture,	as	well	as	the	
capacity	to	differentiate	into	several	epithelial	lineages,	capable	of	recapitulating	
relevant	cell	signalling	(Yin	et	al.	2013).	Structurally,	stem-cell	containing	organoids	
contain	cells	in	an	organ-specific	architecture,	encompassing	physiological	
characteristics,	such	as	intestinal	organoids	that	contain	crypt-like	structures	
surrounding	a	central	‘lumen’with	appropriate	cell	polarity.	Such	spatial	organisation	
of	cell	surface	receptors	engaged	in	interactions	with	surrounding	cells	in	turn	
influence		signal	transduction	from	neighbouring	cells,	influencing	overall	cell	
behaviour	(Edmondson	et	al.	2014).		
	
The	sustainable	growth	of	such	structures	without	a	stroma	were	established	in	the	
form	of	a	3D	matrigel-based	laminin-rich	model	to	support	growth	of	intestinal	
crypts	or	FAC-sorted	Lgr5+	intestinal	epithelium	stem	cells,	and	intricate	growth	
conditions	to	mimic	the	environment	of	the	intestinal	epithelium	(Sato	et	al.	2009).	
The	manipulation	of	highly	conserved	signalling	pathways,	implicated	in	regulating	
the	hierarchy	of	intestinal	cell	renewal	in	the	intestine,	by	addition	of	relevant	
growth	factor	supplements	within	culture	media	was	found	to	be	critical	to	support	
organoid	propagation	and	proliferation.	The	control	of	the	Wnt	signalling,	a	key	
component	in	the	maintenance	of	crypt	proliferation	and	maintenance	of	the	
intestinal	stem	cell	niche	(Pinto	et	al.	2003;	Kuhnert	et	al.	2004)	was	found	to	be	
pivotal	in	maintaining	intestinal	organoid	self-renewal	(Sato	et	al.	2009;	Ootani	et	al.	
2009).	The	addition	of	R-spondin	within	growth	media	further	potentiated	the	
activation	of	the	Wnt	signalling	pathway	within	cells,	recapitulating	conditions	found	
within	the	intestinal	stem	cell	niche.	Wnt	signalling	activation	was	further	found	to	
be	critical	for	organoid	generation	and	proliferation	in	a	concentration-dependent	
manner	(de	Lau	et	al.	2011;	Sato	et	al.	2009).	The	inhibition	of	transforming	growth	
factor-	β	(TGF-β)	and	BMP	signalling,	previously	implicated	in	expansion	of	crypt	
numbers	(Haramis	et	al.	2004),	by	exogenous	addition	of	Noggin	in	media,	as	well	as	
the	inclusion	of	epidermal	growth	factor	(EGF)	for	proliferation	enhancement	were	
also	found	to	be	minimum	additional	components	required	to	sustain	long-term	
culture	of	crypts	(Sato	et	al.	2009).Further	studies	have	demonstrated	that	addition	
of	components	that	manipulate	Notch	signalling		can	specifically	induce	the	
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differentiation	of	intestinal	stem	cells	into	several	different	epithelial	cell	lineages,	
including	enterocytes	and	goblet	cells.	Subsequent	studies	have	identified	small	
molecules	to	manipulate	the	differentiation	capacity	and	lineages	of	intestinal	cells	
within	organoids,	further	emphasising	the	importance	of	the	organoid	environment	
for	sustained	growth	(Yin	et	al.	2013).	
	
These	conditions	were	further	adapted	to	culture	material	from	the	human	colon,	as	
well	as	colorectal	adenoma	and	adenocarcinoma	tissue	from	patient	biopsies	(Sato	
et	al.	2011a).	These	CRC	organoids	were	shown	to	grow	as	complex	irregular	
structures,	and	consisted	of	endocrine,	goblet	cells	and	highly	proliferative	cell	types	
(Sato	et	al.	2011a).	More	recent	studies	have	demonstrated	an	improved	genotypic	
resemblance	and	stability	within	organoids	which	are	thought	to	further	contribute	
to	represent	patient	populations	(Fujii	et	al.	2016a).	
	
Organoids	are	a	promising	model	to	further	study	aspects	of	both	normal	and	
tumour	biology	compared	to	previous	in	vitro	systems,	and	have	thus	far	
demonstrated	a	number	of	applications	from	different	tissues	such	as	liver,	
pancreas,	prostate	under	defined	culture	conditions	for	each	tissue.	An	advantage	of	
organoids	is	the	ability	to	produce	organoids	derived	from	patient	material,	either	
from	resected	surgical	tumours,	or	from	induced	pluripotent	stem	cells	(iPSCs)	
(Watson	et	al.	2014).	Overall,	the	utilities	of	such	a	culture	system	are	extensive;	
from	assessing	individual	cell	populations	and	interactions	implicated	within	tumour	
development,	to	their	capacity	to	be	utilised	for	large-scale	drug	screens.	
	
1.8.2 	 Translational	relevance	of	organoids	for	CRC	therapy;	analysis	of	2D	
lines	versus	3D	models	
	
Despite	the	advances	of	large	scale	in	vitro	assays	as	a	tool	to	assess	efficacies	of	
new	compounds	in	drug	discovery,	as	well	as	establishing	therapeutic	effects	of	
biomarker-driven	therapies	in	patients,	biologically	relevant	results	require	a	
platform	that	will	reflect	cell	responses	in	vivo	(Edmondson	et	al.	2014).	The	
advantages	of	3D	organoid	culture	in	terms	of	representative	tumour	heterogeneity,	
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spatial	cell	organisation,	and	retention	of	a	complement	of	stem	and	differentiated	
cell	types	to	facilitate	long	term	culture,	hold	promise	to	bridge	the	gap	between	
current	in	vitro	studies	and	in	vivo	data	for	oncological	drug	screens,	as	shown	in	
Figure	1.10.	However,	given	the	numerous	aspects	of	cell	biology	that	advanced	3D	
organoid	cultures	can	retain	in	comparison	to	preceding	2D	systems,	there	is	a	
requirement	for	suitable	techniques	that	are	capable	of	analysis	and	quantification	
of	relevant	features	within	complex	structures.		A	number	of	novel	methodologies,	
some	of	which	have	been	adapted	from	utility	in	2D	cell	lines,	have	become	more	
apparent	in	the	literature	to	facilitate	the	transition	of	organoids	to	a	more	high	
throughput	platform	(Li	et	al.	2015;	Di,	Klop,	Rogkoti,	Devedec,	Water	van	de,	et	al.	
2014;	Edmondson	et	al.	2014).		
	
	The	use	of	metabolic	assays	as	a	quantifiable	readout	of	drug-induced	effects	in	the	
form	of	fluorescent	or	luminescent	based	measurements	have	been	well	established	
for	2D	systems,	and	have	been	somewhat	adapted	further	for	utility	in	3D	cultures.		
Quantifiable	assays	such	as	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium	
bromide	(MTT)	staining,	whereby	MTT	is	converted	to	a	measurable	form	in	the	
presence	of	viable	cells	and	subsequently	quantified	by	absorbance	measurements,	
have	been	utilised	in	mouse	organoids	to	assess	drug-induced	toxicity	(Grabinger	et	
al.	2014).		However,	as	measurements	of	MTT	absorbance	relies	on	lysis	of	cells	in	
DMSO	to	solubilize	formazan	crystals,	an	additional	step	to	solubilise	matrigel	was	
required	to	facilitate	measurements.	Whilst	this	demonstrated	a	successful	
application	of	MTT	in	this	format,	such	adjustments	are	not	necessarily	compatible	
for	high	throughput	measurements	(Young	and	Reed	2016).	
	
Commercially	available	end	point	assays	have	also	been	utilised	to	test	drug	
responses	within	3D	systems,	such	as	the	luciferase	based	Cell-Titer	Glo	assay	
(Promega),	an	end-point	assay	that	quantifies	relative	ATP	levels	within	samples.	In	a	
recent	study,	this	assay	was	utilised	to	assess	the	effects	of	a	titration	of	a	panel	of	
83	compounds	upon	a	biobank	of	patient-derived	organoids	(Wetering	et	al.,	2015).	
Whilst	responses	were	relatively	reproducible,	assay	noise	was	observed	in	some	
individual	experiments,	most	likely	as	a	result	of	variability	in	organoid	numbers	and	
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sizes	between	and	across	assays.	Quantifiable	detection	of	compounds	with	subtler	
effects,	other	than	cytotoxicity,	was	also	found	to	be	more	challenging	in	terms	of	
generating	reproducible	readouts.	Such	studies	also	highlight	the	need	for	
standardised	protocols	for	the	effective	scale-up	of	organoids),	enabling	them	to	be	
generated	from	little	resected	patient	material	to	facilitate	a	rapid	transition	to	
reproducible,	robust	and	more	high	throughput	assay	formats.	Furthermore,	there	is	
a	need	to	determine	the	relevance	of	organoids	to	reflect	patient	responses.	
	
The	structural	organisation	and	cellular	composition	of	organoids,	whilst	improving	
biological	relevance	compared	to	2D	cell	lines,	introduces	many	challenges	for	their	
use	in	image	analysis	methods	to	facilitate	robust	and	sensitive	detection	
measurements(Edmondson	et	al.	2014).	Assessing	changes	in	cellular	morphology	
using	light	microscopy,	facilitates	basic	morphometric	measurements	such	as	overall	
number	of	structures	and	diameters,	at	multiple	points	in	culture,	is	frequently	
limited	to	one	plane	of	view,	restricting	quantifiable	parameters	(Grabinger	et	al.	
2014).	In	recent	years,	a	paradigm	shift	in	3D	tumour	models	has	pushed	
technologies	towards	more	sophisticated	phenotypic	screening	methods	compatible	
with	high	throughput	technology	(Li	et	al.	2016;	Sandercock	et	al.	2015),	
incorporating	appropriate	immunofluorescent	staining	protocols	for	confocal	
imaging,	as	well	as	analysis	software	capable	of	measuring	numerous	morphometric	
parameters	of	3D	structures,	to	further	capture	subtle	effects	of	drug-induced	
phenotypes	(Sandercock	et	al.	2015;	Di	et	al.	2014).			
	
The	structural	and	biological	complexity	of	3D	organoids	compared	to	preceding	in	
vitro	models	therefore	introduces	many	challenges	for	their	use	in	large-scale	
screens,	where	reproducible,	robust	and	sensitive	detection	methods	are	critical.	
Before	organoids	can	therefore	be	established	as	a	sufficient	model	system,	there	is	
a	need	to	explore	their	relevance	to	current	clinical	applications	as	well	as	novel	drug	
discovery.	
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Figure	1.10	2D	versus	3D	culture	from	normal,	adenoma	and	adenocarcinoma	cells.	
For	2D	cell	line	culture,	cells	often	undergo	many	changes	to	adapt	to	proliferating	on	plastic.	Growing	cells	in	the	3D	environment	that	is	more	physiologically	relevant	
enables	long	term	culture	of	normal,	adenoma	and	adenocarcinoma	cells	from	the	intestine.	Image	adapted	from	Sachs	and	Clevers	(2014).
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1.9 Project	aims	and	objectives	
	
The	understanding	of	complex	mutational	landscapes	that	confer	drug	sensitivity	is	
fundamental	to	identify	suitable	therapeutic	agents	for	CRC	patients.	However,	the	
identification	of	biomarker-driven	therapeutics	based	upon	genomic	analyses	of	a	
tumour	does	not	necessarily	correlate	with	an	inhibitory	effect	upon	tumour	growth,	
and	thus	lacks	predictive	power	in	the	clinic.	An	understanding	of	the	functionality	of	
genomic	alterations	and	their	influence	upon	treatment	responses	remains	limited	
due	to	a	lack	of	preclinical	models	that	can	fully	recapitulate	tumour	responses	to	
therapy.	The	need	for	such	a	model	system	is	therefore	imperative	to	understand	
mechanistic	effects	of	biomarker-driven	treatments	in	patients,	as	well	as	to	indicate	
potential	novel	targets	for	the	treatment	of	CRC.	Consequently,	the	overarching	aim	
of	this	thesis	is	to	assess	whether	patient	derived	CRC	organoids	are	suitable	models,	
capable	of	generating	functional	readouts	for	precision	oncology	as	well	as	the	drug	
discovery	pipeline.	To	address	this,	the	results	chapters	presented	herein	are	
comprised	of	three	distinct	aims.			
	
The	first	aim	of	this	thesis,	discussed	in	Chapter	3,	was	to	develop	and	optimise	
suitable	methodologies	to	facilitate	the	expansion	of	novel	CRC	patient-derived	
organoids,	representative	of	clinically	relevant	tumour	subtypes,	towards	a	
functional,	robust	and	reproducible	assay	system	that	could	be	exploited	for	
subsequent	studies.		
	
This	thesis	also	aimed	to	evaluate	the	efficacy	of	organoids	as	a	functional	readout	
for	biomarker-driven	therapies	in	the	context	of	a	clinical	trial	for	CRC,	to	explore		
their	potential	as	matched	models	of	patient	responses	to	therapy.	To	address	this,	
organoids	were	used	within	a	purely	“in	vitro	clinical	trial”	setting,	whereby	drug	
sensitivity	profiles	of	a	cohort	of	organoids	were	generated	to	mirror	compounds	
administered	to	patients	within	the	stratified	arms	of	the	FOCUS	4	clinical	trial.		
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The	final	key	objective	of	this	thesis	was	to	ascertain	the	role	of	organoids	as	a	
suitable	pre-clinical	model	system	within	the	drug	discovery	pipeline.	To	facilitate	
this,	novel	Wnt	signalling	inhibitors	(Merck	Serono)	were	utilised	to	evaluate	
treatment-specific	responses	of	organoids	and	potential	effects	on	prospective	CSC	
populations,	enhancing	the	premise	of	organoids	as	tools	to	study	effects	of	
therapeutic	agents	that	target	complex	signalling	networks.	
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2 Materials	and	Methods	
2.1 Processing	of	Primary	material	
2.1.1 Human	Tissue	
	
All	samples	from	our	full	patient	cohort	were	provided	by	the	Wales	Cancer	Bank	
(WCB,	University	Hospital	of	Wales)	with	informed	consent.	All	patient	derived	
material	was	treated	in	concordance	with	the	Human	Tissue	Act	(HTA),	and	any	
patient	derived	samples	provided	remain	anonymous.		All	samples	provided	from	
patient	material	were	assigned	a	number	(‘isolation	x’)	for	our	internal	records,	and	
could	be	traced	to	an	I.D	number	from	the	WCB.		Any	waste	material	generated	as	
part	of	the	isolation	process	was	disposed	of	in	compliance	with	the	HTA.		
2.1.2 Processing	of	human	material	
Following	surgical	resection,	a	sample	each	of	tumour	and	surrounding	healthy	
tissue	of	approximately	30mm	-150mm	in	diameter	of	the	colonic	epithelium	were	
obtained	and	stored	at	4°C	in	Hibernate	A	(Invitrogen)	prior	to	processing.	Samples	
were	stored	for	minimal	time,	typically	between	1	and	12	hours,	and	only	isolated	if	
stored	within	optimal	conditions	(i.e	stored	in	Hibernate	A	medium).	Isolation	of	
both	normal	crypts,	and	tumour	cell	fragments	were	performed	in	parallel.	In	some	
cases	within	our	subset,	a	‘methylene	blue’	stain	was	applied	to	our	samples	prior	to	
histopathological	inspection.		
2.1.2.1 Dissection	of	intestinal	epithelium	
Human	tissue	was	processed	as	described	by	Sato	et	al	(2011).	Briefly,	carcinoma	
samples	were	placed	within	storage	media	within	a	petri	dish	and	dissected	to	
remove	connective	tissue,	then	further	dissected	into	pieces	approximately	2mm	in	
diameter.	
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2.1.2.2 Enzymatic	digestion	and	chelation	
Following	dissection,	tumour	tissue	was	placed	in	respective	50ml	falcon	tubes	and	
subjected	to	multiple	washes	in	Phosphate	Buffered	Saline	(PBS,	Invitrogen)	at	room	
temperature	until	their	surrounding	suspension	solution	was	clear.	Following	
washes,	pieces	of	carcinoma	epithelium	were	incubated	in	enzyme	digestion	buffer	
(DMEM	containing	2.5%	Foetal	Bovine	Serum	(FBS),	1%	Penicillin/Streptomycin	
,125μg/ml	Dispase	(all	Invitrogen),1mg/ml		Collagenase	from	Clostridium	
histolyticum	(Sigma))at	37°C	for	30	minutes.	After	incubation,	enzyme	digestion	
buffer	was	removed,	and	tissue	was	triturated	in	PBS	at	room	temperature	to	
remove	fragments	of	cells.	Supernatants	generated	in	processing	both	normal	and	
carcinoma	tissue	were	collected	into	50ml	Falcon	tubes	coated	with	FBS.	The	process	
was	repeated	approximately	three	times	to	isolate	all	cell	fragments	from	tissue.	
	
2.1.2.3 Isolation	of	tumour	cells	
Following	trituration	and	isolation	of	cells,	supernatants	collected	intestinal	were	
centrifuged	at	4°C	for	5	minutes	at	800	RPM.		After	removal	of	supernatants,	the	
pellets	were	resuspended	in	basal	‘3+’	media	(Advanced	DMEM	F12	(Invitrogen)	with	
1%	GlutaMAX	(Invitrogen),	1%	HEPES	buffer	solution	(Invitrogen)	and	1%	Penicillin/	
Streptomycin)	and	then	filtered	(70	μm)	to	separate	cell	clusters.	Isolated	carcinoma	
fragments	from	colonic	epithelium	were	then	counted	and	resuspended	in	desired	
volume	of	growth	factor	reduced	Matrigel	(BD	Biosciences)	to	contain	approximately	
1000	fragments	per	50μl	of	Matrigel.	50μl	droplets	of	Matrigel	was	then	seeded	onto	
pre-incubated	24	well	plates	(Nunc)	and	then	incubated	at	37°C	to	allow	full	
polymerisation	
	
2.2 Tumour	organoid	culture	
2.2.1 Generation	of	3D	organoids	
Culture	conditions	previously	reported	by	Sato	et	al.,	(2011)were	applied	to	cell	
fragments	in	polymerized	matrigel.	A	previous	study	by	Sato	et	al.	(2009)	reportedly	
screened	multiple	growth	factors	and	hormones	to	determine	the	essential	
requirements	of	efficient	plating	of	murine-derived	organoids,	then	furthermore	for	
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human	colonic	organoids.	Organoids	required	various	growth	factors	to	enhance	
proliferation.	In	addition	to	3+	basal	media,		B27	(1X	,Invitrogen)	,	N2	(1X,	
Invitrogen),		N-acetylcysteine	(1mM,	Sigma)	were	added.	Advanced	Wnt3a	condition	
media	(40%)	secreted	from	LWnt3a	cells	was	found	to	be	a	necessary	requirement	to	
maintain	proliferation,	in	addition	to	conditioned	R-spondin	(10%).	A	panel	of	
growth	factors	including	Epidermal	Growth	Factor	(50ng/ml,Peprotech),	Noggin	
(100ng/ml,	Peprotech)	were	found	to	be	essential	for	maintenance	of	culture.	
Nicotinamide	(10mM,	Sigma)	was	also	used	to	maintain	expansion	in	culture.	2	small	
molecule	modulators	of	mitogen-activated	protein	kinases	,	A83-01	(0.5μM,	Tocris)	
and	SB202190	(10μM,	Sigma)	improved	expansion	of	crypts.	This	‘Full’	media	was	
added	to	organoids	derived	from	healthy	colonic	epithelium.	
For	the	propagation	of	carcinoma	organoids,	it	was	found	that	organoids	had	an	
enhanced	survival	rate	when	culture	in	two	different	media	types	(	Table	2.1);	
(i) 7+	Media:	3+	media	with	B27	(1X	,Invitrogen)	,	N2	(1X,	Invitrogen),		N-
acetylcysteine	(1mM,	Sigma)	and	Fungizone	were	added		
(ii) ‘Full’	Media,	as	described	as	above	
The	Rho-associated	protein	kinase	(ROCK)	inhibitor	Y-27632	(10	μM,	R&D)	was	
included	in	both	Full	and	7+	plus	media	conditions	for	the	first	5	days	in	culture,	and	
for	the	first	3	days	after	organoid	passage.		
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Table	2.1	Table	denoting	components	required	for	7+	and	Full	media	conditions.	
	Asterisk	(*)	denotes	components	that	are	withdrawn	from	media;	fungizone	was	applied	on	
organoids	between	0-6	weeks	following	culture	to	limit	infections.	Y-27632	ROCK	inhibitor	was	
applied	for	first	5	days	following	isolation.	Underlined	components	are	requirements	for	3+	basal	
media.	Further	details	are	included	in	the	Appendix.		
	
Component	 Target/	purpose	 3+	
Media	
7+	
Media	
Full	
Media	
ADV-DMEM/F12	 	 1X	 1X	 1X	
Penicillin/Streptocymcin		 	 100	
U/ml	
100	
U/ml	
100	U/ml	
HEPES	(1M)	 	 10mM	 10mM	 10mM	
GlutaMAX	(100X)	 	 2mM	 2mM	 2mM	
N2	(100X)	 	 	 1X	 1X	
B27	(50X)	 	 	 1X	 1X	
N-acetylcysteine	 Anti-oxidant	 	 1mM	 1mM	
Epidermal	Growth	Factor	
(EGF)	
Epidermal	Growth	
Factor	Receptor	
	 	 50ng/ml	
Mouse	recombinant	
Noggin	
TGF-ß	modulator	 	 	 100ng/ml	
A-83-01	 Alk4/5/7	inhibitor	 	 	 500µM	
SB202190	 P38/MAP	kinase	
inhibitor	
	 	 10µM	
Wnt3A	conditioned	
medium	
Wnt	signalling	
activator	
	 	 40%	(v/v)	
R-spondin	conditioned	
medium	
Wnt	signalling	
enhancing	
	 	 10%	(v/v)	
Fungizone*	 Anti-fungal	agent	 	 2µl/ml	 2µl/ml	
Y-27632*	 ROCK	inhibitor	 	 10µM	 10µM	
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2.2.2 Routine	organoid	culture	maintenance		
2.2.2.1 	Organoid	passage	
Organoids	were	passaged	as	whole	colonies,	at	a	split	ratio	between	1:2-1:8	
approximately	every	two	weeks,	or	as	required.	Culture	medium	was	removed	from	
wells	and	replaced	with	fresh	basal	medium.	Organoids	embedded	within	matrigel	
were	lifted	from	wells	in	media	and	centrifuged	at	40g	for	approximately	5	minutes.	
Organoids	were	triturated	(physically	sheared)	using	a	P200	pipette	tip,	and	washed	
in	fresh	media	to	remove	residual	matrigel.	Fragments	of	triturated	organoids	were	
then	resuspended	in	fresh	matrigel	as	previously	described.	
2.2.2.2 Freeze-down	of	organoids	
Frozen	stocks	of	organoids	were	generated	within	early	passages	(p4-p10),	
depending	on	abundance	of	material.	Organoids	were	passaged	as	previously	
described	(2.2.2.1)	and	cultured	for	3-4	days.	Media	was	then	lifted	from	each	well	in	
media	and	transferred	to	1ml	eppendorfs	and	centrifuged	at	40g	for	5	minutes.	
Organoids	within	matrigel	were	then	resuspended	in	Cell	Recovery	Solution	(life	
technologies)	and	transferred	to	cryovials	(Nunc)	at	a	final	volume	of	500	μl.	2-4	
wells	of	a	24	well	plate	typically	provided	sufficient	organoid	numbers	for	a	single	
cryovial.	Cryovials	were	then	placed	in	a	freezing	container	at	room	temperature	
prior	to	storage	within	a	-80°C	freezer.	For	recovery,	cryovials	were	quickly	warmed	
in	a	water	bath	at	37°C	and	once	thawed	were	resuspended	in	basal	media,	washed	
twice,	and	finally	resuspended	in	matrigel	and	plated	as	described	previously	(2.2.2).	
Organoids	used	in	this	study	showed	successful	recovery	from	frozen	after	18	
months	of	storage.	Banks	of	frozen	organoids	facilitated	experiments	that	could	be	
carried	out	within	approximately	10	passages	of	another.		
	
2.3 General	Organoid	analysis	techniques	
2.3.1 Immunohistochemistry	(IHC)	techniques	
	
Organoids	embedded	within	matrigel	were	fixed	in	10%	formalin	(Sigma)	overnight	
at	4°C.		Organoids	were	fixed	after	5-14	days	post	isolation/passage.		After	overnight	
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fixation,	organoids	were	washed	with	Phosphate	Buffered	Saline	(PBS,	Invitrogen)	
and	stored	in	PBS	until	processing.	For	processing,	pre-chilled	PBS	was	added	to	
wells	to	dissociate	matrigel	from	wells.	All	material	was	then	transferred	into	
eppendorf	tubes	and	gently	washed	in	PBS	to	remove	matrigel	fragments	from	
organoids.	Organoids	were	then	centrifuged	at	1000X	RPM	for	1	minute.	The	
remaining	suspension	was	removed	and	replaced	with	4%	(w/v)	low	melting	point	
agarose	(Sigma).	Fixed	organoids	were	resuspended	in	low	melting	point	agarose	
and	set	at	room	temperature.	Agarose	disks	embedded	with	organoids	were	stored	
in	70%	EtOH	prior	to	sectioning.	Organoid	sections	were	then	mounted	onto	slides	
prior	to	Hematoxylin	&	Eosin	(H&E)	staining.		
2.3.2 Whole-mount	Immunocytochemistry	
This	protocol	was	adapted	from	Lee	at	al	(2007).	Briefly,	organoids	were	seeded	
within	Matrigel	in	black,	optical-	bottomed,	96	well	Nunc™MicroWell™	plates.	9µl	of	
organoids	embedded	within	matrigel	was	dispensed	per	well	and	incubated	with	
Basal	7+	media	containing	10µM	ROCK	inhibitor.	Plates	were	then	incubated	for	
defined	durations	prior	to	fixation	by	4%	formalin	at	room	temperature	for	30	
minutes.		Wells	were	then	washed	with	PBS	containing	100mM	glycine	three	times	
for	10	minutes	at	room	temperature.	Following	washes,	an	overnight	blocking	step	
was	performed	by	adding	10%	horse	serum	in	Immunofluorescence	(IF)	buffer	(PBS	
containing	0.1%	Bovine	Serum	albumin,	0.2%	Triton	X-100,	0.05%	Tween	20)	to	
chosen	wells.	Primary	antibodies	(	Table	2.2)diluted	in	IF	buffer	were	then	applied	
overnight	at	4°C	prior	to	another	overnight	incubation	in	IF	buffer.		Secondary	
antibodies	diluted	in	IF	buffer	(Table	2.3)	were	then	exposed	to	wells	overnight,	prior	
to	washes	and	an	overnight	incubation	in	IF	buffer.	Secondary	antibodies	used	were	
Rabbit	IgG	AlexaFluor®	568	(Life	Technologies)	and	Mouse	AlexaFluor®	488	(Life	
Technologies),	both	at	a	dilution	of	1:500.	Hoechst	was	implemented	as	a	
counterstain	and	washed	with	PBS	prior	to	imaging.		
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Table	2.2	Outline	of	primary	antibodies	used	for	Immunofluorescence	(IF)	
Primary	
Antibody	
Marker	type	 Source	 Catalogue	
Number	
Dilution	 IgG	
Ki67	 Proliferation	 Millipore		 AB9260	 1/100	 Rabbit	
Caspase	3	 Apoptosis	 R&D	 AF385	 1/100	 Rabbit	
Beta-catenin	 Wnt	signaling	 BD		 610154	 1/250	 Mouse	
Cyclin	B1	 Proliferation	 Santa	Cruz	 SC-752	 1/50	 Rabbit	
Lgr5	 Intestinal	
stem	cell	
BD	 562733	 1/250	 Rat	
Cytokeratin	
20	
Differentiation	 Abcam	 AB76126	 1/100	 Rabbit	
	
	
Table	2.3	Outline	of	secondary	antibodies	used	for	Immunofluorescence	(IF)	
Secondary	antibody	 Source	 Catalogue	
Number	
Dilution	
Alexa	Fluor	488	
Phalloidin	
Thermo	Fisher		 A12379	 1:100	
AlexaFluor®	488	Goat	
anti	mouse	
Life	Technologies	 A11029	 1:500	
AlexaFluor®	568	Goat	
anti	rabbit	
Life	Technologies	 A11011	 1:500	
	
2.3.3 Confocal	Imaging	and	quantitative	analysis	
Images	were	acquired	within	96	optical	(clear	bottomed)	black	plates	using	a	
Confocal	Microscope,	Leica	TCS	SP2	AOBS.	A	20X	objective	was	used	to	capture	
images,	and	were	then	subsequently	processed	using	FIJI	software,	and	IMARIS8	cell	
counting	software,	where	appropriate.	To	quantitate	proliferation	levels	in	normal	
and	treated	conditions,	the	number	of	Ki67-positive	stained	cells	per	organoid	was	
divided	by	the	total	number	of	cells	within	the	corresponding	organoid,	to	obtain	a	
percentage	value	of	cells	undergoing	active	proliferation.		
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2.3.4 Lightsheet	Microscopy	
Organoids	were	seeded	in	usual	culture	conditions,	either	from	triturated	pieces	or	
as	single	cells	as	specified	previously.	Following	recovery	and	growth	for	a	period	of	
five	days,	organoids	were	fixed	within	matrigel	by	addition	of	a	‘5X	Fix	&	Stain’	
solution	(courtesy	of	OcellO)	which	facilitates	a	one-step	stain	of	Phalloidin	and	
Hoechst	simultaneously.	Fixation	and	staining	took	place	overnight	at	room	
temperature,	whilst	organoids	within	the	well	were	placed	on	a	rocker.	Following	
overnight	incubation,	structures	within	matrigel	were	lifted	from	wells	and	washed	
twice	with	PBS.	For	mounting,	10	µL	of	organoid	suspension	was	added	to	
approximately	10µL	of	low	melting	point	agarose	and	placed	in	a	glass	capillary	
provided	by	Zeiss.	Fluorescent	images	were	taken	on	a	Lightsheet	Z.1	(Zeiss)	
microscope	and	images	rendered	within	the	Zeiss	software	package	to	generate	
maximum	projection	images.		
2.3.5 	Organoid	genotyping	
2.3.5.1 DNA	extraction	
Organoids	in	culture	between	5	and	7	days	were	extracted	for	DNA,	taken	between	
passages	5	–	12.	DNA	was	extracted	from	organoids	using	the	Qiagen	DNeasy	blood	
and	tissue	kit	as	per	the	manufacturer’s	guidelines.		
2.3.5.2 Next	Generation	Sequencing	
Analysis	of	organoid	genotypes	was	performed	using	the	Next	Generation	
Sequencing	(NGS)	SureSeq	Solid	Tumour	60-gene	panel	by	Oxford	Gene	
Technologies	(OGT).	Sequencing	was	performed	on	the	Illumina	MiSeq	platform	
using	TruSeq	b3	chemistry	in	order	to	generate	2	X	150	base	reads.	Analysis	was	
further	carried	out	by	Dr	Kenneth	Ewan	(Dale	Lab)	to	identify	significant	mutations	
per	sample.		
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2.3.6 Measurements	of	organoid	growth	parameters	
2.3.6.1 Assessing	organoid	growth	
In	order	to	assess	organoid	growth,	organoid	cultures	plated	in	24	well	plates	were	
imaged	at	different	time	points	using	GelCount™	scanner	(Oxford	Optronix).	Images	
were	then	subject	to	data	analysis	using	defined	CHARM	settings	which	recognised	
organoid	structures	within	a	well	and	provided	various	measurements	(including	
organoid	number,	diameter	average	per	well,	organoid	area).	CHARM	settings	(Table	
2.4)	were	established	for	an	individual	organoid	line,	dependent	on	their	
morphological	features	in	culture	(Figure	2.1).	Data	was	acquired	on	a	well-by-well	
basis	and	further	analysed	using	Microsoft	Excel	and/or	GraphPad	Prism.	In	general,	
a	minimum	of	three	wells	was	used	for	analysis	per	biological	repeat,	unless	
otherwise	stated.	Where	possible,	data	was	collected	from	more	than	one	biological	
repeat.		
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Table	2.4	Charm	Settings	for	GelCount	software	
Figure	2.1Representative	masks	for	individual	organoids	using	GelCount	Charm	settings	
A.	Representative	well	of	a	24	well	plate	containing	organoids	B.	Mask	settings	applied	to	identify	
structures	and	generate	basic	morphometric	readout.		
	
	
Charm	se)ngs	
Established	
cultures	 Cultures	from	single	cell	suspensions	
All	isola(ons	 Iso	50,	Iso	72	
Iso	48,	Iso	
49	 Iso	34	
Iso	75,	Iso	
78,	Iso	73	
All	isola(ons/	
general	se8ng	
Edge	detec(on	sensi(vity	 75.4	 32.9	 32.9	 32.9	 59.7	 48.5	
Center	detec(on	sensi(vity	 64.2	 43.5	 50.8	 50.8	 97.2	 71.5	
SoD	colony	lower	diameter	(µm)	 40	 60	 35	 55	 25	 30	
SoD	colony	upper	diameter	(µm)	 1000	 600	 600	 600	 70	 600	
Minimum	center	to	center	
sepera(on	 40	 60	 35	 55	 25	 30	
Smoothing	 3	 3	 3	 3	 3	 3	
Circularity	factor	 62	 80	 62	 62	 52	 82	
Edge	distance	threshold	 0.88	 0.74	 0.74	 0.74	 0.74	 0.81	
Number	of	spokes	 32	 32	 32	 32	 32	 32	
Filter	size	 3	 3	 4	 4	 3	 3	
Shape	processing	
best	ﬁt	
circle	
best	ﬁt	
circle	
best	ﬁt	
circle	
best	ﬁt	
circle	
best	ﬁt	
circle	 best	ﬁt	circle	
Colony	diameter	minimum	(µm)	 40um	 70	 55	 55	 10	 30	
Colony	diameter	maximum	(µm)	 1000um	 375	 375	 375	 70	 375	
Colony	minimum	intensity	
(	op(cal	density)	 0.1	 0.05	 0.05	 0.05	 0.01	 0.01	
Colony	maximum	intensity	
(op(cal	density)	 0.32	 10	 10	 10	 10	 10	
Good	edge	factor	 0.57	 0.06	 0.06	 0.06	 0.06	 0.06	
Borders	from	centeroids	 yes	 yes	 yes	 yes	 yes	 yes	
Merge	overlapping	objects	 yes	 yes	 yes	 yes	 yes	 yes	
Overlap	threshold	 0.67	 0.75	 0.75	 0.75	 0.75	 0.75	
overlap	calcula(on	 area	 area	 area	 area	 area	 area	
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2.3.6.2 Mitochondrial	activity	‘PrestoBlue’	assay	
Organoids	were	culture	in	clear,	round	bottomed	96	well	plates	at	varying	seeding	
densities.	10µl	of	Presto	Blue	reagent	(Invitrogen)	was	added	per	100µl	of	organoid	
growth	media.		100µl	of	media	and	10µl	Presto	Blue	Reagent	was	also	added	to	
three	wells	of	a	96	well	plate	to	serve	as	a	negative	control.		Following	a	three	hour	
incubation	at	37°C,	50µl	was	transferred	from	each	well	into	a	black,	clear	bottomed	
96	well	plate	(Matrix).	Fluorescent	signal	was	read	in	a	BMG	Fluostar	platereader	
with	an	excitation/emission	spectra	of	560nm/610nm.	Relative	fluorescence	of	
samples	was	calculated	by	subtracting	‘blank’	value	i.e	negative	controls	from	
samples	to	compensate	for	background	signal.		
	
2.4 Quantitative	Reverse	Transcription	Polymerase	Chain	Reaction	(q-RTPCR)	
qRT-PCR	was	used	to	quantify	relative	expression	levels	of	genes	within	tumour	
organoids.	For	qRT-PCR	experiments,	organoids	were	plated	to	single	cells	as	
previously	described	(2.5.1)	using	a	minimum	of	8	wells	of	a	24	well	plate	per	
condition.	
2.4.1 RNA	extraction	
	RNA	extraction	was	performed	using	a	trizol	(Life	Technologies)	based	method,	
whereby	organoids	within	matrigel	were	resuspended	in	trizol	containing	125µg/ml	
glycogen	(Life	Technologies).		The	suspension	was	then	transferred	into	1ml	
microtubes	prior	to	the	addition	of	160µl	chloroform	per	800µl	trizol/glycogen	mix.	
Samples	were	then	vortexed	and	centrifuged	for	15	minutes	at	12000	g,	at	4°C.	The	
aqueous	layer	formed	was	collected	from	each	sample	and	pipetted	into	fresh	
microtubes	prior	to	the	addition	of	an	equal	volume	of	isopropanol.	Samples	were	
centrifuged	again	for	10	minutes,	and	the	supernatant	discarded.	The	remaining	
pellets	were	washed	three	times	with	70%	EtOH,	centrifuging	at	500g	for	5	minutes	
between	each	wash.	The	remaining	pellets	were	left	to	air	dry	for	5	minutes	and	
then	resuspended	in	components	of	a	TURBO	DNA-free	kit	to	remove	any	residual	
DNA.	Samples	were	then	incubated	at	37°C	for	30	minutes.	Extracted	RNA	from	each	
sample	was	quantified	using	the	NanoDrop	machine.		
	 66	
2.4.2 Reverse	Transcription	reaction	
cDNA	was	synthesised	from	the	RNA	template	of	each	sample	using	the	Improm	II	
Kit	(Promega).	The	components	required	for	the	reverse	transcription	reaction	
mastermix	are	listed	in	Table	2.5.	A	mastermix	containing	no	reverse	transcriptase	
enzyme	was	also	generated	as	an	additional	control	for	each	sample.	The	mixtures	
were	then	incubated	in	a	thermocycler	at	70°C	for	a	total	of	5	minutes.	Samples	
were	then	diluted	in	nuclease	free	water	and	stored	at		-20°C,	or	remained	on	ice	
prior	to	gene	expression	analysis.	
2.4.3 Gene	expression	analysis	
q-RTPCR	was	performed	using	the	SensiFAST	SYBR	green	Hi-ROX	kit	(Bioline)	and	was	
carried	out	in	MicroAmp	Fast	optical	96	well	reaction	plates	(Life	Technologies).	
Primers	were	designed	(Sigma)	and	listed	below	(Table	2.6).	For	qrt-pcr	reactions,	
10µl	of	2X	SensiFAST™SYBR®	No-ROX	,	3µl	cDNA	and	0.1µl	of	individual	forward	and	
reverse	primers	(10mM	)	and	6.8µl	of	Nuclease	free	water	were	added	to	each	well.	
All	samples	were	measured	in	triplicate,	with	gene	expression	normalized	to	a	
housekeeping	gene,	GAPDH.	Plates	were	then	sealed	and	reactions	were	measured	
on	a	Step	One	Plus	real-time	PCR	instrument	(Applied	Biosystems).	A	fluorescent	
readout	from	the	incorporation	of	SYBR	product	into	the	PCR	product	was	used	to	
determine	the	relative	abundance	of	mRNA	within	each	sample.	The	cycle	times	
used	were	as	follows:	
1. 95°C	for	2	minutes		
2. 95°C	for	5	seconds	
3. 60°C	for	10	seconds		
4. 72°C	for	20	seconds	
Cycles	2-4	were	repeated	approximately	40	times.		
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Table	2.5	Mastermix	for	reverse	transcription	
		
RT	reaction	
(µl)	
No	RT	
control	
(µl)	
Reverse	Transcription	Mix	 1x	 1x	
Nuclease-Free	Water	(to	a	final	volume	of	15µl)	 6.1	 7.1	
ImProm-II™	5X	Reaction	Buffer		 4	 4	
MgCl2	(6	uM	final	from	25	uM	stock)	 2.4	 2.4	
dNTP	Mix	(final	concentration	0.5mM	each	dNTP)	 1	 1	
Recombinant	RNasin®Ribonuclease	Inhibitor	(optional)		 0.5	 0.5	
ImProm-II™	Reverse	Transcriptase		 1	 0	
	
	Table	2.6	Primers	used	for	qRT-PCR	by	SYBR	green.		
Gene	 Forward	sequence	 Reverse	sequence	
AXIN1	 CTGGATACCTGCCGACCTTA	 CCGGCATTGACATAATAGGG	
AXIN2	 GCGATCCTGTTAATCCTTATCAC	 AATTCCATCTACACTGCTGTC	
TNKS1	 CCGCGTGTCTGTTGTAGAGT	 ACAGAAGCCCCATGCCTTAC	
TNKS2	 TGGTGTGGGAGCCAAGTCTA	 GTGGCAATTCACTCCTCTTCA	
LGR5	 GAGTTACGTCTTGCGGGAAAC	 TGGGTACGTGTCTTAGCTGATTA	
ASCL2	 TGACCTGGGGCGTAATAAAG	 ACACAGGCTTCTCCCTAGCA	
KRT20	 ACGCCAGAACAACGAATACC	 ACGACCTTGCCATCCACTAC	
DKK1		 CCCAGGCTCTGCAGTCAGCG	 CGCACGGGTACGGCTGGTAG	
GAPDH	 TGAAGGTCGGAGTCAACGGA	 CCATTGATGACAAGCTTCCCG	
	
1.1.1 ΔΔCT	method	
Quantification	of	relative	gene	expression	was	calculated	using	the	ΔΔCT	method.		
Within	each	assay,	the	cycle	threshold	value	(CT	value)	was	determined	by	the	
number	of	thermocycles	carried	out	by	each	well	to	reach	a	pre-assigned	fluorescent	
threshold.	CT	values	for	each	triplicate	sample	were	then	normalized	to	the	
housekeeping	gene	(GAPDH)	to	generate	a	ΔCT	value.		The	ΔCT	of	the	control	cohort	
was	then	subtracted	from	the	ΔCT	of	the	test	cohort	to	determine	relative	fold	
changes	in	gene	expression.	Triplicate	wells	from	each	reaction	were	then	averaged	
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to	generate	a	ΔΔCT	value.	To	eliminate	the	possibility	of	primer	contamination,	melt	
curves	were	performed	on	samples	following	their	end	cycle	times.	
	
2.5 Endpoint	Viability	measurements	for	drug	assays	
2.5.1 Passaging	to	single	cell	
For	single-cell	passage,	growth	medium	was	removed	from	organoids	in	culture.	
Organoids	were	washed	with	PBS	and	incubated	for	approximately	5	minutes	with	
TrypLE	Express,	a	form	of	trypsin	(Invitrogen).	Following	incubation,	matrigel	was	
suspended	in	TrypLE	Express	and	placed	in	an	eppendorf	tube.	If	large	fragments	
remained	within	tubes,	Basal	media	was	added	with	10%	FBS	to	inhibit	Trypsin	
activity.	The	suspension	was	then	filtered	through	a	40	µm	filter	and	washed	several	
times	with	3+	media.	The	number	of	cells	within	the	suspension	were	counted	by	
staining	cells	using	an	Acridine	Orange/Propidium	Iodide	Stain	,	and	subsequently	
counting	on	an	automated	LUNA-FL™	fluorescence	cell	counter.	Cells	were	then	
resuspended	in	Matrigel	at	a	desired	concentration	/µl	of	matrigel.	9µl	of	Matrigel	
was	then	seeded	in	white,	clear-bottomed	96	well	plates	(Matrix)	and	incubated	at	
37°C.		Following	incubation,	50µl	of	growth	medium	was	then	added	to	each	well.	
2.5.2 Addition	of	Drug	Treatments	
All	compounds	were	prepared	according	to	manufacturers’	instructions	(Table	2.7),	
typically	dissolved	in	100%	DMSO	(Sigma).	A	range	of	stock	solutions	at	different	
concentrations	were	prepared,	serially	diluted	in	DMSO	to	make	100X	stock	
solutions	(1%	DMSO).	The	intermediate	stocks	were	then	diluted	ten-fold	so	that	
final	concentrations	of	DMSO	were	0.1%	in	50µl	growth	media	for	any	given	sample.		
All	experiments	were	performed	in	triplicate	for	each	concentration.	
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Table	2.7	Table	of	compounds	and	concentrations	used	in	organoid	drug	assays	
	
Focus	4	
ARM	
Compound	
iden2ﬁer	
Name	 Mechanism	 Diluted	in	 Source	 Dilu2on	range	(nM)	 Fold	change	
in	dilu2on	minimum	 maximum	
BRAF	
muta*on	
	
	
GSK12118473	 Dabrafenib	 BRAF	inhibitor	 DMSO	 Stratech	Ltd	 0.12	 500	 2	
	 Panitumumab	 EGFR	inhibitor	 PBS	 clinic	 0.02	 62.5	 2	
GSK1120212	 Trame*nib	 MEK	inhibitor	 DMSO	 Stratech	Ltd	 0.06	 250	 2	
PIK3CA	
muta*on	 	 Salicylic	acid	 unclear	 DMSO	 Sigma	 19	 5000	 2	
KRAS/p53	
muta*on	 AZD1775	 MK1775	 Wee1	inhibitor	 DMSO	 Stratech	Ltd	 19	
5000	
	 2	
WT	with	
PTEN	
func*on	 AZD8931	 Sapi*nib	
HER	1,2,3	
inhibitor	 DMSO	 Stratech	Ltd	 8	 1250	 2	
ATM	
deﬁcient	 AZD6738	 	AZ20	 ATR	inhibitor	 DMSO	 R&D	 19	 5000	 2	
Non	
stra*ﬁed	 	 5FU	
thymidylate	
synthase	
inhibitor	 DMSO	 Tocris	 19	 10000	 2	
MSC2501490A	 TNKS	inhibitor	 DMSO	 Merck	Serono	 4	 1250	 2	
	MSC2572070A	 TNKS	inhibitor	 DMSO	 Merck	Serono	 0.80	 250	 2	
MSC2524070A	 TNKS	inhibitor	 DMSO	 Merck	Serono	 0.39	 100	 2	
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Table	2.8	Concentrations	of	compounds	used	in	single	inhibitor,	double	inhibitor,	and	triple	inhibitor	combination	assays	
Single	agent	(nM)	 Double	agents	(nM)	 Triple	agents	(nM)	
Dabrafenib		 Trame7nib	 Panitumumab	 Dabrafenib	+	Trame7nib	(2:1)	
Trame7nib	+	
Panitumumab	
(4:1)	
Panitumumab	
+	Dabrafenib	
(1:8)	
Dabrafenib,		
Trame7nib	+	
Panitumumab	
(8:4:1)	
500.00	 250.00	 62.50	 750.00	 312.50	 562.50	 812.50	
250.00	 125.00	 31.25	 375.00	 156.25	 281.25	 406.25	
125.00	 62.50	 15.63	 187.50	 78.13	 140.63	 203.13	
62.50	 31.25	 7.81	 93.75	 39.06	 70.31	 101.56	
31.25	 15.63	 3.91	 46.88	 19.53	 35.16	 50.78	
15.63	 7.81	 1.95	 23.44	 9.77	 17.58	 25.39	
7.81	 3.91	 0.98	 11.72	 4.88	 8.79	 12.70	
3.91	 1.95	 0.49	 5.86	 2.44	 4.39	 6.35	
1.95	 0.98	 0.24	 2.93	 1.22	 2.20	 3.17	
0.98	 0.49	 0.12	 1.46	 0.61	 1.10	 1.59	
0.49	 0.24	 0.06	 0.73	 0.31	 0.55	 0.79	
0.24	 0.12	 0.03	 0.37	 0.15	 0.27	 0.40	
0.12	 0.06	 0.02	 0.18	 0.08	 0.14	 0.20	
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2.5.3 Endpoint	Cell	Titer	Glo	3D	ATP	Measurements	
For	assay	endpoint	readout,	50µl	of	Cell	Titre	Glo	3D	reagent	was	added	per	50µl	of	
growth	media	to	each	well	of	a	96	well	plate.	50µl	of	media	and	reagent	were	also	
added	to	three	wells	of	a	96	well	plate	to	serve	as	a	control	(Blank	values).		Following	
an	agitation	step	on	a	Rickman	shaker	for	five	minutes	to	initiate	cell	lysis	for	ATP	
extraction,	the	plate	was	incubated	on	the	shaker	for	up	to	one	hour	at	room	
temperature.		Relative	Luminescence	values	were	obtained	on	a	BMG	Fluostar	
platereader.	‘Blank’	control	values	were	subtracted	from	samples	of	interest	to	
accomodate	background	signal.	
2.5.4 Drug	combination	assays	
2.5.4.1 Experimental	design	
	
For	assessing	the	collective	growth	inhibition	of	EGFR,	BRAF	and	MEK1/2	on	BRAF-
mutant	organoids,	methods	developed	by	Chou	and	colleagues(Chou	and	Talalay	
1984;	Chou	2007)	were	implemented	to	determine	whether	compounds	were	
additive,	synergistic,	or	antagonistic	using	the	Combination	Index	(CI)	equation.		
Organoids	were	firstly	treated	with	single	agents	to	determine	a	suitable	titration	
range,	and	potency	of	individual	compounds.		To	investigate	the	effects	of	paired	
and	triple	drug	combinations,	ratios	were	selected	according	to	the	potency	(IC50	
values)	of	each	agent	alone,	as	determined	by	an	ATP	assay	readout,	and	maintained	
within	a	fixed	ratio	from	the	other	(8:4:1	for	Dabrafenib:Trametinib:Panitumumab).	
Seven	white,	clear-bottomed	96	well	plates	were	seeded	as	described	in	section	
2.5.1.	Individual	plates	used	for	each	single	agent,	double	agent	combinations	and	
triple	agent	combination.	Cultures	were	overlaid	with	media,	and	following	three	
days	of	recovery,	were	treated	with	each	single	agent,	double	agent	in	a	fixed	IC50	
ratio,	or	triple	agent	in	their	established	IC50	ratio.	A	14	point	titration	of	compounds	
was	administered	in	single	agent	conditions,	as	well	as	in	paired	and	three-drug	
mixtures,	whereby	titrations	were	in	a	constant	ratio	of	IC50.,	as	detailed	in	Table	2.8.		
The	constant	ratio	of	IC50	values	of	each	of	the	compounds	allows	the	measurement	
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of	outcome	CI	values	across	the	whole	dilution	range	in	a	series	of	experiments.	In	
cases	whereby	a	single	drug	demonstrated	insufficient	growth	inhibition	of	BRAF-
mutant	organoids,	relative	potency	levels	were	determined	from	cellular	IC50	values	
within	the	literature	(King	et	al.	2013;	Yamaguchi	et	al.	2011;	Freeman	et	al.	2009).	A	
minimum	of	4	replicate	wells	were	established	per	treatment	condition.		Following	4	
days	of	treatment,	all	plates	were	assayed	simultaneously,	using	a	Cell	Titer	Glo	3D	
kit.		
2.5.4.2 Chou-Talalay	data	analysis	for	drug	combinations	
	
Interactions	of	two-	or	three-	drug	combinations	were	quantitatively	analysed	using	
Calcusyn™	software.	Drug	dose	response	curves	generated	from	input	raw	data	
obtained	from	Cell	Titer	Glo	3D	luminescent	readouts,	to	calculate	the	average	
fraction	affected	(fa)	and	fraction	unaffected	(fu)	per	treatment	condition.	The	dose	
response	curves	were	then	transformed	by	linear	regression	using	the	median-effect	
principle	(Equation	2.1)	to	assess	both	potency	(Dm)	and	shape	(m)	of	the	dose-
effect	curve	for	each	dose	of	compound.	Linear	regression	was	performed	by	
plotting	the	log[(1/fu)-1]	against	the	log(Dose),	generating	a	line	used	to	then	
calculate	the	log	(IC50)		at	the	x	intercept	of	the	line.	The	median	effect	equation	
(Equation	2.1)	then	enabled	a	calculation	of	the	inhibitor	IC50	of	each	Dose	(D)	at	the	
median	effect	(Dm).	
	
Equation	2.1	 !"!! =  !!" 	
whereby	
D:	Dose	
Dm:	Median-effect	dose	
fa:	fraction	affected	
fu:	fraction	unbound	
	
Following	linearization	of	each	respective	drug	dose	response	curve,	drug	
combinations	were	analysed	by	the	Combination	Index	(CI)	equation	(Equation	2.2).	
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By	assigning	multiple	data	points	for	constant-ratio	combinations	i.e.	the	IC50	value	
for	each	compound,	the	potency	and	shape	of	the	curve	can	be	determined	across	
the	entire	spectrum	which	can	then	be	used	to	equate	the	CI	values	for	all	doses.	For	
the	combination	index	equation,		(D)1	and	(D)2	were	the	concentrations	of	each	drug	
in	combination	to	inhibit	x,	whilst	(Dx)1	and	(Dx)2	were	the	dose	of	each	drug	as	a	
single	agent	to	generate	the	same	x	inhibition.	CIs	of	<1,	1,	and	>1	are	indicative	of	
synergism,	additive	effect	and	antagonism,	respectively.		Upon	treatments	of	
organoids	with	two	or	three	agents	at	a	fixed	ratio,	the	dose	of	the	combination	
required	to	produce	fractional	survival	could	be	separated	into	D1,	D2,	D3	of	agents	
1,2,3	respectively	(equation	shows	two	components	only).	For	each	level	of	
cytotoxicity,	or	whereby	the	fraction	affected,	the	combination	index	was	thereby	
calculated.		
	
The	Dose	Reduction	Index	(DRI)	was	then	calculated	to	determine	the	degree	to	
which	a	particular	drug	combination	can	achieve	a	given	effect.		The	DRI	measures	a	
fold	reduction	in	dose	of	each	drug	used	in	combination	to	reach	an	equivalent	
effect	level	(normally	IC50)	comparative	to	the	degree	of	effect	observed	as	a	single	
agent	(Chou	2007)).		
	
Equation	2.2	 CI =  (!)!(!")! +  (!)!(!")!  = 1(!"#)! + 1(!"#)! 	
	
	
2.6 3D	phenotypic	profiling	(OcellO	analysis)	
High-throughput	image	acquisition	and	data	analysis	were	performed	in	
collaboration	with	OcellO	(Leiden)	as	described	previously	(Di,	Klop,	Rogkoti,	
Devedec,	van	de,	et	al.	2014;	Sandercock	et	al.	2015;	Herpers	et	al.	2014).			
2.6.1 384	well	plate	set-up	
Organoid	lines	in	culture	were	detached	to	single	cells	as	previously	described	in	
section	2.5.1.	Cells	were	resuspended	in	growth	factor-reduced	Matrigel	at	400	cells/	
µl	MT	within	black,	clear-bottomed	384	well	plates	(Greiner).	Following	an	
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incubation	of	15	minutes	at	37°C	to	enable	Matrigel	polymerisation,	25µl	of	7+	
media	containing	ROCK	inhibitor	was	added	to	each	well.		Compounds	or	control	
DMSO	(0.1%)	conditions	were	added	upon	seeding,	or	following	3	days	in	culture,	
dependent	on	experimental	procedures.	At	day	7,	plates	were	fixed	using	a	‘fix	and	
stain’	solution,	as	described	by	Di	et	al.,2014,	comprising	of	3.7%	formaldehyde	in	
phosphate-buffered	saline	(PBS)	containing	0.2%	Triton	X-100,	0.25	μM	
Tetramethylrhodamine	(TRITC)	phalloidin	(Sigma)	and	1	μg/mL	Hoechst	blue	dye.	
Following	overnight	fixation	at	4°C,	wells	were	subsequently	topped	up	with	PBS	and	
sealed	with	foil	lids	prior	to	shipping	for	imaging.	Upon	arrival,	plates	were	washed	
twice	with	PBS	and	stored	at	4°C.		
2.6.2 High-throughput	imaging	
Imaging	was	performed	on	a	high	throughput	XLS	MetaXpress	confocal	imaging	
platform,	courtesy	of	OcellO	(Leiden).	Image	z-stacks	were	collected	per	well	of	a	
384	well	plate,	with	25	image	stacks	taken	at	10	micron	steps	per	well.	Images	were	
taken	at	4X	magnification	with	image	stacks	captured	from	TRITC	channel	(f-actin	
stain,	EX=548,	EM=	645)	and	DAPI	staining	channel	(nuclear	stain,	EX=380m	EM	
=435).		
2.6.3 Multi-parametric	phenotypic	analysis	
2.6.3.1 OMiner™	phenotypic	feature	extraction	software	
	
Phenotypic	analysis	was	performed	within	OMiner™	software	(OcellO,	Leiden),	as	
described	previously	(Di,	Klop,	Rogkoti,	Devedec,	van	de,	et	al.	2014;	Sandercock	et	
al.	2015).	Briefly,	upon	acquisition	of	multiple	images	within	the	z-plane	of	each	well,	
image	segmentation	was	performed	to	define	individual	objects	generated	from	
each	channel,	resulting	in	the	identification	of	distinct	morphometries.	A	Gaussian	
filter	radius	was	applied	to	enhance	noise	suppression.	Overall,	information	
gathered	per	individual	channel,	as	well	as	combined	channels,	could	be	enhanced	
or	deducted	as	appropriate.	For	segmentation	of	individual	organoids	within	a	well,	
information	from	both	the	nuclear	and	TRITC	channels	were	used	to	enhance	
separation	of	individual	organoids.	To	identify	individual	lumen	within	wells,	
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information	gathered	from	the	F-actin	channel	was	used;	this	was	of	particular	
importance	to	distinguish	multiple	luminal	structures	within	an	organoid.	Object	
filtering	was	then	performed	on	all	three	of	the	segmentation	parameters	to	remove	
irrelevant	objects,	such	as	fractions	of	loose	cells	and	debris.		
	
Masks	were	then	generated	from	intensities	of	each	channel;	the	outermost	f-actin	
staining	of	an	individual	organoid	was	used	to	generate	a	‘whole	organoid’	mask,	the	
internal	f-actin	staining	used	to	generate	a	‘lumen’	mask,	and	a	nuclear	staining	used	
to	generate	‘nucleus’	information	per	section	within	an	organoid.	Intensity	
information	gathered	from	both	channels	simultaneously	were	also	utilised	to	
produce	feature	analysis	per	object.	Objects	within	a	single	image	that	were	out	of	
focus	were	filtered	and	discarded	from	feature	analysis.	
	
Following	the	generation	of	relevant	organoid	masks,	Ominer™	software	was	used	to	
extract	morphological	features	from	projections	of	the	F-actin	and	nuclei-derived	
image	stacks	to	generate	masks	of	individual	organoids,	internal	lumen	structures	
and	nuclei.	Individual	measurements	acquired	per	object	were	subsequently	
accumulated	to	represent	collective	objects	within	all	sections	imaged	per	well,	
generating	a	mean	value	for	each	feature.	Approximately	600	quantified	features	
were	then	extracted	per	well	by	assessing	shape	and	fluorescence	intensity	of	
organoid,	lumen,	and	nuclear	masks,	some	of	which	are	represented	in	Table	2.9.	
Data	was	pooled	on	a	well	by	well	basis,	to	define	the	average	parameter	with	
standard	deviation.	Any	outliers	were	removed	from	analysis	such	as	wells	where	
the	matrigel	had	been	disrupted	(as	a	result	of	plating	or	shipping	conditions).		
	
	
	
	
	
	
	
	 76	
Table	2.9	Description	of	a	subset	of	features	extracted	from	intensity	information	of	images	
gathered	and	corresponding	outcomes	of	measurement	
Feature	 Measurement	
Organoid	count	 Total	organoid	counts	from	a	whole	image	stack	
Organoid	sum	size	 The	total	volume	of	organoids	within	a	well	
Organoid	average	size	 The	average	organoid	size	per-section	
Organoid	roundness	 Values	assigned	(0-1)	to	organoid	roundness,	with	1	
depicting	a	spherical	object	
Nucleus	count	 Measurement	of	cell	density	per	organoid	
Organoid	nucleus	to	
organoid	centre	
distance		
Measurement	of	the	average	distance	between	the	
centre	of	an	organoid,	and	centre	of	corresponding	
nuclei	to	represent	nuclear	spread	within	and	organoid	
Organoid	nucleus	to	
organoid	boundary	
distance	
Measurement	of	the	average	distance	between	the	
organoid	edge,	and	centre	of	corresponding	nuclei	to	
represent	nuclear	spread	within	and	organoid	(to	be	
used	in	conjunction	with	organoid	nucleus	to	organoid	
centre	distance)		
Organoid	branching	 Identification	of	branching	structures	in	the	main	
architecture	of	an	organoid	
Lumen	size	 Average	measurement	of	overall	area	of	lumen/lumens	
within	an	organoid	structure	
Number	of	lumen	 Total	number	of	lumen	within	an	organoid	to	identify	
complexity	of	structure	
Lumen	branching	 Number	of	protrusions	from	lumen	
	
2.6.3.2 Basic	feature	extraction	
Over	600	variables	were	collected	and	analysed	using	OMiner	software	to	generate	a	
well	by	well	profile	of	different	organoid	features.		Basic	analysis	of	dose	dependent	
responses	according	to	variable	(e.g.	organoid	average	size)	was	carried	out	on	
Microsoft	Excel/	Graphpad	Prism.		
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2.6.3.3 Principal	Component	Analysis	(PCA)	and	Distance	metric	measurements	
	
PCA	was	used	to	transform	data	from	multiple	quantified	variables	from	phenotypic	
analysis,	to	a	new	coordinate	system	in	order	to	identify	components	that	attributed	
to	the	most	variation	in	the	data	between	control	and	negative	control	samples.	The	
greatest	variance	in	data	(across	variables	within	different	conditions)	therefore	lies	
within	the	first	coordinate,	until	all	data	points	are	assigned	coordinates	in	
descending	order	of	variance	in	data.	For	each	organoid	line	and	treatment,	a	
Mahalanobis	distance	metric	was	applied	across	the	top	5	principle	components,	
between	negative	controls	and	each	sample	observation	(dose),	in	order	to	classify	
the	degree	of	change	in	variables	between	control	and	treated	samples.	A	distance	
metric	would	have	the	highest	value	in	conditions	whereby	observations	were	
distinctly	different	from	negative	controls,	as	reflected	in	the	quantified	data.	
Alternatively,	no	observed	change	between	treatment	and	negative	control	would	
result	in	a	small	distance	metric	in	multidimensional	space.	Further	details	of	analysis	
methods	implements	can	be	found	in	Di	et	al	2014	and	Caie	et	al	2010.	PCA	analysis	
was	carried	out	using	R	studio	software(http://cran.r-project.org).	Multi-dimensional	
analysis	described	in	Chapter	5	was	carried	out	by	OcellO.	The	principles	of	this	
analysis	were	identical,	with	the	exception	that	an	Euclidean	Distance	metric	was	
used	to	represent	variance	in	parameter	space.				
	
2.7 	Experimental	animals	
NOD-SCID	gamma	irradiated	mice	were	used	to	perform	in	vivo	organoid	
engraftment	experiments.	All	animals	were	obtained	commercially	from	Charles	
River	and	housed	under	UK	Home	Office	regulations.		
2.7.1 Experimental	procedures	
Licensed	individuals	with	appropriate	training	performed	experimental	procedures.	
All	mouse	experiments	described	in	this	thesis	were	carried	out	by	Dr	Kenneth	Ewan	
(Dale	lab).	
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2.7.2 Organoid	transplantation	
For	organoid	transplantation,	organoids	were	taken	to	single	cells	and	treated	with	
DMSO	or	treatment	for	24	hours	prior	to	transplantation	subcutaneously	into	one	
flank	per	mouse.	Animals	were	checked	every	two	days	for	tumour	growth	by	
palpation,	according	to	protocol	by	Home	office	regulations.		
	
2.8 Data	and	Statistical	analysis	
Raw	data	obtained	was	analysed	using	Microsoft	Excel	for	Mac	or	GraphPad	Prism	
software	for	Mac.	Graphical	representation	of	data	included	standard	deviation	or	
standard	error	of	means.	Statistical	analysis	was	performed	using	GraphPad	Prism	
sofrware	for	Mac.	Statistical	test	used	are	dented	in	figure	legends.	Comparisons	of	
means	were	performed	using	a	T-test.	Comparisons	between	experimental	repeats	
were	perfomed	using	analysis	of	variance	analysis	(ANOVA),	with	Dunnett’s	post-hoc	
analysis	for	comparison	against	one	control.		Statistically	significant	differences	were	
determined	when	p	values	were	less	than	or	equal	to	(≤)	0.05.		
	
2.8.1 Generation	of	Drug	dose	response	curves	
	
Raw	data	obtained	from	relative	luminescence	of	samples	(2.5.3)	was	corrected	for	
background	absorption	as	determined	from	‘blank’	wells	containing	the	
reagent/media	mix.	Drug	dose	response	curves	were	generated	using	an	‘XLFit’	
Microsoft	Excel	Plug-in.		Within	each	experiment,	curves	were	fitted	for	three	
technical	replicates	which	then	allowed	the	output	of	an	IC50	value.	For	the	analysis	
of	experimental	repeats,	the	mean	of	obtained	IC50	were	used	as	a	representation,	
with	experiments	largely	n=3	unless	otherwise	stated.	For	drug	combination	studies,	
data	was	plotted	as	a	survival	curve	using	GraphPad	Prism	software.	For	exploration	
of	drug	synergy,	data	was	analysed	using	Calcusyn™	software	(Biosoft)	to	generate	
Combination	Index	values	as	well	as	Dose	reduction	Indexes.	
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2.8.2 Kaplan	Meier	Survival	analysis	
A	survival	curve	was	generated	using	GraphPad	Prism.	Statistical	analysis	was	
conducted	using	the	Log-rank	(Mantel-Cox)	test.	Statistically	significant	differences	
were	determined	when	p	values	were	less	than	or	equal	to	(≤)	0.05.		Statistical	
analysis	of	survival	was	carried	out	by	Dr	Kenneth	Ewan	(Dale	lab).		
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3 Development	and	optimisation	of	high-throughput	
patient-derived	colorectal	cancer	organoid	assays	
	
3.1 Introduction	
	
The	 generation	 of	 3D	 organoids	 from	 patient	 material	 could	 not	 only	 provide	 a	
valuable	tool	to	gain	 insights	 into	tumour	and	stem	cell	biology	alike,	but	also	hold	
potential	as	a	relevant	pre-clinical	platform	to	validate	oncological	therapeutics.		An	
experimental	platform	that	more	closely	represents	all	characteristics	of	a	tumour	in	
vivo	as	well	 as	 response	 to	 therapeutic	agents,	whilst	 simultaneously	 retaining	 the	
usability	of	high	throughput	2D	cultures	to	facilitate	the	testing	of	a	high	number	of	
compounds,	 is	 instrumental	 for	 drug	 discovery	 purposes.	 In	 order	 to	 establish	
organoids	as	a	 successful	 in	 vitro	modelling	 system,	 their	 setup	and	use	had	 to	be	
optimised	 to	 ensure	 both	 relevance	 to	 patient	 tumours,	 as	well	 as	 reproducibility	
within	 robust	assay	 formats,	 compatible	 for	 the	analysis	of	 complex	3D	structures.		
Here,	we	show	the	expansion	of	a	cohort	of	patient-derived	organoids	cultures	from	
primary	CRC	 tumour	material	 based	on	 culture	 systems	 that	 have	previously	 been	
described	 (Sato	et	al.,	 2011).	As	organoids	are	complex	3D	structures,	which	 show	
variability	both	within	and	across	populations,	we	developed	assay	formats	with	the	
aim	of	generating	quantitative	data	to	assess	the	impact	of	small	molecule	inhibitors	
and	drugs.	
	
In	summary,	the	key	aims	here	were:	
	
(i) To	generate	and	characterise	colorectal	tumour-derived	organoids	
(ii) To	 optimise	 suitable	 growth	 conditions	 to	 facilitate	 maximal	 organoid	
expansion	in	culture	which	retain	key	characteristics	of	parental	tumours	
(iii) To	determine	optimal	 assay	 formats	 and	plating	 conditions,	 in	 terms	of	
speed	and	output,	which	show	high	sensitivity	as	a	readout	for	organoid	
responses	to	growth	inhibition.	 	
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3.2 Results	
3.2.1 Establishing	epithelial	organoids	from	patient	derived	colorectal	cancer	
material	
3.2.1.1 ‘Tumour,	Node,	Metastasis’	(TNM)	and	Dukes’	staging	of	colon	tumour	
samples	obtained	from	patient	material	
	
To	generate	a	cohort	of	patient-derived	organoids,	a	sample	stream	was	established	
in	collaboration	with	the	Wales	Cancer	Bank,	whereby	surgically	resected	colorectal	
carcinoma	tissue	were	retrieved	with	full	patient	consent.	Collected	material	was	
examined	and	appropriately	sectioned	by	histopathologists	(University	Hospital	
Wales);	for	each	tumour	sample,	a	section	of	live	tissue	was	collected	for	our	
organoid	establishment	purposes,	as	described	in	Methods	(2.1).	Clinical	samples	
were	further	characterised	by	histopathologists	(University	Hospital	Wales)	following	
sectioning	of	tumour	material	and	fixation	for	histological	assessments.	This	ensured	
that	basic	patient	metrics	were	established	from	the	same	tumour	region	from	
which	corresponding	organoids	were	generated.		
	
For	routine	diagnostic	purposes,	histopathologists	obtained	samples	of	each	
specimen	as	well	as	approximately	8	surrounding	lymph	nodes	to	determine	the	
tumour	grade,	and	to	assess	whether	tumour	cells	had	infiltrated	into	surrounding	
tissue.	These	samples	were	then	cryosectioned	prior	to	hematoxylin	and	eosin	(H&E)	
staining	for	diagnostic	analysis.	Following	both	gross	and	microscopic	analysis,	
tumour	stage	were	set	according	to	Dukes	tumour	grading,	and	the	Tumour,	Node,	
Metastasis	criteria	as	noted	in	Table	3.1,	respectively.	All	samples	used	within	this	
study	were	isolated	from	different	regions	of	the	colon	from	both	male	and	female	
patient	within	an	age	range	of	43-83.	6	out	of	11	samples	were	from	patients	with	
tumours	that	had	spread	into	adjacent	lymph	nodes	(N),	with	N1-2	indicative	of	
increasing	proportions	of	lymph	nodes	containing	cancer	cells.		1	of	11	samples	
((Iso)48)	was	derived	from	a	patient	with	a	known	history	of	metastasis	of	the	
primary	tumour,	as	indicated	by	a	‘metastasis’	(M)	score	of	1.	The	10	remaining	
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samples	analysed	were	given	a	‘Mx’	score	to	indicate	unknown	evidence	of	
metastasis	from	patient	data	(Wales	Cancer	Bank).		 	
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Table	3.1	Patient	tumour	Staging.		
Fragments	of	carcinoma	isolated	from	surgically	resected	tissue	have	successfully	generated	
organoids	as	indicated	by	‘Isolation	number’.	Patient	ages	range	between	43-83	in	this	subset,	and	
include	mostly	tissue	derived	from	male	patients	(M	denotes	males,	F	denotes	females).	Dukes’	
tumour	stages	are	denoted	A-C2.	Tumour,	Node,	Metastasis	(TNM)	staging	is	graded	T1-4,N0-2,Mx-1.	
Data	collated	by	the	Wales	Cancer	Bank.		
	
Isolation	
number	
Age	 Sex	 Tumour	
Site	
Tumour	
Differentiation	
Dukes’	
Stage	
TNM	
Stage	
29	 73	 M	 Upper	
Rectum	
Well/	
Moderate	
C1	 T1N1Mx	
34	 69	 M	 Transverse	
Colon	
Well/Moderate	 A	 T2N0Mx	
36	 77	 F	 Rectum	 Well/Moderate	 B	 T3N0Mx	
38	 64	 M	 Sigmoid	
Colon	
Well/Moderate	 C1	 T3N1Mx	
48	 43	 M	 Rectum	 Poor	 C2	 T4N2M1	
49	 75	 M	 Lower	
Sigmoid	
Well/Moderate	 C1	 T3N1Mx	
50	 75	 M	 Rectum	 Poor	 C2	 T3N1Mx	
72	 83	 F	 Caecum	 Well/Moderate	 B	 T3N0Mx	
73	 60	 M	 Sigmoid	
Colon	
Well/Moderate	 B	 T3N0Mx	
75	 76	 F	 Caecum	 Poor	 C1	 T3N1Mx	
78	 66	 F	 Caecum	 Well/Moderate	 C1	 T3N1Mx	
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3.2.1.2 Generation	and	establishment	of	growth	conditions	for	epithelial	
organoids	derived	from	primary	tumour	material	
	
Previous	and	on-going	work	within	the	Dale	lab	(Dr	Kenneth	Ewan	&	Dr.	Andrew	
Hollins)	has	demonstrated	success	in	the	processing	of	isolating	epithelial	cell	
fragments	from	colorectal	tissue	to	generate	organoids	(denoted	by	Isolation	
number,	‘Iso’),	based	on	methods	in	the	literature	(Sato	et	al	2011)	whereby	patient	
material	has	successfully	established	in	3D	culture.	For	the	purposes	of	a	wider	study	
to	generate	a	CRC	organoid	platform,	the	tissue	isolation	process	and	optimisation	of	
organoid	growth	conditions	was	divided	equally	between	Dale	lab	members	(	Iso	29-
78	between	Dr	Andrew	Hollins	and	Luned	Badder,	with	previous	samples	having	
been	generated	between	Dr	Kenneth	Ewan	and	Dr	Andrew	Hollins).	Of	the	78	
samples	processed	to	date,	there	has	been	an	approximate	70%	success	rate	in	
initial	organoid	establishment	from	tumour	tissue,	with	improvements	made	over	
time	following	experience	with	culture	requirements.	For	the	purposes	of	this	study,	
a	subset	of	these	were	generated	from	fresh	tumour	tissue	(with	the	exception	of	Iso	
38,	generated	and	characterised	for	optimal	media	conditions	by	Dr.	Andrew	
Hollins),	characterised,	and	further	utilised	for	assay	development.	Fresh	tissue	was	
routinely	collected	and	processed	within	3-15	hours	following	surgical	resection.	
	
As	depicted	in	Figure	3.1,	following	digestion	and	trituration	of	washed	tissue	pieces,	
cellular	fragments	derived	from	tumour	tissue	were	filtered	through	a	70µm	filter	to	
ensure	minimal	aggregation,	and	resuspended	in	10ml	‘3+’	media,	components	of	
which	are	previously	listed	(Table	2.1).	For	counting	purposes,	10μl	samples	were	
dispensed	onto	tissue	culture	plates,	and	clusters	of	cells	were	counted	to	seed	1000	
per	50μl	of	growth	factor-reduced	Matrigel.	Such	protocols	were	established	
previously	(Sato	et	al.	2011a)	in	the	literature;	by	counting	fragments	as	opposed	to	
unsorted	single	cells,	it	prevented	any	other	cell	types	that	could	be	present	(such	as	
fibroblasts)	from	skewing	the	data.	Preliminary	work	based	on	guidance	within	the	
literature	(Sato	et	al.	2009;	Sato	et	al.	2011b)	was	carried	out	on	a	subset	of	
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organoids	samples	to	establish	optimal	seeding	densities.	Following	processing	of	
tissue	to	epithelial	cell	fragments,	organoids	were	plated	at	1000	cell	fragments	or	
2000	cell	fragments	per	50	µl	Matrigel,	in	‘Full’	or	‘7+’	media	conditions.	The	number	
of	organoids	generated	were	then	counted	on	a	well	by	well	basis	in	each	condition.	
As	shown	in	Figure	3.2,	it	would	suggest	that	1000	cells	per	50	µl	Matrigel	was	
sufficient	to	generate	the	highest	yield	of	organoids.	However,	the	number	of	
organoids	generated	from	primary	material	varied	between	patient	samples	due	to	
nature	of	material,	ranging	from	seeding	a	minimal	8	wells	to	a	higher	yield	of	20	
wells	of	a	standard	tissue	culture	24-well	plate.	A	limiting	factor	on	the	number	of	
different	growth	and	seeding	conditions	that	could	be	implemented	was	thus	due	to	
the	number	of	cell	fragments	isolated	from	tumour	tissue,	meaning	that	optimal	
seeding	densities	from	fresh	fragments	could	not	always	be	calculated	for	each	
sample.	All	samples	following	Iso	29	were	therefore	seeded	at	a	density	of	1000	cell	
fragments	/	50	µl	matrigel.	This	difference	is	most	likely	due	to	a	variety	in	necrotic	
regions	within	a	primary	tumour	that	reduce	the	number	of	viable	cells	that	could	
potentially	expand	within	culture.		Once	suspended	and	embedded	within	matrigel,	
fragments	of	cells	formed	multiple	closed	structures	within	12	hours	of	seeding.	
	
	
Figure	3.1	Depiction	of	organoid	isolation	process	from	human	surgically	resected	colorectal	tissue.	
Surgically	resected	colorectal	material	undergoes	a	process	of	dissection,	digestion	and	trituration	to	
release	cellular	fragments.	Cells	are	then	transferred	to	growth	factor-reduced	Matrigel	and	overlaid	
with	growth	media.			
Patient 
consent (Wales 
Cancer Bank) 
Fragment of 
colorectal 
tumour 
resection 
Tumour 
dissection to 
small 
fragments 
Fragment 
washes in 
PBS 
Cell 
fragments 
isolated 
from tissue 
Cell Fragments 
resuspended in 
matrigel and 
growth media 
Enzymatic 
digestion at 
37°C 
	 86	
	
	
Figure	3.2	Establishment	of	optimal	organoid	seeding	densities	from	isolation.	
Following	dissection,	digestion	and	trituration	of	primary	patient	CRC	material	(Iso	29)	from	freshly	
resected	specimens,	cellular	fragments	were	counted	at	a	density	of	1000	or	2000	cells	per	50	µl	of	
Matrigel,	prior	to	plating	.	Cellular	fragments	embedded	within	matrigel	were	then	overlaid	in	‘Full’	or	
‘7+’	Media.	The	number	of	organoids	per	well	were	counted	using	GelCount	charm	settings.	A	
minimum	of	n=3	wells	were	used	per	condition.	Data	shows	mean	±	standard	deviation,	paired	
student’s	t-test.	For	routine	samples	generated	for	this	study,	a	density	of	1000	cell	fragments	per	50	
µl	matrigel	was	deemed	as	a	sufficient	number	to	enable	organoid	formation.		
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3.2.1.3 Optimisation	of	culture	conditions	for	CRC	organoids	
	
In	order	to	maximise	yield	from	patient	material,	basic	growth	requirements	of	
structures	derived	from	patient	material	were	ascertained	by	treating	fragments	of	
tumour	cells	immediately	following	seeding	(passage(P)0)	with	two	different	culture	
media	compositions:	‘7+’	basic	media,	and	‘full’	growth-factor	rich	media	(Table	2.1).	
Both	conditions	were	based	on	previous	findings	in	the	literature	and	were	sought	to	
enhance	the	growth	of	tumours	with	differential	requirements	of	surrounding	
environmental	factors.	Many	colon	cancer	cells	require	little	addition	of	growth	
factors	for	culture	as	they	typically	harbour	mutations	which	facilitate	their	own	
niche	requirements	(Sato	et	al.	2009).	The	niche	dependency	of	other	CRC	organoids	
means	that	they	require	exogenous	stimulation,	such	as	those	provided	by	‘full’	
media	conditions,	with	additional	Wnt	and	R-spondin	conditioned	media,	as	well	as	
epidermal	growth	factor	(EGF),	Noggin,	TGF-β	inhibitor	(A83-01)	and	a	p38	inhibitor	
(SB202190).	Recent	studies	have	further	highlighted	the	manipulation	of	niche	
dependencies	of	CRC	required	to	support	the	growth	of	different	tumour	subtypes	in	
culture	(Fujii	et	al.	2016b)	and	will	be	considered	further	in	the	discussion	section	of	
this	thesis.		
	
In	order	to	quantitatively	analyse	the	most	favourable	growth	parameters	for	each	
organoid	line,	organoid	counts	were	generated	using	an	automated	colony	counter,	
GelCount™	technology.	To	facilitate	organoid	detection	and	counts	from	structures	
present	within	each	well,	CHARM	settings	were	established	with	threshold	values	for	
parameters	such	as	optical	density,	size,	circularity	and	quality	of	structure	edges,	as	
well	as	background	detection	to	ensure	minimal	aggregates	were	detected	as	
organoids.	The	software	enabled	automated	morphometric	readouts	from	organoid	
images	taken	from	wells	by	generating	a	script,	entitled	CHARM	settings.	For	CHARM	
settings	generation,	threshold	values	were	firstly	established	to	remove	outliers	of	
data.	Parameters	such	as	optical	density,	size,	and	definitive	object	outlines	were	
used	to	determine	objects	that	could	be	counted	as	organoids.	Following	one	
organoid	line	(Iso	75),	it	was	shown	that	the	number	of	organoids	formed,	as	
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counted	using	established	CHARM	settings	of	GelCount™	technology,	were	reliant	on	
media	conditions	used.	As	shown	in	Figure	3.3,	an	average	of	332(±94)	organoids	
were	generated	in	‘7+’	basal	conditions,	as	opposed	to	601±110	on	average	per	well	
in	‘full’,	growth	factor-rich	conditions.		It	is	however	worth	noting	that	both	counts	
and	visual	inspection	were	required	to	determine	the	best	media	conditions	as	
masks	generated	using	GelCount™	technology	calculate	the	(unlikely)	assumption	
that	all	structures	are	viable.	As	noted	in	previous	assessments	of	organoid	viability	
in	mouse	model	systems	(Grabinger	et	al.	2014)	,	non-viable	organoids	are	
characterised	by	a	loss	of	cellular	organisation	on	the	outermost	edge	of	structures,	
surrounding	cellular	debris,	and	a	lower	optical	density	as	structures	overall	contain	
a	dark	core	.	Collectively,	such	assessments	enabled	a	determination	of	sufficient	
growth	conditions	for	maximal	expansion	of	each	of	organoid	line,	as	listed	in	Table	
3.2	.	9	out	of	11	organoid	lines	established	for	this	study	demonstrated	sufficient	
growth	in	basic	‘7’+	media	conditions,	whilst	2	lines	were	dependent	on	propagation	
in	‘full’	media	conditions.	Given	that	organoids	were	derived	from	a	variety	of	
tumour	origins	and	stages,	it	was	unsurprising	that	to	reliance	on	particular	niche	
factors	for	growth	were	variable.			
	
Once	media	conditions	for	optimal	growth	had	been	established,	the	specified	media	
was	then	utilised	to	grow	continuing	organoids	throughout	subsequent	studies	
(Table	3.2).	By	means	of	this	selection	process,	it	was	possible	to	facilitate	maximal	
survival	for	tumours	with	varying	niche	requirements	for	growth,	despite	being	
unable	to	fully	interrogate	individual	niche	factors	required	for	each	line.			
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Figure	3.3	Analysis	of	media	requirements	for	organoid	growth	
Following	isolation	of	material	from	surgically	resected	colorectal	tissue,	Iso	75	organoids	were	
seeded	as	fragments	of	cells	at	a	density	of	1000	cells	per	50µl	of	growth	factor-reduced	Matrigel.	
Cultures	were	overlaid	with	two	media	conditions	to	determine	optimal	growth	requirements;	basal	
‘7+	Media’	or	Full	Media	containing	growth	factors,	10%	R-spondin	conditioned	media	and	40%	Wnt	
conditioned	media.	(A)	Bar	chart	depicts	the	average	number	of	organoids	formed	from	seeding	a	
1000	fragments	per	well	of	a	24	well	plate,	using	GelCount™		technology.	Data	are	presented	as	
mean±	standard	deviation,	whereby	n=3	wells.	(B)	Representative	images	from	each	well	per	
condition	were	obtained	using	GelCount™	software,	using	standard	settings	as	detailed	in	methods	
(2.3.6.1)	
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Table	3.2	Established	media	requirements	for	organoid	subset.	
Following	isolation	of	material	from	surgically	resected	colorectal	tissue,	two	media	conditions	were	
used	to	determine	optimal	growth	requirements.	Optimal	media	requirements	were	assessed	using	
basic	growth	parameters	such	as	changes	in	gross	morphometry	as	well	as	visual	inspection	of	
organoids	to	qualitatively	assess	the	amount	of	potential	dead	cells	present	in	culture.	An	
accumulation	of	cellular	debris	as	a	result	of	cell	death	would	often	be	visualised	in	sub-optimal	
conditions.	Media	conditions	for	Iso	38	were	determined	by	Dr.Andrew	Hollins	(Dale	lab).		
	
	
Isola&on	number	 Media	condi&ons	
Seeding	density	
(number	of	wells	
of	a	24	well	plate)	
29	 7+	 16	
34	 7+	 12	
36	 7+	 8	
38	 7+	 16	
48	 7+	 10	
49	 7+	 14	
50	 7+	 8	
72	 7+	 14	
73	 7+	 10	
75	 Full	 20	
78	 Full	 16	
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3.2.1.4 Patient-derived	tumour	organoids	exhibit	various	morphologies	and	
growth	rates	in	tailored	culture	conditions	
	
Based	on	early	observations	in	organoid	establishment,	as	well	as	findings	from	the	
literature,	it	was	clear	that	a	variety	of	tumour	organoid	morphologies	were	
obtained,	possibly	reflective	of	mutational	backgrounds	or	as	a	result	of	their	
surrounding	environment	(Sato	et	al.	2011a;	Yin	et	al.	2013;Riemer	et	al	2017).	Given	
that	organoids	could	be	generated	from	a	range	of	CRC	subtypes,	it	was	therefore	
necessary	to	establish	suitable	methods	to	quantify	changes	in	morphometry	and	
organoid	growth	over	time	to	ensure	stability	in	culture.	Using	an	automated	colony	
counter,	CHARM	settings	were	optimised	per	organoid	line	to	monitor	growth	in	
morphologically	variable	organoids	to	account	for	a	variety	of	structure	types.		
Organoids	that	formed	generally	more	cystic	structures	for	example	required	
different	density	thresholds	to	be	set	compared	with	denser	organoid	structures.	
CHARM	settings	were	then	used	to	generate	masks	around	individual	objects	within	
a	well	to	detect	basic	morphometric	features	of	the	2D	image	such	as	overall	
organoid	size,	(calculated)	volume,	density	and	number	within	a	well.	
	
Following	initial	selection	of	appropriate	growth	conditions,	complex	structures	of	
colonic	epithelial	organoids	grew	typically	for	between	seven-	fourteen	days	prior	to	
passage,	with	a	split	ratio	between	1:2	–	1:8	(wells)	implemented	every	7-10	days,	or	
as	necessary.	Epithelial	organoids	derived	from	different	patients	exhibited	a	variety	
of	growth	rates	within	the	first	few	passages	of	culture,	as	depicted	in	Figure	3.4.	As	
depicted,	growth	in	basal	7+	media	conditions	was	sufficient	to	yield	an	increase	in	
overall	organoid	diameter	over	several	days	within	these	three	organoid	types.	
Defined	culture	conditions	demonstrated	that	organoids	were	able	to	expand	to	
sizes	between	100μm-	500μm	on	average	over	two	weeks,	as	calculated	by	
GelCount™software	from	images	over	repeated	measurements.	Settings	were	
	 92	
established	for	each	organoid	line	and	altered	according	to	overall	morphologies	and	
cell	densities	per	structure.	
	
Distinct	morphological	variation	was	also	seen	across	different	patient-derived	
organoids,	as	shown	in	Figure	3.4	.	Iso	29	was	shown	to	yield	a	population	of	mainly	
cystic	organoids,	with	occasional	smaller,	denser	structures	observed.	Iso	36	
demonstrated	more	complex	morphologies,	with	budding	structures	protruding	
from	the	central	‘lumen’-like	structure.	Differential	morphology	was	further	
corroborated	by	images	of	various	organoids	fixed	and	stained	(day	5)	
simultaneously	with	a	Hoechst	and	Phalloidin	(F-actin)	stain,	and	captured	using	light	
sheet	microscopy,	as	seen	in	Figure	3.5.	These	images	showed	a	clear	distinction	
between	internal	morphologies	of	organoids;	Iso	75,	for	examples	showed	multiple	
lumen	structures	throughout	the	internal	cellular	composition	whereas	Iso	50	and	72	
had	a	more	basic	internal	morphology	with	occasional	branching	structures.	Overall,	
organoid	morphology	and	ratio	of	splitting	remained	stable	over	several	passages,	an	
important	requirement	of	future	drug	screening	studies,	retaining	morphologies	
observed	in	early	culture,	and	was	therefore	suitable	for	expansion	for	subsequent	
assays.		
	
As	well	as	establishing	optimal	growth	conditions,	this	work	also	aimed	to	maximise	
organoid	yields	to	facilitate	subsequent	experimental	repeats.	A	suitable	organoid	
freeze-	thaw	protocol	was	therefore	optimised	to	improve	organoid	recovery	from	
freezing	conditions.	Organoids	cultured	for	4	days	were	lifted	from	matrigel	and	
resuspended	in	cell	recovery	freezing	medium	(Invitrogen™).	The	suspension	was	
then	placed	in	cryovials	and	stored	in	-80°C	conditions.	For	organoid	recovery,	
cryovials	were	placed	in	the	water	bath	at	37°C	and	thawed	rapidly.	Structures	in	
suspension	were	then	washed	in	3+	media	prior	to	embedding	in	growth	factor-
reduced	matrigel,	and	then	overlaid	with	media.	To	examine	whether	addition	of	
ROCK	inhibitor	Y-27632,	previously	implicated	in	improving	cell	survival	(Ashley	et	al.	
2014),	could	enhance	organoid	formation	efficiency,	a	subset	of	Iso	49	organoids	
were	dissociated	to	single	cells	immediately	after	thawing,	plated	in	matrigel	and	
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overlaid	with	media	±	ROCK	inhibitor.	As	shown	in	Figure	3.6	,single	cell	recovery	and	
subsequent	organoid	formation	for	Iso	49	was	enhanced	when	media	contained		
10	µM	ROCK	inhibitor	Y-27632	for	the	first	three	days	in	culture.	Recovery	prior	to	
passage	was	established	between	5-10	days,	dependent	on	organoid	line.		
	 94	
	 	
	
Figure	3.4	Intestinal	organoids	show	a	variety	of	morphologies	and	morphometries	in	defined	culture	conditions	between	different	patient	subsets.	
Microscope	images	taken	at	day	7	in	culture	conditions	(Scale	bar=	100μm)	and	corresponding	growth	profiles	from	3	different	patient	carcinoma	samples	(A)	Iso29	(B)	
Iso36	(C)	Iso34.	Growth	is	indicated	as	diameter	per	organoid	average	per	well	(μm)	±Standard	deviation	measured	by	GelCount	charm	settings.		
(Ai) 
(Aii) 
(Bi) 
(Bii) 
(Ci) 
(Cii) 
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Figure	3.5	F-actin	staining	reveals	internal	complexity	of	organoid	structures.	
Organoids	were	passaged	by	trituration	(p4-p10)	prior	to	seeding	within	growth	factor	reduced	
matrigel	in	defined	media	conditions.	Following	5-7	days	of	growth,	cultures	were	fixed	and	stained	
simultaneously	using	a	Fix&	stain	solution	comprising	of	PFA	(4%),	Hoechst	and	TRITC-Phalloidin	to	
stain	F-actin.	Organoids	were	then	washed	before	transferred	to	agarose	for	imaging	purposes.	Scale	
bars	depicted	on	each	image	are	as	follows;	Iso	48,	Iso	50=	100µm,	Iso	72=200	µm,	Iso	75=	50	µm.
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Figure	3.6	Organoid	freeze-thaw	recovery.	
	Iso	49	organoids	were	frozen	in	Cell	Recovery	freezing	medium	and	stored	at	-80°C.	For	recovery,	
cryovials	were	thawed	rapidly	at	37°C,	prior	to	organoid	washes	and	embedding	within	matrigel.	
Organoids	were	plated	as	whole	structures,	or	further	trypsinised	to	calculate	the	number	of	cells	
present	in	culture	after	thawing,	then	overlaid	with	defined	media	conditions.	(A)	Representative	
images	of	organoids	derived	from	whole	frozen	organoids(‘pieces’),	or	single	cells,	±	ROCK	inhibitor.	
Scale	bar	=	100µm.	(Bi)	Bar	chart	to	represent	average	number	of	organoids	and	(Bii)	organoid	
formation	efficiency	(%)	calculated	by	GelCount	software.	Data	shows	mean	±	standard	deviation	
(n=3	wells),	unpaired	t-test;	**	p<0.01.
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3.2.2 Organoids	retain	overall	histological	architecture	of	matching	primary	
tumours	
	
In	order	to	assess	the	capacity	of	organoids	to	recapitulate	in	vivo	tumour	biology,	
histological	parameters	were	compared	between	clinical	samples	and	counterpart	
organoids.	Previous	studies	using	such	morphological	parameters	have	enabled	the	
identification	and	characterisation	of	clinical	features	in	both	patient	colorectal	
tumours	and	the	organoids	from	which	they	are	derived	(Fujii	et	al.,	2016).		
	
Hematoxylin	and	eosin	(H&E)-stained	primary	tumour	sections	were	processed	
(Wales	Cancer	Bank)	and	analysed	by	the	Histopathology	team	at	University	Hospital	
Wales	(Dr.	Delyth	Badder).	For	comparative	histology,	organoids	were	freshly	
passaged	into	Matrigel	and	cultured	for	4-7	days,	prior	to	fixation	(PFA,	4%	)	for	15	
minutes	at	room	temperature.	Organoids	were	then	washed	following	an	incubation	
on	ice	to	remove	matrigel	fragments,	then	resuspended	in	4%	low	melting	point	
agarose	prior	to	cryo-sectioning,	mounting	and	H&E	staining.		
	
Samples	derived	from	the	poorly	differentiated	samples	(Iso)	48	(metastatic)	and	
(Iso)	75	were	defined	as	particularly	aggressive	tumours,	as	indicated	by	vascular	
invasion	as	well	as	a	high	level	of	lymphocyte	infiltration	as	a	result	of	an	immune	
response,	shown	in	Figure	3.7.	Due	to	the	epithelial	nature	of	organoids	such	
observations	could	not	be	captured	in	matching	material.	Iso	48	and	Iso	75	samples	
were	also	found	to	contain	high	numbers	of	mitotic	bodies	reflective	of	multiple	cell	
divisions.	Overall,	it	was	found	that	many	epithelial	characteristics	found	in	parental	
tumours	were	also	observed	in	counterpart	organoids,	with	individual	structures	
retaining	similar	features.	Primary	tumours	containing	high	numbers	of	glandular	
structures,	for	example,	were	reflected	by	multiple	lumen	structures	within	organoid	
sections	such	as	those	observed	in	Figure	3.7	in	which	Iso	75	organoids	are	reflective	
of	matching	tumour	tissue.	An	overall	poorly	differentiated	tumour	containing	few	
small	glands	of	differentiation	(Iso	50)	was	shown	to	be	capable	of	deriving	a	mixed	
morphology	of	organoids;	some	mono-cellular	structures	with	a	cystic	phenotype	
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(Figure	3.7,	black	arrows)	,	as	well	as	structures	with	a	thick	epithelial	cell	layer	
containing	glandular	structures	within	the	organoid	(Figure	3.7,	purple	arrows).			
	
It	was	observed	that	Iso	72	was	derived	from	a	highly	mucinous	adenocarcinoma,	as	
indicated	by	a	significant	component	of	extracellular	mucin	pools	within	the	tumour	
section,	as	highlighted	in	Figure	3.7	Interestingly,	features	were	retained	in	culture	
as	identified	by	mucinous	vacuoles	within	corresponding	organoid	sections.	Previous	
studies	have	identified	that	such	adenocarcinomas	are	characterised	by	a	high	
proportion	of	Mucin	2-positive	goblet	cells	within	tumours,	and	have	successfully	
linked	patient	histology	with	specific	gene	expression	signatures,	such	as	goblet-,	
stem	cell-,	transit-amplifying-	and	enterocyte-like	tumours	(Sadanandam	et	al.	
2013).	
	
For	three	CRC	samples	(Iso	50,	Iso	72,	Iso	75),	organoids	were	additionally	
immunostained	for	Mucin	2	to	evaluate	the	presence	of	goblet	cells	within	samples	
and	to	further	determine	if	primary	cultures	were	able	to	retain	differentiation	
characteristics	observed	in	primary	tumours.	As	shown	in	Figure	3.8,	it	was	observed	
that	Iso	72	organoids	were	heavily	stained	for	Mucin	2,	suggestive	of	a	high	goblet	
cell	population,	in	concordance	with	observations	from	primary	material.	Iso	75	
organoids	demonstrated	some	mild	staining,	and	no	Mucin	2	positive	staining	was	
identified	in	Iso	50	cultures.		
	
Due	to	limitations	in	retrieving	organoid	sections	from	paraffin	blocks,	a	subset	of	
only	six	patient	and	corresponding	cultures	were	analysed	from	a	variety	of	graded	
clinical	samples.	Observations	collected	from	primary	tumour	samples	were	largely	
represented	by	counterpart	organoids,	with	the	exceptions	of	non-epithelial	
characteristics	such	as	vascular	invasion	(Figure	3.7,	yellow	arrows),	and	filtration	of	
neutrophils	and	lymphocytes	(Figure	3.7,	blue	arrows)	into	tumour	tissue.	However,	
this	data	strongly	indicates	that	histological	grading	and	the	cellular	differentiation	
status	is	largely	retained	between	patient	and	corresponding	organoid	culture	within	
the	samples	analysed,	in	line	with	current	knowledge	of	in	vivo	tumour	histology.		
	
	 99	
	
Figure	3.7	Representative	images	of	immunohistochemical	stains	from	surgically	resected	patient	
tumours.		
Organoids	were	cultured	in	defined	conditions,	embedded	in	paraffin,	sectioned,	and	stained	to	
define	cellular	architecture.	H&E	stained	patient	tumours	were	kindly	provided	by	the	WCB,	and	
analysed	and	imaged	with	the	histopathology	team	(UHW)	Scale	bar=100µm.	Arrows	denote	the	
following;	(ç)cystic	structures;	( )	dense	epithelial	structures	( )mucin	pools;	( )neutrophil	and	
lymphocyte	invasion;	( )	vascular	invasion;	( )	gland-like	structures/	organoid	lumen.		
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Figure	3.8	Organoids	derived	from	primary	material	resemble	differentiation	profiles	of	primary	
tumours.	
Organoids	were	cultured	in	defined	growth	conditions	prior	to	fixation	by	PFA	(4%)	prior	to	
immunostaining	with	anti-muc2	antibody	to	detected	mucin	positive	cells	as	an	indication	of	the	
presence	of	goblet	cells.	Scale	bar	=	50	µm.
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3.2.3 Genotypic	analysis	of	an	organoid	cohort	reveals	mutations	in	colorectal	
cancer-associated	genes	
	
In	order	to	classify	organoids	according	to	their	mutation	status	and	investigate	
whether	our	cohort	would	encompass	CRC	relevant	mutations,	DNA	was	isolated	
from	tumour	organoids,	using	a	Qiagen	DNA	extraction	kit	as	per	the	manufacturer’s	
protocol,	and	subject	to	analysis	using	the	Next	Generation	Sequencing	(NGS)	
SureSeq	Solid	Tumour	panel	carried	out	by	Oxford	Gene	Technologies	(OGT).		This	
panel	encompassed	genomic	regions	of	interest	to	characterise	the	status	of	60	
genes	previously	identified	in	cancer	development	and	progression.		A	variant	
analysis	report	was	carried	out	by	OGT	to	generate	the	mutation	status	of	each	gene	
of	interest	from	8	organoid	lines.	Mutations	were	detected	in	both	activating	
oncogenes	and	inactivating	tumour	suppressors	frequently	affected	in	colorectal	
tumours,	including	APC,	KRAS,	BRAF,	PIK3CA,	and	TP53.	The	severity	of	detected	
mutations	and	subsequent	impacts	upon	cellular	functions	were	determined	by	
integrating	outputs	of	individual	variants	with	the	Sanger	COSMIC	database	
(Catalogue	of	somatic	mutations	in	cancer),	as	shown	in	Table	3.3,	which	highlight	
relevant	mutations	within	a	particular	tissue.	Mutations	that	were	identified	in	the	
sequencing	data,	but	not	previously	noted	in	the	COSMIC	database	were	labelled	as	
‘no	COSMIC	record’.		It	remains	uncertain	whether	these	mutated	genes	would	
significantly	impact	cellular	function,	as	they	have	not	been	previously	identified	
within	colorectal	tissue	as	frequent	mutations.	Given	that	sequencing	was	only	
carried	out	for	tumour	organoids	and	not	matched	normal	DNA,	it	is	difficult	to	fully	
distinguish	between	mutations	as	opposed	to	polymorphisms,	and	whether	events	
were	from	germline	or	somatic	variants.	Analysis	was	therefore	carried	out	in	
comparison	to	sources	within	the	literature.		
	
CRC	is	heavily	associated	with	activating	mutations	within	components	of	the	Wnt	
signalling	pathway,	including	APC	and	β-catenin	encoded	by	APC	and	CTBNN1.	
Mutations	in	APC	were	observed	in	8	organoid	lines,	with	5	out	of	8	lines	harbouring	
mutations	that	resulted	in	a	truncated	protein.	Some	lines	possessed	mutations	
previously	unidentified	within	the	COSMIC	database	therefore	their	relevance	to	APC	
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function	is	unknown.		Previously	identified	CTNNB1	mutations	were	present	in	3	of	
the	organoid	lines,	Iso	48,	75	and	78.	Interestingly	Iso75,	and	Iso	78	were	reliant	on	
full	media	conditions	that	contained	exogenous	Wnt	and	R-spondin	conditioned	
media,	demonstrating	a	complex	niche	requirement	to	be	maintained	within	culture.	
In	principle,	ß-catenin	mutations	result	in	an	overall	activation	of	the	Wnt	signalling	
pathway,	suggesting	that	such	organoids	would	be	capable	of	growth	in	absent	Wnt	
or	R-spondin.	However	without	a	complete	dissection	of	required	growth	factors	
within	the	media,	it	is	possible	that	growth	within	Iso	75	and	Iso	78	are	reliant	on	
other	exogenous	components	within	Full	media.		
	
Mutations	in	genes	involved	in	DNA	Damage	Response	(DNA)	were	prevalent	in	most	
organoids	sequenced.	For	the	purposes	of	categorising	organoids	into	clinically	
relevant	biomarkers,	the	mutation	status	of	ATM	and	TP53	were	assessed.			
Mutations	within	ATM,	which	has	been	previously	associated	with	DNA	replication	
stress,	was	identified	in	3	out	of	8	organoid	lines.	Whilst	these	had	not	been	
previously	identified	within	the	COSMIC	database,	these	changes	resulted	in	
deleterious	events	and	truncating	mutations.	The	comparative	analysis	of	germline	
DNA	would	therefore	be	useful	for	further	studies	of	these	organoid	lines.	It	was	also	
observed	that	TP53	was	frequently	mutated	among	organoids,	impacting	5	out	of	8	
lines	sequenced.		
	
Genetic	alterations	in	the	PI3K	and	RAS-MAPK	pathway	have	previously	been	
identified	within	CRC.	The	PIK3CA	gene	encodes	the	p110a	catalytic	subunit	of	
phosphatidylinositol	3-kinase	(PI3K),	with	mutations	resulting	in	aberrant	activation	
of	the	PI3K/	AKT	pathway	that	promotes	cell	division.	Within	our	organoid	cohort,	
Iso	48	was	found	to	harbour	a	missense	mutation	at	codon	1625	(A>T),	previously	
implicated	in	the	large	intestine	according	to	the	COSMIC	database.	Other	mutations	
identified	within	Iso	49,	75	and	78	were	not	previously	identified	as	having	a	high	
implication	in	other	colorectal	cancer	tissue	samples,	however	resulted	in	
deleterious	events.	A	comprehensive	molecular	characterisation	of	CRC	has	
previously	revealed	that	genomic	amplifications	or	mutations	of	the	gene	ERBB2,	is	
altered	in	approximately	6%	of	colorectal	tumours	(Cancer	Genome	Atlas	Network	
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2012).	In	the	organoids	assessed,	it	was	found	that	Iso	34,	48	and	78	contained	
alterations	previously	identified	within	the	COSMIC	database	as	pathogenic.	It	was	
found	that	most	organoids	also	contained	alterations	within	EGFR,	that	could	lead	to	
amplification	of	the	EGFR	receptor,	however	none	of	these	could	be	identified	as	a	
mutation	that	could	be	classed	as	targetable	within	the	clinic.	
	
BRAF	mutations	occur	in	approximately	8-15%	of	patients	with	CRC,	and	are	often	
associated	with	a	poorer	prognosis	in	patients.	Based	on	previous	findings	within	the	
literature,	BRAF	mutations	within	CRC	are	an	activating	missense	mutation	at	amino	
acid	position	600;	whereby	a	glutamic	acid	amino	acid	is	substituted	for	valine	
(V600E).	Iso	75	was	shown	to	harbour	a	mutation	at	this	position,	as	well	as	a	
truncation	at	residue	40	(previously	not	identified	within	COSMIC).	Iso	34	was	also	
shown	to	carry	a	BRAF	mutation	at	amino	acid	position	601,	which	has	been	lesser	
implemented	in	previous	colorectal	cancer	tissues	analysed.	KRAS	mutations,	
particularly	G12V	mutations	resulting	in	a	substitution	at	amino	acid	position	12	in	
KRAS	are	observed	in	approximately	40%	of	colorectal	cancers,	with	21%	of	these	at	
the	G12V	position	(Forbes	et	al.	2015).	Iso	50,	Iso	72,	and	Iso	73	were	shown	to	have	
harboured	these	KRAS	mutations	from	eight	organoid	lines	sequenced.		Another	
frequent	mutation	associated	with	CRC	is	a	p.G12D	mutation	which	results	in	the	
expression	of	constitutively	active	KRAS,	and	was	identified	within	2	of	our	organoid	
lines.
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Table	3.3	Organoids	harbour	CRC-relevant	mutations	
Table	depicting	key	gene	mutations	(by	amino	acid)	in	a	cohort	of	organoids.	
DNA	extraction	was	carried	out	by	Dr.	Andrew	Hollins	(Dale	lab).	OGT	(Oxford	Gene	Technologies)	
performed	NGS	and	subsequent	analysis	of	8	organoid	lines.	COSMIC	database	comparison	analysis	
was	carried	out	by	Dr.	Kenneth	Ewan	(Dale	lab).	
	
Iso	 APC	 CTNNB1	 BRAF	 ATM	 EGFR	 ERBB2	 KRAS	 TP53	 PIK3CA	 PTEN	
34	 p.E1451	
No	
COSMIC	
record	
	
p.K601E	
No	
COSMIC	
record	
	
p.T862A,p.
P1170A	
No	
COSMIC	
record	
	
48	 p.R259W	 p.S33F	
No	
COSMIC	
record	
	
p.P1170A	 p.E542V	
49	 p.Q1447	p.R1450	
p.G12D	
	 p.R248Q	
No	
COSMIC	
record	
	
50	 p.E1286	p.R232	
	
p.G12V	
	
p.R248Q	
72	 p.Q1291	 p.G12V		
73	 p.Q1228	 p.G12V	 p.R248R		
75	
No	
COSMIC	
record	
p.L46P	 p.V600E	p.D693N	
No	
COSMIC	
record	
	
No	
COSMIC	
record	
No	
COSMIC	
record	
	
No		
COSMIC	
record	
78	 p.R876	p.E1451	 p.WC38C	
p.P1170A	 p.G12D	 p.H193D		
No	
COSMIC	
record	
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3.2.4 Tumour	organoids	demonstrate	highest	metabolic	activity	within	the	first	
seven	days	of	culture	after	seeding	
	
To	ascertain	optimal	conditions	for	maximal	organoid	viability	to	facilitate	
subsequent	drug	titration	experiments,	metabolic	readouts	were	established	from	
organoids	in	culture,	as	opposed	to	relying	on	basic	parameters,	such	as	organoid	
size,	as	an	indication	of	growth.		
	
Organoids	(Iso	34)	previously	established	in	culture	were	split	by	trituration	and	
embedded	within	growth	factor-reduced	matrigel.	Media	changes	occurred	every	3	
days,	or	as	necessary.	To	determine	a	live	readout	of	metabolic	activity,	as	a	
proportional	measure	to	the	number	of	viable	cells	Presto	Blue	(Sigma),	a	resazurin-
based	reagent	that	is	reduced	in	the	presence	of	metabolic	activity	in	surrounding	
media	of	cells,	was	added	to	cells	in	culture	at	specific	time	points	over	a	period	of	
14	days.	As	depicted	in	Figure	3.9,	repeated	fluorescent	readouts	of	metabolic	
activity	was	shown	to	reach	a	peak	within	the	first	seven	days	of	culture	following	
routine	organoid	trituration.	There	was	no	significant	increase	in	mitochondrial	
activity	observed	thereafter,	indicating	that	exponential	growth	took	place	within	
the	first	seven	days	of	culture.		
	
Haematoxylin	&	Eosin	(H&E)	stained	sections	of	Iso	34	cultured	in	parallel	for	14	days	
demonstrated	that	organoids	were	composed	of	seemingly	necrotic	cores	when	
cultured	for	a	period	of	14	days.	This	would	suggest	that	a	number	of	cells	had	been	
shed	into	the	central	lumen	of	the	organoid	and	/	or	that	the	structures	became	too	
large	for	sufficient	nutrient	access	to	cells	in	the	centre.	Collectively,	this	data	
indicates	a	period	of	7	days	in	culture	is	sufficient	for	optimal	organoid	growth,	a	
prerequisite	required	for	generating	optimal	output	from	patient	material	in	terms	
of	expansion	in	culture.			
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Figure	3.9	Metabolic	activity	of	organoids	increases	within	the	first	seven	days	of	seeding.	
Iso	34	organoids	were	split	by	trituration,	embedded	within	growth	factor-reduced	matrigel	and	
seeded	within	round,	clear-bottomed	96	well	plates	in	defined	media	conditions.	(A)	Presto	Blue	
reagent	was	administered	to	organoids	at	day	3,7,10,14	following	seeding,	prior	to	collecting	
fluorescence	measurements	from	supernatant	on	a	Fluostar	OPTIMA	platereader	(BMG	Labtech)	with	
an	excitation	of	570nm,	emission	610nm	as	an	indication	of	metabolic	activity.	Data	is	shown	as	fold	
change	in	fluorescence	signal	from	first	measurement	(day	3)	in	culture	±	standard	deviation	(n=4	
wells).	**p	≤	0.01	using	a	paired	student’s	t-test	(B)	Following	14	days	in	culture,	Iso	34	organoids	
were	fixed	(4%	PFA),	embedded	within	paraffin,	and	sectioned	prior	to	hematoxylin	and	eosin	
staining.	Scale	bar	50	µm.			
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3.2.5 Organoid	formation	from	single	cells	
	
Given	previous	indications	that	organoid	size	is	not	necessarily	correlated	to	the	
number	of	metabolically	active	cells	within	a	structure,	it	was	investigated	whether	
further	regulation	of	organoid	size	could	be	beneficial	for	generating	organoids	
containing	viable,	proliferating	cells.	Here,	the	organoid	line	Iso	34,	an	organoid	line	
generated	within	the	first	stages	of	this	study,	was	used	to	explore	whether	
organoids,	enzymatically	digested	to	near-single	cell	could	recover	appropriately	to	
form	elaborate,	viable	structures	for	subsequent	assays.		
	
Established	cultures	were	dissociated	using	TrypLE	(Life	Technologies)	and	seeded	at	
an	approximate	density	of	2000	cells	in	20µl	of	Matrigel	in	96	well	clear,	round	
bottomed	plates	(Nunc),	and	incubated	in	Basal		‘7+’	Media,	containing	10μM	ROCK	
inhibitor	Y-27632	for	three	days.	ROCK	inhibitor	Y-27632	has	previously	been	
implemented	in	promoting	survival	of	intestinal	epithelial	cells	which	are	likely	to	
undergo	anoikis	following	disruptive	procedures	such	as	trypsinisation	(Ashley	et	al.	
2014;	Dr.Mairian	Thomas	-	personal	communication	and	PhD	thesis).	Iso	34	
organoids	were	formed	within	less	than	24	hours	of	culture,	and	further	developed	
to	form	more	lobular	structures	representative	of	previous	structures	identified	from	
organoids	cultured	by	trituration.	It	is	worth	noting	that	trypsinisation	alone	is	
unlikely	to	obtain	definitive	single	cells,	and	that	many	doublets	and	cell	aggregates	
would	remain	which	could	also	influence	growth	rates.		Over	a	period	of	15	days	in	
culture,	organoids	developed	to	form	morphologically	similar	structures	to	those	
previously	obtained	by	whole	trituration.		
 
To	assess	proliferation	rates	of	single	cell-derived	organoids,	quantitative	analysis	of	
mitochondrial	activity	was	taken	using	Presto	Blue.		Multiple	readouts	were	taken	
from	the	same	wells	(n=4	technical	replicates)	at	different	intervals	over	14	days,	
with	changes	in	media	taking	place	at	each	time	point.	Fluorescent	readouts	were	
measured	using	a	Fluostar	OPTIMA		(BMG	Labtech™)	platereader	at	excitation	of	
570nm	and	emission	of	610nm.	As	depicted	in	Figure	3.10(B),	the	greatest	increase	
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in	mitochondrial	activity	was	observed	between	days	2	and	7	in	culture,	with	no	
significant	increase	in	proliferation	thereafter	(p=<0.05,	student’s	t-test).	
Morphologically,	single	cells	formed	whole	structures	capable	of	proliferation,	as	
indicated	by	positive	Ki67	immunostain	in	Iso	34	organoids	at	day	7	in	culture.		
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Figure	3.10	Iso	34	proliferation	from	near-single	cells.	
Iso	34	organoids	were	trypsinised	to	near-single	cells	and	seeded	at	2000	cells	per	25	μl	of	matrigel	in	
round,	clear-bottomed	96	well	plates.	7+	media	conditions	were	applied,	with	ROCK	inhibitor	(Y-
27632)	included	for	6	days	to	aid	cell	recovery	from	the	trypsinisation	process.	(A)	Representative	
images	of	organoids	at	24	hours	(day	1)	and	15	days	following	seeding	respectively.	Scale	=	100µm.	
(B)	Proliferation	was	assessed	at	different	time	points	in	culture	using	a	presto	blue	cell	viability	kit.	
Presto	blue	was	added	to	media	in	wells	and	incubated	for	3	hours,	prior	to	fluorescent	readings.	
Graph	displays	the	fold	change	in	fluorescent	signal	from	spent	media	collected	at	each	time	point,	
normalized	to	first	measurement.	*	p	≤	0.05	(n=1,	4	technical	repeats)	from	student’s	t-test	(C)	
Confocal	images	of	immunofluorescent	staining	of	Iso	34	organoids	derived	from	single	cells,	staining	
for	Ki67.	Nuclei	were	counterstained	with	Hoechst.
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3.2.6 Optimal	seeding	densities	are	a	necessity	for	maximal	organoid	viability	
	
A	plethora	of	factors	have	the	potential	to	influence	the	rate	of	organoid	growth	and	
number	of	viable	cells	in	culture.	Previous	studies	in	the	literature	have	
demonstrated	the	potential	of	influencing	cell	fates	of	intestinal	stem	cells	by	
controlling	self-renewal	and	differentiation	(Yin	et	al.	2013).	Furthermore,	the	niche	
environment	that	tumour	organoids	themselves	generate	has	shown	to	be	a	
deciding	factor	in	dependency	on	exogenous	growth	factors	within	culture	(Fujii	et	
al.	2016a).	It	would	therefore	be	a	fair	assumption	that	subsequent	organoid	
formation	and	growth	can	be	influenced	by	the	number	of	cells	seeded	initially.	To	
enhance	organoid	compatibility	with	a	high	throughput	assay	format,	optimisation	of	
appropriate	seeding	densities	was	performed	using	an	organoid	line,	Iso	50.	
	
Trypsinised	cells	of	previously	established	organoids	(Iso	50)	were	seeded	at	a	range	
of	densities	within	white	clear-bottomed	96	well	plates	(n=6	wells).	A	range	of	
seeding	densities	(100	-	1000	cells/	µl	of	Matrigel)	within	a	total	volume	of	9	µl	of	
matrigel	were	plated	within	each	well.	Cell	seeding	was	based	on	calculations	of	
viable	cell	counts,	by	counting	trypan	blue-negative	stained	cells	only.	Following	a	7	
day	incubation	in	‘7+’media,	a	Cell	Titer	Glo	3D	endpoint	assay	(Figure	3.11)	was	
implemented,	in	which	the	quantitation	of	ATP	in	relative	luminescence,	and	thus	
quantity	of	metabolically	active	cells	per	well.	If	there	were	indeed	an	optimal	
seeding	density	for	tumour	organoids,	it	would	be	expected	that	under-	and	over-
seeding	could	be	detrimental	to	the	balance	of	important	secretory	niche	factors	
upon	which	organoids	rely	which	could	harbour	growth.		
	
Results	demonstrated	an	overall	increase	in	the	relative	luminescence	signal	
obtained	with	increasing	number	of	cells	seeded	.	ATP	readouts	were	however	
shown	to	plateau	beyond	an	initial	seeding	density	of	of	500	cells/µl	of	Matrigel.	A	
standard	curve	of	Cell	Titer	Glo	3D	measurements	obtained	from	known	ATP	
concentrations	generated	simultaneously	indicated	that	the	relative	luminescence	
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values	obtained	from	cultures	were	still	within	the	range	of	the	assay	window,	as	
shown	in	Figure	3.11	(A).	This	would	therefore	indicate	that	organoids,	beyond	a	
threshold	seeding	density	of	500cells/µl	of	Matrigel,	were	perhaps	restricted	by	
limiting	factors	for	growth	such	as	physical	space	and	nutrient	access.			
	
Organoid	formation	efficiency,	as	calculated	by	the	percentage	of	organoids	formed	
from	viable	single	cells,	was	somewhat	inversely	correlated	with	seeding	density	as	
depicted	by	Figure	3.11	(E).	Since	trypsinisation	of	organoids	are	unlikely	to	form	
absolute	single	cells,	the	proportion	of	doublets	or	triplet	cells	could	influence	the	
rate	of	growth	of	organoids.	However,	it	is	more	likely	that	a	lack	of	physical	space	
within	a	well	would	prevent	such	efficient	organoid	formation	as	they	compete	for	
nutrient	access.	Taken	together,	the	optimal	seeding	density	for	plating	was	
established	at	400	cells/µl	of	matrigel.	With	the	advantages	of	single-cell	seeding	
formats	clear,	this	density	was	incorporated	as	a	standard	across	all	organoid	lines	to	
incorporate	sufficient	number	of	organoids	per	well,	maintaining	maximal	yields	and	
viability.		
	
Using	established	seeding	densities,	organoids	formation	efficiencies	from	three	
different	isolations	(Iso	34,	Iso	49	and	Iso	50,	Figure	3.12)	were	calculated	over	three	
consecutive	passages	to	ensure	that	growth	characteristics	remained	stable	for	the	
purposes	of	experimental	repeats.	Despite	some	variation	observed	in	formation	
efficiencies	of	Iso	50	organoids,	overall	it	was	deduced	that	organoid	behaviour	
remained	largely	stable	over	passages	with	fluctuations	more	as	a	result	of	minor	
variations	in	seeding	accuracy	from	manual	counts.		
	
Overall,	these	data	demonstrate	the	establishment	of	optimal	seeding	densities	
required	to	facilitate	future	drug	titration	experiments.	Although	data	were	only	
collected	on	the	basis	of	one	organoid	line,	it	is	worth	noting	that	the	consistency	
from	one	assay	to	the	next	across	organoid	lines	was	also	a	factor	to	consider	to	
facilitate	further	drug	titration	experiments.
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Figure	3.11	Assigning	optimal	cell	seeding	density	for	optimal	organoid	growth	from	single	cell.	
Iso	50	organoids	were	dissociated,	seeded	at	a	range	of	densities	(100-1000	cells	per	µl	of	matrigel)	and	cultured	in	‘7+’	media	before	ATP	measurements	(A)	Standard	
curve	measured	from	known	ATP	concentrations	within	media	measured	using	the	Cell	Titer	Glo	3D	reagent	(n=3	technical	replicates).	(B)	Representative	images	of	
organoids	seeded	from	a	range	of	densities	(day	7),	Scale	bar	=	100	µm.	(C)	Cell	Titer	Glo	3D	readouts	from	organoids	at	day	7,	(n=6	well).	(D)	Average	number	of	organoids	
counted	(n=6	wells)	using	GelCount	software	after	7	days	in	culture.	(E)	Average	organoid	formation	efficiency	generated	per	known	viable	cells	seeded,	per	well.	Data	are	
presented	as	mean	±standard	deviation,	whereby	(n=6	)	replicate	wells.	*p<0.05;**p<0.01;***p<0.001,	ANOVA	with	Tukey’s	post	hoc	comparison.	
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Figure	3.12	Organoid	formation	efficiency	stability	over	three	consecutive	passages	
The	organoid	lines	(	Iso	34,	Iso	49,	Iso	50)	were	digested	with	TrypLE,	prior	to	plating	at	a	density	of	
400	cells/	µl	of	growth	factor-reduced	matrigel	within	white,	96	well	plates	,	and	overlaid	with	
defined	media.	Organoid	formation	efficiencies	were	calculated	by	the	percentage	of	organoids	
formed	from	the	known	number	of	cells	seeded	per	well.	Data	shown	from	n=3	technical	replicates	±	
standard	deviation.	*p<0.05;**p<0.01;***p<0.001,	Two	way	ANOVA	with	Tukey’s	multiple	
comparison	test.	
	
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
4.5 
5 
P1 P2 P3 
O
rg
an
oi
d 
fo
rm
at
io
n 
ef
fic
ie
nc
y 
(%
) 
Passage Number 
Iso 34 
Iso 49 
Iso 50 
**	
	 114	
	
3.2.7 Organoids	seeded	from	single	cells	enhance	assay	quality	in	a	96	well	plate	
format		
	
To	determine	whether	robust,	reproducible	treatment-dependent	responses	could	
be	measured	in	tumour	organoids	in	a	high	throughput	setting,	a	proof-of-principle	
assay	format	was	established,	in	which	organoid	viability	was	quantified	following	
treatment	with	5-Fluorouracil,	a	current	standard	of	care	(SOC)	chemotherapeutic	
for	CRC.	
	
Iso	34	cultures	were	established	from	freshly	dissociated	cells	and	were	incubated	in	
basal	‘7+’	media	containing	10µM	of	ROCK	inhibitor	for	the	first	three	days	in	culture	
to	enhance	organoid	recovery	from	single	cells.	Given	that	a	log	phase	of	growth	was	
previously	observed	during	the	first	seven	days	following	seeding,	treatment	was	
administered	during	this	period	to	ensure	the	inhibitor	would	exert	maximal	impact	
on	overall	organoid	viability.	Following	three	days	of	culture	from	dissociated	cells,	
DMSO	control	conditions	(0.1%	in	media)	and	a	titration	dose	of	5FU,	ranging	from	
9.76	nM	to	2500	nM,	were	applied	within	media.	Treatments	were	administered	for	
a	total	of	4	days	prior	to	an	endpoint	Cell	Titer	Glo	3D	viability	readout,	whereby	
luminescence	values	were	used	to	quantify	ATP	levels	as	an	indication	of	the	number	
of	metabolically	active	cells	present.	Representative	images	of	organoids	acquired	at	
day	5	and	day	7	in	culture	(2	days,	and	4	days	following	treatment,	respectively)	
demonstrated	that	5-FU	exerted	effects	in	a	dose	dependent	manner	within	2	days	
of	treatment	at	highest	concentrations;	multiple	structures	demonstrated	a	lack	of	
integrity,	with	smaller	cells	and	an	overall	darker	appearance,	indicative	of	increased	
cell	death.	
		
The	obtained	results	indicate	that	the	number	of	viable	cells	were	treatment-
dependent,	as	demonstrated	in	Figure	3.13	(A).	IC50	values,	the	concentration	of	
compound	required	to	induce	a	50%	inhibition	of	luminescence	readouts	compared	
to	control	conditions,	were	obtained	from	the	dose	response	curve	shown	in	Figure	
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3.13.	Based	on	Cell	Titer	Glo	3D	readouts,	the	IC50	values	identified	for	Iso	34	
organoids	treated	with	5FU	for	4	days	were	120	nM.		
	
Taken	together,	these	results	demonstrated	that	a	uniform	population	of	organoid	
sizes	during	initial	plating	generated	relatively	robust	assay	readouts	in	terms	of	
well-to-well	variation,	which	could	be	quantified	in	response	to	treatments,	further	
validating	such	assay	formats	for	subsequent	studies.	Attempts	to	recapitulate	this	
assay	format	in	triturated	organoids	as	opposed	to	those	seeded	from	single	cells	
(data	not	shown)	further	emphasised	the	importance	of	organoid	size	regulation	in	
delivering	more	reproducible	results.	
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Figure	3.13	Effects	of	5-FU	treatment	on	Iso	34	organoids	derived	from	dissociated	cells.	
Organoids	were	plated	in	96	well	plates	at	an	optimal	density	of	400	cells/	µl	of	Matrigel,	and	treated	with	a	two	fold	titration	range	(9	nM	–	2500	nM)	of	5-Fluorouracil,	or	
0.1%	DMSO	control	within	media,	following	three	days	in	culture.	(A)	Representative	organoid	images	at	day	5	and	7	in	culture.	(B)	Representative	diagram	of	optimised	
assay	format.	(C)	Drug-dose	response	curve	generated	from	an	endpoint	Cell	Titer	Glo	3D	viability	assay	(	mean	±±	standard	deviation,	n=3	wells)	IC50	values	generated	
were	of	120nM.	(n=3	wells)	
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3.3 Summary	
Here,	the	establishment	and	continuous	culture	of	a	cohort	of	patient-derived	CRC	
organoids	was	explored	to	facilitate	drug	studies	further	discussed	in	chapters	4	and	
5.	Appropriate	isolation	protocols	and	media	conditions	propagated	the	generation	
of	organoids	that	retained	key	histological	characteristics	from	parental	tumour	
sections	generated	from	an	array	of	TNM	stages.	A	genotyped	cohort	were	also	
shown	to	harbour	CRC-relevant	mutations,	further	highlighting	their	utility	as	a	
relevant	model	system	for	CRC	therapeutics.		
	
Work	described	here,	using	a	subset	of	organoids	to	optimise	suitable	assay	formats,	
demonstrated	that	organoids	established	from	dissociated	cells	generate	relevant,	
viable	structures	that	could	expand	sufficiently	from	little	material	to	yield	maximal	
organoid	outputs;	facilitating	the	transition	towards	a	high-throughput	system.		
Reproducibility	both	within	and	across	assays	was	also	explored;	plating	conditions	
enabled	sufficient	assay	sensitivity	to	highlight	treatment-dependent	responses,	
whilst	the	generation	of	sufficient	organoid	freezing	protocols	enables	repeats	to	be	
performed	within	a	few	passages.		
	
Furthermore,	this	preliminary	work	provides	a	strong	foundation	for	subsequent	
analysis	formats	that	can	be	further	adapted	to	explore	organoid-inhibitor	
relationships,	demonstrated	in	Chapters	4	and	5,	validating	this	amenable	system	for	
future	compound	testing.	
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4 Towards	modelling	a	clinical	trial	in	vitro:	optimisation	and	
utilisation	of	patient-derived	colorectal	organoid	models	
	
4.1 Introduction	
	
The	stratification	and	targeted	treatment	of	patients	according	to	the	molecular	
profile	of	their	tumour	has	shown	some	promise	for	the	future	of	CRC	therapeutics.	
Nevertheless,	genomic	profiling	as	a	basis	for	therapy	underestimates	the	complexity	
of	signalling	pathways	in	tumour	cells,	and	therefore	have	limitations	to	accurately	
predict	patient	outcomes	in	the	clinic	(Pauli	et	al.	2017).	Current	methods	to	assess	
functional	effects	of	therapies	rely	heavily	on	2D	clonal	culture	models	as	pre-clinical	
proxies	for	patient	tumour	drug	sensitivity	and	responses.	However,	cell	line	models	
fail	to	represent	some	tumour	subtypes	and	lack	both	phenotypic	cellular	and	
genotypic	heterogeneity,	limiting	their	relevance	to	tumours	assessed	within	clinical	
trials.			
	
The	generation	of	a	3D	colorectal	organoid	platform	could	thus	serve	as	an	
alternative	in	vitro	model	system	to	provide	a	better	representation	of	tumour	
biology	in	a	more	‘in	vivo’	like	context.	Given	the	volume	and	complexity	of	pre-
clinical	data	required	to	support	clinical	trials,	further	information	is	needed	to	
support	the	utility	of	organoids	in	the	context	of	live-cell	biomarker	readouts.	
The	data	presented	here	therefore	aims	to	ensure	whether	sufficient	data,	through	
the	use	of	organoids,	can	be	generated	to	guide	subsequent	trial	designs,	
complementary	to	genomic	analyses.	Within	this	study,	the	FOCUS	4	clinical	trial	was	
used	as	a	basis	to	examine	whether	organoids	could	be	utilised	as	suitable	tools	to	
capture	beneficial	in	vitro	data.		
	
Employing	methods	described	in	chapter	3,	the	work	presented	in	this	chapter	
details	advances	made	towards	an	organoid	screen	against	a	panel	of	biomarker-
driven	therapies	relevant	to	the	FOCUS	4	trial.	To	achieve	this,	a	cohort	of	organoids	
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were	treated	with	agents	used	in	a	number	of	arms	of	FOCUS	4,	and	assessed	using	
viability	and	imaging	analysis	readouts.		The	outcome	of	this	purely	in	vitro	study	
should	allow	us	to	make	a	preliminary	assessment	of	the	value	of	specific	tumour	
biomarkers	as	indicators	of	drug	response	in	CRC	organoids.	Furthermore,	this	work	
should	enable	us	to	eventually	cross-compare	organoid	responses	with	a	population	
of	independent	patients	who	have	been	stratified	with	the	same	biomarkers	within	
the	FOCUS	4	trial.	This	will	allow	us	to	assess	whether	organoid	responses,	have	the	
potential	for	independent	power,	from	that	of	biomarkers,	in	the	assessment	of	
patient	responses.		
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4.2 	Results	
As	previously	discussed	(section	1.5.1),	the	MRC	FOCUS	4	trial	is	a	randomised	
multicentre	clinical	trial	that	aims	to	stratify	patients	according	to	the	molecular	
profile	of	their	tumour	and	treat	them	accordingly	with	hypothesis-driven	therapies.	
As	such,	there	are	several	potential	drug	candidates	targeting	several	pathways	
within	tumour	development.	Following	genotyping	of	organoids,	described	in	
chapter	3,	work	described	here	aimed	to	characterise	organoid	responses	to	each	
relevant	arm	of	the	FOCUS4	trial,	essentially	enabling	a	small	scale	in	vitro	study.	The	
main	aim	of	this	work	is	to	establish	whether	organoid	responses	might	be	
incorporated	into	future	clinical	trial	designs.	
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4.2.1 Cell	cycle	inhibitors	induce	cell	cycle	arrest	in	CRC	organoids.	
	
As	previously	discussed	in	section	1.5.4,	deficiencies	in	DDRs	are	contributing	factors	
in	tumour	initiation	and	progression,	and	are	therefore	an	attractive	target	for	
therapy.		Several	targets	of	the	DDR	pathway	have	been	identified	and	subject	to	
manipulation	by	many	drug	candidates,	in	order	to	induce	synthetic	lethality	within	
tumour	cells.	Targets	within	the	pathway,	Wee1	and	ATR,	are	currently	under	
investigation	within	the	FOCUS	4	clinical	trial	to	assess	whether	selective	compounds	
(Mk1775	and	AZD6738)	will	result	in	improving	progression	free	survival	in	patients	
harbouring	KRAS/TP53	and	ATM	mutations,	respectively.	
	
In	order	to	validate	whether	organoids	can	be	used	within	an	in	vitro	trial	setting,	a	
selection	of	organoids	that	were	well	established	in	culture	(as	listed	in	Table	3.3)	
were	administered	with	a	Wee1	inhibitor	(MK1775)	and	ATR	inhibitor	(AZ20,	an	
analogue	of	AZD6738	suitable	for	in	vitro	use)	to	recapitulate	two	treatment	arms	of	
FOCUS	4,	and	assessed	for	readouts	of	viability	as	a	representation	of	tumour	growth	
inhibition.	Preclinical	in	vitro	and	in	vivo	data	have	previously	demonstrated	the	
efficacy	of	AZD6738,	particularly	(but	not	exclusively)	within	ATM-deficient	tumours,	
generating	IC50	values	of	less	than	1	µM	in	cell-based	assays	(Kim	et	al.	2017).	
MK1775	has	also	demonstrated	promising	pre-clinical	results	as	a	DNA-damaging	
agent	(Kreahling	et	al.	2013).			
	
A	set	of	organoids	previously	seeded	from	single	cells,	at	day	3	in	culture,	were	
administered	with	a	titration	of	MK1775	(0	nM	–	5000	nM),	AZ20	(0nM-	5000	nM)	as	
well	as	a	DMSO	control	(0.1%),	within	the	tailored	media	conditions	as	required	for	
each	organoid	line	(Table	3.2).	Following	4	days	of	exposure	to	compounds,	an	ATP	
endpoint	viability	readout	was	generated	from	each	condition	and	plotted	to	
generate	dose	response	curves	per	organoid	line	(data	not	shown	for	all	lines).	From	
each	curve,	EC50	(half	maximal	effective	concentration)	values	were	obtained	from	
n=3	independent	experiments,	as	listed	in	Table	4.1.	All	8	organoids	tested	
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demonstrated	a	range	of	sensitivities	to	both	compounds	with	EC50	values	in	the	
range	of	0.3	µM	–	21	µM	for	AZ20,	and	0.1	µM	–	1	µM	for	MK1775,	as	indicated	in	
Table	4.1.	It	was	clear	that	Iso	48,	Iso	50	and	Iso	78	were	the	most	sensitive	organoid	
lines,	mirroring	EC50	values	obtained	in	previous	studies	using	LoVo	colorectal	
adenocarcinoma	cells	(Foote	et	al.	2013).	Iso	49	was	shown	to	be	the	most	resistant	
organoid	line,	generating	EC50	values	of	approximately	21	µM,	suggesting	that	any	
changes	in	organoid	viability	were	only	obtained	at	the	highest	doses.	Whilst	the	
degree	of	sensitivities	varied,	overall,	all	organoids	were	responsive	to	Wee1	
inhibition,	obtaining	cellular	EC50	values	in	a	range	identified	previously	in	the	
literature,	of	approximately	0.08	–	0.3	µM	(Hirai	et	al.	2009).	Overall,	given	that	
many	organoids	harboured	TP53,	KRAS	or	ATM	mutations,	further	studies	using	a	
larger	sample	cohort	and	appropriate	controls	such	as	wild	type	organoids	would	be	
beneficial	to	investigate	whether	ATR	and	Wee1	inhibition	sensitivity	is	correlated	
with	high	levels	of	DNA	damage.		
	
Representative	images	from	a	sensitive	organoid	line,	Iso	72,	as	illustrated	in	Figure	
4.1,	demonstrated	the	presence	of	extensive	cellular	debris	following	4	days	of	
treatment,	indicative	of	cell	death,	following	treatment	with	both	AZ20	and	MK1775.	
This	in	turn	was	concordant	with	data	from	ATP	endpoint	viability	readouts	at	day	7	
in	culture.		To	further	explore	the	impact	of	MK1775	and	AZ20	treatment	upon	
organoid	growth,	Iso	72	organoids	were	further	scored	according	to	number	of	Ki67	
positive	cells	per	organoid.	Following	4	days	of	treatment,	organoids	were	stained	
with	a	nuclear	(Hoechst)	and	proliferation	(Ki67)	marker,	prior	to	acquisition	of	z-
stacks	on	a	confocal	microscope.	Quantification	was	facilitated	using	IMARIS	
software	(BITPLANE),	as	an	automated	counting	tool	to	identify	nuclei,	as	well	as	
positively	stained	cells.	The	number	of	Ki67-positive	cells	were	recorded	as	a	
percentage	per	organoid,	with	a	minimum	of	5	organoids	counted	per	condition.	
Within	control	(DMSO,	0.1%)	conditions,	it	was	shown	that	80%±13%	of	cells	within	
organoids	were	positively	immunostained	for	Ki67.	Treatment	with	150	nM	MK1775	
resulted	in	a	significant	reduction	in	proliferation,	whereby	an	average	of	57%±17%	
of	cells	per	organoid	were	Ki67	positive	(p	≤	0.01,	Welch	two	sample	t-test).	
Following	4	days	of	treatment	with	AZ20,	a	similar	trend	was	observed,	as	shown	in	
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images	acquired	(Figure	4.2).	However,	given	the	overall	diminished	organoid	size	
induced	by	drug	addition,	compared	to	control	conditions,	smaller	organoid	
structures	were	more	readily	lost	in	wash	steps	required	as	a	result	of	technical	
artefacts	of	methodology,	limiting	the	number	of	organoids	that	could	be	counted.		
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Figure	4.1	Iso	72	organoids	respond	to	a	Wee1	and	ATR	inhibitor	
Freshly	dissociated	Iso	72	organoids	were	seeded	in	growth	factor-reduced	Matrigel	at	a	density	of	
400	cells/	µl	Matrigel	and	overlaid	with	media.	Following	three	days	of	recovery,	a	titration	of	(A)	
MK1775	(19	nM	–	5000	nM)	or	(B)AZ20	(39	nM	–	10	µM)	or	DMSO	(0.1%)	negative	control	were	
supplemented	within	media.	Following	4	days	of	treatment,	a	Cell	Titer	Glo	3D	assay	was	performed	
to	quantify	relative	ATP	levels	per	well	(Relative	Luminescence	Units,	n=3).	(C)	Representative	
microscope	images	at	day	7	following	treatment	with	DMSO,	MK1775	or	AZ20.	Data	shows	
representative	dose	response	from	triplicate	wells.		
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Figure	4.2	Scoring	proliferation	in	CRC	organoids	following	treatment	with	Wee1	inhibitor,	ATR	inhibitor.	
Iso	72	Organoids	were	seeded	as	single	cells	prior	to	treatment	with	MK1775	(150	nM),	AZ20	(625	nM)	and	DMSO	(0.1%)	within	media	for	four	days,	then	fixed	with	4%	
PFA,	prior	to	immunostaining	with	Hoechst	and	Ki67.	Image	z-stacks	of	organoids	were	captured	on	a	confocal	microscope	and	then	quantified	using	IMARIS	software	(A)	
Flow	chart	depicting	counting	of	whole	3D	organoids	using	IMARIS	software	(B)	Representative	images	of	organoids	treated	and	stained	with	Ki67	and	Hoechst.	Scale	bar	=	
50	µm.	(C)	Quantification	of	the	average	number	of	Ki67	positive	cells	per	organoid,	n=	5-15	organoids.	Significance	of	number	of	proliferating	cells	were	calculated	using	
Welch	two	sample	t-test	and	Mann	Whitney	two-tailed	test	*p≤0.01,	**	p≤0.05.Images	and	IMARIS	counts	were	collected	and	analysed	by	Kate	Densley	under	my	
supervision.
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4.2.2 High-throughput	phenotypic	screening	for	robust	quantification	of	
responses	to	DDR	inhibitors.	
	
Despite	the	results	obtained	from	proliferation	counts	of	organoids	exposed	to	AZ20,	
the	extent	to	which	measurements	of	cellular	proliferation	could	be	interpreted	
biologically	was	limited	for	several	reasons.	Firstly,	the	technical	process	involved	
limits	the	number	of	organoids	counted	as	many	smaller	organoids,	as	a	result	of	
growth	inhibition,	are	washed	away	during	processing.	This	was	particularly	the	case	
for	Iso	75	organoids,	as	the	structures	were	generally	smaller	in	culture	than	
organoid	from	other	lines	(data	therefore	not	shown).	This	was	also	a	relatively	low-
throughput	readout	to	characterise	drug	effects.	In	order	to	further	characterise	the	
effects	of	cell	cycle	inhibitors	upon	organoids	at	greater	detail	to	overcome	
limitations	previously	introduced,	introducing	stains	that	would	be	more	compatible	
to	fewer	washes,	a	high	throughput	3D	image	based	screening	process,	in	
collaboration	with	OcellO	(Leiden,	Netherlands),	was	implemented.	Such	technology	
enabled	the	examination	of	morphological	parameters	from	individual	nuclei	to	
whole	organoid	population	levels	that	can	be	quantified.		
	
All	organoids	were	therefore	prepared	as	single	cells	and	cultured	in	384	well	plates	
in	optimal	media	conditions	(as	previously	outlined	in	Table	2.1)	for	3	days,	then	
treated	with	a	titration	of	AZ20	and	a	DMSO	(0.1%)	control.	Following	4	days	of	
treatment,	organoids	were	fixed	and	stained	simultaneously	with	4%	PFA,	Nuclear	
stain	(Hoechst)	and	cytoskeletal	stain	(TRITC-Phalloidin),	as	described	in	(Di,	Klop,	
Rogkoti,	Devedec,	Water	van	de,	et	al.	2014).	Wells	were	then	washed	twice	with	
PBS	following	fixation.		
	
Individual	z-stack	images	of	whole	384	well	plates	were	collated	on	a	MetaXpress®	
high-content	microscope	at	OcellO,	then	inputted	into	the	novel	OMiner	analysis	
software	developed	by	OcellO,	as	detailed	previously	in	Chapter	2.	Briefly,	
projections	of	F-actin	and	hoechst	from	individual	z-stacks	were	used	to	extrapolate	
masks	of	individual	organoids,	internal	lumen	structures	and	nuclei	from	each	well.	
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Image	segmentation	and	filters	were	applied	to	distinguish	individual	objects	per	
well,	and	enhance	noise	suppression	to	balance	sensitivity	of	analysis.	Relevant	
masks	were	then	used	to	acquire	approximately	650	quantifiable	morphological	
features,	as	well	as	fluorescence	intensities	per	channel	(Di,	Klop,	Rogkoti,	Devedec,	
Water	van	de,	et	al.	2014).	Data	from	individual	organoids	were	pooled	on	a	well-by-
well	basis,	with	data	from	individual	wells	(minimum	of	8	per	condition)	then	
gathered	to	yield	average	parameter	readings	per	condition.		
	
Following	ATR	treatment,	several	parameters	were	measured	as	an	indication	of	
organoid	response.	It	was	shown	that	ATR	inhibition	resulted	in	a	slight	decrease	in	
overall	organoid	area,	limiting	complex	internal	features	as	shown	in	control	
conditions.	Figure	4.3	depicts	the	effects	on	phenotypic	profile	of	Iso	75	as	an	
example.	Assessing	organoid	mean	area	as	a	response	to	treatment,	as	previous	data	
indicate,	is	somewhat	limiting,	as	structures	can	appear	larger	as	a	result	of	
accumulated	cellular	debris.	Given	that	alterations	in	nuclear	morphology	have	
previously	been	associated	within	activation	of	cell	death	(Eidet	et	al.	2014;	
Edmondson	et	al.	2014),	and	the	role	of	ATR	inhibition	within	this	response,	the	
effects	of	AZ20	on	nuclear	morphology	was	studied.	Several	morphological	hallmarks	
of	apoptotic	events	upon	the	nucleus	have	previously	been	reported	in	the	
literature,	such	as	chromatin	condensation,	visualized	by	Hoechst,	overall	nuclear	
shrinking	as	well	as	an	increase	in	nuclear	circularity	(Ziegler	and	Groscurth	2004).	
Here,	it	was	found	that	similar	features	were	influenced	in	a	dose-dependent	
manner	by	ATR	treatment.	Nuclei	profiles	of	Iso	75	organoids	revealed	that	an	
increasing	concentration	of	AZ20	were	correlated	with	an	increase	in	average	
nuclear	circularity,	a	decrease	in	the	average	number	of	nuclei	per	organoid	
structure,	as	quantified	from	individual	masks	nuclei	per	organoid.	Taken	together,	it	
was	found	that	there	was	a	convincing	correlation	between	hallmarks	of	apoptosis	
and	reduction	in	overall	organoid	area.				
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Figure	4.3	Phenotypic	analysis	reveals	nuclear-dependent	effects	of	ATR	inhibitor	treatment	within	
CRC	organoids.	
Iso	75	Organoids	were	seeded	as	single	cells	within	384	well	plates	prior	to	treatment	with	a	dose	
titration	of	AZ20	(0nM	–	2500	nM)	and	DMSO	control	(0.1%)	within	media	for	four	days,	then	fixation	
and	staining	with	Hoechst	and	Phalloidin.	Image	z-stacks	of	organoids	were	captured,	and	parameters	
were	quantified	by	OcellO.	(A)	Representative	images	of	a	well	of	organoids	treated	with	AZ20	(2.5	
µM)	and	DMSO	control,	and	masked	according	to	Hoechst	and	Phalloidin	channels.	Hoechst	channel	
information	was	used	to	generate	nuclear	profile	of	organoids.	(Bi-iv)	Scatterplots	of	measurements	
acquired	of	(i)	average	organoid	area(ii)	average	nucleus	area	and	(iii)	average	nucleus	circularity	
(iv)fraction	of	apoptotic	cells	per	organoid,		per	dose	titration	within	Iso	75	organoids.	Images	
captured	at	OcellO.	Scale	bar	=	1mm.		
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4.2.3 Organoids	demonstrate	differential	sensitivities	to	an	aspirin	metabolite	
irrespective	of	PIK3CA	mutation	status	
	
As	discussed	within	Chapter	1	(1.5.3),	retrospective	studies	within	the	literature	have	
associated	the	reduction	of	tumour	burden	in	CRC	patients	harbouring	PIK3CA	
mutations	when	treated	with	aspirin	compared	to	non-PIK3CA	mutant	tumours.	The	
FOCUS	4	trial	aims	to	identify	whether	PIK3CA	can	be	used	as	a	biomarker	for	aspirin	
responsiveness,	and	whether	aspirin	treatment	will	ultimately	benefit	patients	
harbouring	PIK3CA	mutations.	In	vitro	studies	have	demonstrated	a	concurrent	
effect	of	many	non-steroidal	anti-inflammatory	drugs	(NSAIDs),	including	aspirin,	
upon	colorectal	cancer	cells,	suggesting	that	such	compounds	predispose	tumour	
cells	to	apoptotic	events.	Here,	organoids	were	administered	with	the	active	
metabolite	of	aspirin,	salicylic	acid,	and	assessed	for	responses.				
	
A	set	of	organoids	were	digested	to	(near)	single	cells,	counterstained	with	a	dual	
Acridine	Orange/Propidium	Iodide	live/dead	cell	stain	and	counted	using	an	
automated	LUNA-FL™	fluorescence	cell	counter.	400	cells/	µl	matrigel	were	then	
plated	in	96	well	plates,	overlaid	with	optimum	growth	media	per	line,	and	
incubated	for	3	days.	Orally-administered	low	dose	aspirin	can	reach	a	peak	plasma	
concentration	of	approximately	7µM	(Alfonso	et	al.	2014).	Organoids	were	therefore	
subject	to	treatment	of	a	dose	titration	range	of	salicylic	acid	between	0.19	nM	–	5	
µM,	as	well	as	a	volume	matched	DMSO	control	(0.1%)	within	triplicate	wells	for	a	
further	4	days.	An	endpoint	Cell	Titer	Glo	3D	viability	assay	was	implemented,	in	
which	the	quantification	of	ATP	and	thus	metabolically	active	cells	per	well	
demonstrated	that	treatment	salicylic	acid	induced	a	clear	dose-dependent	response	
in	some	organoid	lines.	Each	experiment	was	composed	of	a	minimal	of	three	
technical	replicates	per	condition.	Growth	curves	generated	from	Cell	Titer	Glo	3D	
readouts	of	Relative	Luminescence	Units	indicated	that	multiple	organoid	lines	were	
responsive	to	treatment,	generating	average	IC50	values	0.4	µM	–	5	µM,	as	indicated	
in	Table	4.1.	Interestingly,	organoids	were	more	sensitive	to	effects	of	salicylic	acid	in	
comparison	to	CRC	cell	lines	such	as	SW480,	HT29	and	HCT116,	which	have	
previously	shown	sensitivity	at	IC50	values	ranging	from	2.5	-	5mM	(Pathi	et	al.	2012).	
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As	shown	in	Figure	4.4,	it	was	observed	that	Iso	73,	was	the	most	resistant	organoid	
to	salicylic	acid	effects	(no	EC50	value	obtainable	from	a	drug	dose	response	curve).	
Conversely,	Iso	72	organoids,	as	represented	by	Figure	4.4,	demonstrated	a	degree	
of	sensitivity	to	aspirin	treatment,	with	EC50	values	of	approximately	2	µM	(n=3	
independent	experiments)	obtained.	Having	shown	responses	within	ATP	assays,	Iso	
72	was	further	counterstained	with	the	proliferation	antibody	Ki67	following	4	days	
of	treatment.	Counts	obtained	demonstrated	that	1.2	µM	salicylic	acid	induced	a	
reduction	in	the	number	of	Ki67	positive	cells	(from	80%	proliferation	per	average	
organoid	to	overall	40%	proliferating	cells	per	organoid)	on	an	organoid-by-organoid	
basis	compared	to	matched	DMSO	control.		
	
As	indicated	in	Chapter	3,	Iso	48,	Iso	49,	Iso	75	and	Iso	78	were	shown	to	harbour	
PIK3CA	mutations,	and	therefore	were	expected	to	respond	to	aspirin	treatment	
under	the	assumption	that	PIK3CA	mutations	were	a	suitable	biomarker	for	aspirin	
sensitivity.	Corresponding	EC50	values	from	viability	assays	demonstrated	little	
correlation	between	aspirin	sensitivity	and	PIK3CA	mutation	status,	with	the	most	
sensitive	organoid	lines	having	demonstrated	no	evidence	of	harbouring	PIK3CA	
mutations.	However,	given	the	multiple	mechanisms	of	action	and	targets	that	are	
likely	to	be	involved	in	aspirin-induced	effects,	it	is	somewhat	challenging	to	
delineate	the	exact	correlation	between	aspirin	and	PIK3CA	as	a	biomarker	in	this	
instance.	This	will	further	be	considered	in	the	discussion	section	of	this	thesis	
(Chapter	6).		
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Figure	4.4	Analysis	of	aspirin	metabolite	on	organoid	growth.	
Freshly	digested	organoids	were	seeded	at	densities	of	400	cells/	µl	Matrigel	and	overlaid	with	growth	
media.	Following	3	days	of	culture,	a	titration	range	of	salicylic	acid	(19nM-	5000	nM),	or	a	volume	
matched	DMSO	control	(0.1%)was	administered.	Representative	images	of	(Ai)	Iso	72	and	(Aii)	Iso	73	
at	day	7	in	culture.	Following	4	days	of	treatment,	representative	EC50	curves	were	generated	from	
ATP	quantification	of	(Bi)	Iso	72	and	(Bii)	Iso	73	organoids	expressed	as	Relative	Luminescence	Units	
versus	concentration	of	salicylic	acid	administered,	n=3	.	(Ci)	Representative	images	of	Iso	72	
Organoids	fixed	and	stained	for	ki67(proliferation)	and	caspase	3	(apoptosis)	markers	following	
treatment	with	1.2	µM	salicylic	acid	(Cii)	Ki67-positive	cells	were	counted	using	IMARIS	software.	
Scale	bar	indicates	50	µm,	n=5-12	organoids	per	group.	Levels	of	significance	were	determined	using	
n	unpaired	t-test	with	Welch’s	correction	,	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.	Representative	
images	and	subsequent	data	from	(Ci)	and	(Cii)	were	collected	by	Kate	Densley	under	my	supervision.		
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Given	the	indications	in	the	literature	that	metabolised	aspirin	induces	apoptosis	in	a	
number	of	different	tumour	cell	types	in	vitro,	including	breast,	gastric	and	
colorectal,	we	looked	for	markers	of	apoptosis	in	the	organoid	models.	Following	
treatment	with	salicylic	acid	(1.2	µM)	for	4	days,	Iso	72	organoids	were	further	
counterstained	with	Caspase	3	as	a	marker	for	apoptosis,	demonstrating	some	
degree	of	staining.	To	further	quantify	this,	and	to	ascertain	whether	apoptotic	
events	were	dose	dependent,	phenotypic	profiling	was	implemented,	as	previously	
described.	Briefly,	organoids	were	plated	in	black,	clear-bottomed	384	well	plates	as	
single	cells	and	following	3	days	of	recovery,	were	treated	with	a	9—point	dilution	of	
salicylic	acid,	as	well	as	a	DMSO	control.	Following	4	days	of	treatment,	wells	were	
simultaneously	stained	with	Hoechst	(nuclei)	and	TRITC-phalloidin	(F-actin),	washed,	
and	imaged	on	a	high-content	confocal	microscope	(images	captured	by	OcellO).	Z-
stack	images	were	then	inputted	through	the	OMiner	platform	to	readily	detect	and	
quantify	relevant	features.	For	Iso	72	organoids,	inspection	of	overall	number	and	
size	of	organoids	demonstrated	no	dose-dependent	effect	of	salicylic	acid	treatment.	
However,	quantified	measurements	(Figure	4.5)	were	suggestive	that	aspirin	
treatment	induced	impacts	upon	individual	nuclei.	Whilst	there	was	no	direct	
evidence	of	involvement	of	apoptosis	from	phenotypic	nuclei	profiles,	the	overall	
presence	of	Caspase	3	within	organoids	could	be	indicative	of	apoptotic	effects.	It	is	
most	likely	that	inhibition	of	proliferation	results	in	smaller	organoids	following	
treatment	with	salicylic	acid.	It	is	possible	that	further	quantification	of	Caspase	3	in	
control	and	treatment	conditions	would	enhance	observations,	as	well	as	other	
assay	improvements,	further	discussed	in	Chapter	6.	
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Figure	4.5	Analysis	of	aspirin	metabolite	on	organoid	phenotypes	
Freshly	digested	organoids	were	seeded	at	optimal	densities	of	400	cells/	µl	Matrigel	and	overlaid	
with	growth	media,	prior	to	treatment	of	a	titration	range	of	salicylic	acid	(19nM-	5000	nM),	or	a	
volume	matched	DMSO	control	(0.1%)from	day	4	to	7	in	culture.	Phenotypic	profiling	of	Iso	72	
organoids	using	OcellO	readouts	to	identify	changes	in	nuclei	profiles	in	response	to	treatment	with	a	
dose	range	of	salicylic	acid.	Significant	changes	in	average	number	of	apoptotic	nuclei	(A)	and	average	
area	of	nuclei	per	well	(B)were	calculated	from	a	minimum	of	n=8	wells	per	treatment.	Significant	
changes	in	nuclei	profiles	were	calculated	using	a	one	way	ANOVA	with	Dunnett’s	multiple	
comparison	test,	p<*=0.05.
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4.2.4 Evaluating	the	impact	of	her1-3	inhibition	upon	organoids	
	
AZD8931,	clinically	known	as	Sapitinib,	is	a	potent	ERBB2	and	EGFR	inhibitor,	having	
previously	shown	capability	of	preventing	EGF-driven	cellular	proliferation	in	
multiple	tumour	cell	lines.	Within	the	FOCUS	4	clinical	trial,	Sapitinib	is	a	proposed	
compound	to	treat	patient	carrying	Erbb2	amplification	and	wild	type	for	BRAF,	KRAS	
and	PIK3CA.	As	described	in	studies	elsewhere,	mammary	tumour	cell	lines	
exhibiting	Erbb2	amplification	were	inherently	sensitive	to	Sapitinib	treatment.	A	
study	by	Mu	et	al.,	(2014)	demonstrated	that	inhibition	of	EGFR	dependent	signalling	
resulted	in	a	suppression	of	cell	growth	and	induction	of	apoptotic	events,	findings	
which	were	then	translated	in	vivo,	when	Sapitinib	was	administered	in	combination	
with	a	chemotherapeutic	in	a	xenograft	model	(Mu	et	al.	2014).		
	
To	explore	the	impact	of	Sapitinib	upon	organoid	viability,	established	organoids	
were	digested	to	single	cells	and	plated	in	96	well	plates,	subjected	to	treatment	
with	a	titration	of	Sapitinib	and	administered	with	a	Cell	titer	Glo	3D	reagent	to	
quantify	relative	ATP	levels	(Figure	4.5).	Measurements	indicated	no	clear	dose	
dependent	responses	in	a	number	of	organoid	lines	(Table	4.1),	with	the	exception	
of	some	responses	from	Iso	72	at	the	highest	concentrations	of	Sapitinib	
administered	(1µM	–	5	µM).	Recent	studies	have	further	demonstrated	organoid	
sensitivity,	reporting	IC50	values	of	approximately	0.04	µM	–	1	µM	(Wetering,	et	al.	
2015).		
	
To	further	investigate	the	impact	of	Sapitinib	upon	proliferation	within	Iso	72,	
organoids	were	firstly	treated	with	Sapitinib	(40	nM)	for	four	days	and	analysed	for	
changes	in	Ki67	as	an	indicator	of	proliferation.	It	was	found	that	Sapitinib	treatment	
reduced	the	average	number	of	proliferating	cells	per	organoids	from	proliferation,	
from	81%±13%	to	47%±16%,	without	fully	inhibiting	overall	viability	as	indicated	by	
ATP	readouts.	To	further	investigate	the	effects	of	Sapitinib	upon	organoids,	
phenotypic	profiles	of	control	(DMSO,	0.1%)	versus	a	dose	range	of	Sapitinib	were	
analysed	using	OcellOs	novel	OMiner	platform	(conducted	in	collaboration	with	
OcellO)	,	as	previously	described.	Quantification	of	Iso	72	nuclei	profiles	revealed	a	
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significant	increase	in	the	fraction	of	apoptotic	nuclei	per	organoid	with	increasing	
doses	of	treatment	(Figure	4.5	(C)).	Taken	together,	this	would	support	previous	
indications	in	the	literature	that	Sapitinib	exerts	effects	by	suppressing	proliferation	
and	inducing	apoptosis.	However,	given	that	EC50	values	were	within	a	high	range	
compared	to	expected	values	in	sensitive	organoids,	further	work	would	need	to	
further	confirm	downstream	effects	of	Sapitinib	treatment	upon	EGFR-mediated	
signalling.	
	
As	detailed	in	Chapter	3	(Table	3.3),	many	organoids	exposed	to	Her1-3	inhibitor	
contained	mutations	within	BRAF,	PIK3CA	and	KRAS.	It	is	therefore	possible	that	such	
mutation	profiles	could	interfere	downstream	from	Sapitinib-mediated	signalling	
inhibition,	resulting	in	a	lack	of	strong	responses	from	most	organoid	lines.	
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Figure	4.5	Assessing	the	effects	of	Sapitinib	on	organoid	growth	
Freshly	digested	organoids	were	seeded	at	400	cells/	µl	Matrigel	and	overlaid	with	growth	media	for	3	
days,	prior	to	treatment	of	a	titration	range	of	sapitinib	(19nM-	5000	nM	for	viability	assays,	5nM	–	
1250	nM	for	phenotypic	screening),	or	a	volume	matched	DMSO	control	(0.1%)	for	4	days	in	culture.	
(A)	Iso	72	Organoids	fixed	and	stained	for	ki67(proliferation)	marker	following	treatment	with	39	nM	
Sapitinib,	and	counted	using	IMARIS	software,	n=5-12	organoids	per	group.	Levels	of	significant	were	
determined	using	n	unpaired	t-test	with	Welch’s	correction	,	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001		(B)	
Representative	EC50	best	curves	were	generated	following	4	days	of	Iso	72	organoid	treatment	and	
expressed	as	Relative	Luminescence	Units	versus	concentration	of	sapitinib	administered,	generating	
EC50	values	of	868	nM	(±1193	nM,	n=3).	(C)Phenotypic	profiling	of	Iso	72	organoids	using	OcellO	
readouts	to	identify	changes	in	nuclei	profiles	in	response	to	treatment	with	a	dose	range	of	Sapitinib.	
Data	from	(B)	were	collected	by	Kate	Densley	under	my	supervision.	
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	Table	4.1	Collective	EC
50 	values	of	inhibitors	tested,	generated	from
	ATP	assays.	
Data	acquired	from
	ATP	assay	analysis	of	organoid	lines	tested	w
ith	com
pounds	w
ithin	the	FO
CU
S	4	trial.	Data	show
n	as	m
ean	±	standard	deviation,	n=3	independent	
biological	replicates,	unless	otherw
ise	indicated	by	sym
bols	w
hereby	*	n=2.	EC
50 	curves	w
ere	generated	using	XLFit	plug-in	for	Excel;	w
here	no	curve	fit	w
as	possible	this	is	
indicated	as	such.	
			
	
	
EC
50 	(nM
)	
Iso	34	
Iso	48	
Iso	49		
Iso	50	
Iso	72	
Iso	73	
Iso	75	
Iso	78	
AZ20	
6566(±1046)	416*	
21638(±3537)	453(±136)	
2136(±2646)	4272(±6269)	7011(±5263)	354(±254)	
M
K1775	
1025(±187)	
180(±9)	
130*	
338(±78)	
205(±119)	
327(±150)	
126(±28)	
526(±673)	
Salicylic	acid	486(±108)	
5309(±437)	
732(±519)	
740(±946)	
2912(±3124)	N
o	curve	
1787(±1106)	1761(±24938)	
SapiGnib	
N
o	curve	
N
o	curve	
N
o	curve	
N
o	curve	
2912	(±3124)	N
o	curve	
N
o	curve	
N
o	curve	
5FU
	
80*	
233±116	
1770*	
N
o	curve	
	
4198*	
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4.2.5 Assessing	drug	combination	of	BRAF,	EGFR	and	MEK	inhibitors	within	BRAF-
mutant	organoids	
	
As	discussed	in	chapter	1,	BRAF	mutations	occur	in	approximately	8-12%	of	CRC	
patients	and	are	associated	with	a	poor	prognosis	(Corcoran	et	al.	2015;	Corcoran	
2015).	Despite	the	development	of	BRAF-targeting	agents,	their	use	in	the	clinic	for	
treating	BRAF-mutant	CRCs	has	thus	far	provided	limited	success.	This	is	thought	to	
be	as	a	result	of	an	upregulation	of	EGFR-mediated	activation	as	a	response	to	
inhibition	of	MAPK	pathway	feedback	inhibition,	circumventing	the	effects	of	
treatment	(Corcoran	et	al.	2012).	Based	on	this	rationale,	within	the	FOCUS	4	clinical	
trial,	it	has	been	postulated	that	combination	therapy	targeting	BRAF	and	EGFR	
with/without	MEK	using	Dabrafenib,	Panitumumab	±	Trametinib,	respectively,	will	
improve	progression	free	survival	in	patients	with	BRAF	mutant	CRC,	when	used	as	a	
maintenance	therapy	following	first	line	chemotherapy,	compared	to	standard	of	
care	treatment.	Here,	having	established	the	utility	of	viability	readouts	as	a	system	
to	identify	drug	sensitivity,	it	was	investigated	whether	combination	therapy	regimes	
could	be	administered	to	organoids.	For	the	purposes	of	simplicity,	the	two	BRAF-
mutant	organoids	Iso	34	and	Iso	75	(as	opposed	to	the	whole	organoid	cohort)	only	
were	used	to	investigate	the	effect	of	each	compound	as	single	agents,	with	Iso	34	
utilised	to	measure	the	effects	of	compounds	in	double-	and	triple-	combinations.			
	
4.2.5.1 Trametinib	is	an	effective	growth	inhibitor	in	organoids	as	a	single	agent	
	
In	order	to	assess	whether	combination	treatments	could	impact	the	growth	of	
organoids	matched	to	FOCUS	4	patient	biomarkers,	the	effects	of	each	compounds	
as	single	agents	were	firstly	established	in	a	BRAF-mutant	model.	Iso	75	organoids	
were	treated	with	Dabrafenib	(250	nM),	Panitumumab	(200	nM),	Trametinib	(80	
nM),	respectively,	as	well	as	a	DMSO	control	condition,	for	a	total	of	4	days.	
Following	treatment,	organoids	were	fixed	and	immunostained	with	phalloidin	(F-
actin)	and	Ki67	to	obtain	counts	using	IMARIS	parameters	as	previously	described.		It	
was	observed	that	80	nM	Trametinib	significantly	reduced	the	number	of	
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proliferating	cells	on	average	per	organoid,	compared	to	Panitumumab	and	
Dabrafenib,	both	of	which	showed	no	significant	impact	upon	overall	organoid	
proliferation,	as	shown	in	Figure	4.7.	In	order	to	further	classify	responses	to	
Trametinib	as	a	single	agent,	two	BRAF	mutant	organoids	,	Iso	75	and	Iso	34,	were	
subject	to	phenotypic	screening	process,	as	described	previously.	Briefly,	organoids	
were	digested	to	single	cell,	and	following	three	days	of	recovery,	were	treated	with	
a	dose	titration	range	of	Trametinib	over	4	days.	Organoids	were	then	fixed	and	
stained	simultaneously	with	Hoechst	and	TRITC	phalloidin	to	mark	nuclear	and	f-
actin	structures.	A	total	of	8	replicate	wells	were	used	per	condition.	Z-stack	images	
of	each	well	were	captured,	and	images	were	further	processed	using	OMiner™	
software,	in	collaboration	with	OcellO.	As	shown	in	Figure	4.8,	it	was	found	that	
Trametinib	had	a	dose	dependent	effect	on	overall	organoid	size	indicative	of	
inhibitory	effects	upon	growth.	Interestingly,	Trametinib	also	induced	impacts	upon	
overall	lumen	size	of	both	Iso	34	and	Iso	75	as	demonstrated	in	Figure	4.8.	For	Iso	75	
in	particular,	this	effect	was	observed	at	a	much	lower	concentration	than	effects	
observed	on	overall	organoid	size,	further	emphasising	the	need	to	investigate	
particular	organoid	phenotypes	as	opposed	to	relying	on	organoid	size	as	a	measure	
of	response,	further	discussed	in	Chapter	6.			
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Figure	4.7	Assessing	impact	of	single	agents	EGFR/BRAF	and	MEK	inhibitors	upon	organoid	growth	
Iso	75	organoids	were	dissociated	to	single	cells	and	cultured	for	three	days.	Organoids	were	then	
treated	with	0.1%	DMSO	conditions	and	Trametinib	(20	nM,	40	nM)	for	four	days,	prior	to	fixing	and	
immunostaining	for	Ki67	proliferation	marker	and		phalloidin	for	F-actin	,and	imaging	using	confocal	
microscopy.	Nuclei	were	counterstained	with	Hoechst	(Ai)	Representative	images	of	organoids	
captured	following	treatment	with	each	compound	as	single	agents.(Aii)	The	number	ki67%	positive	
cells	per	organoid	were	counted	using	IMARIS	software.	The	number	of	Ki67-postivie	cells	were	
counted	as	a	percentage	per	organoid	(n=5-15	organoid).	Significance	of	number	of	proliferating	cells	
were	calculated	using	Welch	two	sample	t-test	and	Mann	Whitney	two-tailed	test	*p≤0.01,	**	p≤0.05.	
Images	and	IMARIS	counts	were	collected	by	Kate	Densley	under	my	supervision	
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Figure	4.8	Phenotypic	analysis	reveals	structural	changes	in	response	to	Trametinib	within	
organoids	
Organoids	were	seeded	as	single	cells	within	384	well	plates	prior	to	treatment	with	a	dose	titration	
of	Trametinib	(320	nM)	and	DMSO	control	(0.1%)	within	media	for	four	days,	then	fixed	and	stained	
with	Hoechst	and	Phalloidin.	Image	z-stacks	of	organoids	were	captured,	and	parameters	were	
quantified	by	OcellO.	(A)	Representative	images	of	a	well	of	Iso	34	organoids	treated	with	trametinib	
and	DMSO	control,	and	masked	according	to	Hoechst	and	Phalloidin	channels.	Images	captured	at	
OcellO	(B)	Scatterplots	of	measurements	acquired	of	(i)	average	organoid	area	(ii)average	lumen	area	
in	Iso	34	organoids.	(C)	Scatterplots	of	measurements	acquired	of	(i)	average	organoid	area	(ii)average	
lumen	area	in	Iso	75	organoids.	Scale	bar	0.5mm.
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4.2.5.2 Dabrafenib	and	Panitumumab	administration	on	BRAF	mutant	organoids	
potentiate	growth	inhibition	
	
To	assess	the	whether	therapeutics	exerted	synergistic	effects	upon	organoids,	
experiments	were	designed	as	previously	described	by	Chou-Talalay	(Chou	and	
Talalay	1984;	Chou	2010);	detailed	in	Chapter	2).		This	methodology	has	been	
common	practice	in	a	number	of	studies	in	the	literature	to	determine	synergistic	
activity	of	compounds	by	quantitatively	measuring	dose-effect	relationships	of	
drugs,	with	some	analyses	having	been	performed	on	a	combination	of	three	or	
more	compounds.	A	key	principle	of	Chou-Talalay	combination	studies	is	based	on	
maintaining	the	dose	of	each	compound	in	a	constant	ratio	to	each	other,	most	
commonly	their	IC50,	over	a	titration	range.	In	theory,	this	can	be	applied	to	any	given	
number	of	combinations;	if	multiple	data	points	for	constant-	ratio	combinations	are	
collected,	the	entire	spectrum	of	synergistic	or	antagonistic	effects	can	be	obtained	
at	each	concentration.		
	
The	BRAF-mutant	Iso	34	organoid	line	was	used	to	investigate	synergistic	effects	of	
compounds	upon	organoid	growth.	Iso	34	organoids	were	treated	with	a	14-point	
dose	titration	of	each	respective	compound	to	identify	IC50	values	in	single	inhibitor	
assay	formats,	as	described.	Following	a	Cell	Titer	Glo	3D	ATP	readout,	it	was	
observed	that	Trametinib	had	a	clear	inhibitory	impact	upon	Iso	34	organoids,	
generating	IC50	values	of	3	nM	(Figure	4.9,	Bii)	after	4	days	of	treatment.	Both	
Dabrafenib	and	Panitumumab	failed	to	generate	such	clear	dose	dependent	
responses,	with	Dabrafenib	in	particular	appearing	to	impact	Iso	34	only	at	the	very	
highest	concentrations	administered	(Figure	4.9,	Bi	and	Biii).	Given	the	fundamental	
requirement	of	Chou-Talalay	analysis	methods	to	maintain	compounds	at	fixed	
ratios	of	their	respective	IC50	values	spanning	a	suitable	dose	titration	range	to	then	
assess	combinatory	effects,	it	was	necessary	to	obtain	IC50	values	from	in	vitro	
systems	within	the	literature	under	the	assumption	that	this	would	be	in	the	range	
of	a	cellular	IC50	value.			
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In	order	to	identify	whether	Dabrafenib	and	Panitumumab	would	potentiate	the	
inhibitory	effects,	IC50	values	of	both	compounds	were	set	at	7.8	nM,	0.98	nM,	
respectively,	thus	generating	a	ratio	of	8:1	between	both	compounds.	In	
concordance	with	Chou-Talalay	methodology,	single	inhibitor	assays	of	Dabrafenib	
and	Panitumumab	were	carried	out	in	parallel	with	combination	assays	to	ensure	
subsequent	analysis	was	carried	out	in	comparative	systems.	Following	4	days	of	
treatment	with	Dabrafenib,	Panitumumab	or	a	combination	of	both	inhibitors	
absolute	ATP	values	were	obtained	using	the	Cell	Titer	Glo	3D	reagent.		It	was	
observed	that	a	combination	of	Dabrafenib	and	Panitumumab	induced	a	stronger	
inhibitory	effect	upon	overall	organoid	viability,	as	opposed	to	administration	as	
single	agents	(Figure	4.9).		
	
It	would	be	expected	a	lack	of	interaction	between	compounds,	otherwise	referred	
to	as	an	additive	effect,	would	be	in	the	range	of	110nM	from	single	agent	dose	
response	curves	generated	as	shown	in	Figure	4.9.	However,	when	administered	as	
two	compounds	the	IC50s	of	Dabrafenib	and	Panitumumab	combined	were	instead	
approximately	7nM,	below	expected	values	for	an	additive	effect.	Further	
calculations	(using	Equation	2.1)	enabled	a	determination	of	the	synergistic	action	of	
compounds.	Combination	index	values	calculated	per	dose	of	Dabrafenib	and	
Panitumumab	of	0.02±0.02	(n=3	independent	experiments)	confirmed	that	the	
compounds	potentiated	the	effect	of	one	another.	Specifically,	the	dose	reduction	
index,	representative	of	the	fold	reduction	in	compound	concentration	that	could	be	
administered	to	reduce	organoid	growth	by	50%	demonstrated	that	in	combination,	
Dabrafenib	could	be	theoretically	administered	at	a	133	fold	reduction	in	dose,	
whereas	Panitumumab	could	be	administered	at	>1000	fold	lower	dose.
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4.2.5.3 MEK	inhibition	potentiates	inhibitory	action	of	BRAF/EGFR	inhibitors	upon	
BRAF-mutant	organoids	
	
To	establish	whether	Dabrafenib	and	Panitumumab	activity	could	be	further	
enhanced	by	administration	of	Trametinib,	as	tested	in	the	FOCUS	4	clinical	trial,	Iso	
34	was	administered	with	the	three	compounds	in	combination.	To	determine	the	
effects	of	three-agent	combination,	organoids	were	challenged	with	a	dose	titration	
range	of	compounds	administered	in	a	IC50-constant-ratio	dose	(8:4:1	for	
Dabrafenib:	Trametinib:	Panitumumab)	for	72	hours	prior	to	quantification	of	cell	
viability.	The	ratio	of	IC50s	were	previously	determined	by	those	generated	from	
single-assay	responses,	where	possible,	or	from	IC50	values	gathered	from	in	vitro	
data	within	the	literature.			
	
Following	exposure	to	compounds	in	double	combination	(Dabrafenib	and	
Trametinib,	Trametinib	and	Panitumumab	and	Panitumumab	and	Dabrafenib,	
respectively)	or	as	triple	agents,	the	effects	upon	overall	viability	of	organoids	were	
characterised	by	assessment	of	ATP	levels	using	the	Cell	Titer	Glo	3D	assay,	following	
4	days	of	treatment.	Given	that	Trametinib	as	a	single	agent	induced	a	clear	growth	
inhibitory	response	upon	organoids	it	would	be	expected	that	it	would	perhaps	
potentiate	the	effects	of	both	Dabrafenib	and	Panitumumab.	Following	
establishment	of	dose	response	curves	from	each	treatment	as	well	as	further	linear	
regression	analysis	it	was	found	that	Trametinib	treatment	(MEK	inhibition)	
potentiated	the	effects	of	BRAF	inhibition	by	Dabrafenib	upon	Iso	34.	This	confirms	
observations	from	previous	in	vitro	studies	in	the	literature,	whereby	Dabrafenib	and	
Trametinib	together	work	favourably	to	reduce	the	growth	of	BRAF	mutant	lines	
(Corcoran	et	al.	2015).	More	specifically,	as	noted	in	Table	4.2,	further	calculations	to	
determine	dose	reduction	index	revealed	that	by	addition	of	Trametinib,	Dabrafenib	
could	be	administered	at	>1000	fold	lower	dose	to	achieve	a	50%	inhibition	in	
organoid	growth.	Similarly,	it	was	demonstrated	that	addition	of	Trametinib	to	
	 145	
Panitumumab-treated	organoids	worked	favourable	to	enhance	inhibitory	effects	on	
overall	organoid	viability	in	a	dose	dependent	manner.		
	
An	overall	reduction	in	growth	was	observed	in	Iso	34	organoids	treated	with	
Dabrafenib,	Trametinib	and	Panitumumab	in	combination	(n=3)	compared	to	DMSO	
(0.1%)	control	conditions.	Synergistic	activity	of	the	three	compounds	in	
combination	was	further	confirmed	by	combination	index	value	of	0.03±0.05,	then	
by	application	of	the	dose	reduction	calculation,	which	demonstrated	that	when	all	
three	compounds	were	administered,	both	Dabrafenib	and	Panitumumab	doses	
could	be	reduced	by	1000	fold,	whilst	Trametinib	doses	could	be	reduced	by	3	times,	
to	achieve	an	inhibitory	effect	in	50%	of	Iso	34	organoids,	as	indicated	in	Table	4.2	
	
Whilst	this	data	is	useful	to	demonstrate	the	application	of	organoids	towards	
combination	studies,	it	is	based	on	multiple	assumptions.	Given	the	compounds	
examined	exhibited	complex	modes	of	action,	distinct	IC50	values	were	hard	to	
obtain	for	each	compound	using	viability	readouts	and	therefore	subsequent	
analyses	needed	to	consider	this	caveat.	Overall,	data	indicated	that	agents	were	
able	to	potentiate	the	effects	of	another	to	inhibit	organoid	growth.
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Table	4.2	Combination	index	values	(CI)	and	Dose	reduction	index	(DRI)	per	treatment.	
All	data	was	inputted	into	Calcusyn	software	to	generate	combination	index	values	(n=3	biological	
repeats)	and	Dose	Reduction	Index	(DRI)	at	IC50	values	of	each	combinations..	
	
	
	
DRI at IC50 (fold change in dose at 
combination) 
CI Values 
(IC50) 
Dabrafenib Trametinib Panitumumab 
Dabrafenib+ 
Trametinib 
>1000 59 0.92±1.28 
Trametinib+ 
Panitumumab 
>1000 
 
>1000 
 
0.02±0.03 
 
Panitumumab
+ Dabrafenib 
>1000 
 
133 0.02±0.02 
Dabrafenib, 
Panitumumab 
+ Trametinib 
>1000 3.21 >1000 0.03±0.05 
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4.2.6 Phenotypic	screening	variably	aids	discrimination	between	subtle	dose	
dependent	responses	in	cellular	morphologies	
	
Phenotypic	profiling	of	pharmacologic	responses	is	becoming	an	apparent	approach	
to	assess	therapeutic	effects	upon	distinct	cellular	morphologies	and	are	beyond	the	
scope	of	limited	basic	readouts.	Using	Principal	Component	Analysis	(PCA),	such	
platforms	have	condensed	multiple	phenotypic	measurements	to	assess	subtle	
changes	in	changes	to	nuclear,	cellular	and	structural	changes	in	cells	in	exposure	to	
compounds	(Caie	et	al.	2010;	Reisen	et	al.	2013;	Sandercock	et	al.	2015;	Di,	Klop,	
Rogkoti,	Devedec,	van	de,	et	al.	2014).	This	has	facilitated	an	enrichment	of	
phenotypic	data	beyond	basic	metrics.	Within	this	thesis,	such	analyses	were	found	
to	be	critical	to	identify	organoid-specific	signatures	of	response	to	Wnt	inhibitors,	as	
discussed	within	Chapter	5.	
	
Relevant	treatments	from	the	FOCUS	4	clinical	trial	elicited	a	number	of	effects	upon	
viability	and	basic	phenotypic	readouts	in	an	organoid	cohort.	Further	discrimination	
of	drug-induced	effects	could	therefore	be	beneficial	to	improve	readouts	of	
response	to	compounds.		Here,	it	was	investigated	whether	PCA	of	multiparametric	
data	could	capture	drug-induced	variance	more	successfully	than	a	single	parametric	
measurement	(	e.g.	ATP	viability	readout).	It	was	hypothesised	that	multiple	
phenotypic	readouts	would	facilitate	a	more	robust	readout,	facilitating	the	
dissection	of	drug-dependent	mechanisms.	Ultimately,	this	would	enable	the	
identification	of	active	compounds	based	upon	subtle	changes	in	organoid	
morphologies.			
	
To	investigate	phenotypic	profiles,	a	set	of	6	organoids	(Iso	34,49,50,72,75,78)	were	
seeded	as	single	cells	and	following	a	recovery	for	3	days,	were	treated	with	a	
titration	range	of	compounds	administered	within	FOCUS	4	for	a	total	of	4	days.	
Samples	were	then	fixed	and	stained	simultaneously	for	24	hours	at	room	
temperature,	as	described	in	(Di,	Klop,	Rogkoti,	Devedec,	van	de,	et	al.	2014)	to	
visualise	Hoechst	(nuclear)	and	Phalloidin	(F-actin).	Following	washes	in	PBS,	3D	
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structures	were	then	imaged	on	a	MetaXpress®	high-content	confocal	microscope	
(carried	out	by	OcellO,	Leiden),	which	facilitated	the	acquisition	of	z-stacks	from	384	
well	plates.	
	
Individual	images	from	each	z-stack	were	then	inputted	within	the	bespoke	
OMiner™	analysis	platform	developed	by	OcellO,	as	depicted	within	Figure	4.10.	
Briefly,	projections	of	the	F-actin	and	nuclei-derived	image	stacks	were	used	to	
extrapolate	masks	of	individual	organoids,	internal	lumen	structures	and	nuclei.	
Image	segmentation	and	filters	were	then	applied	to	identify	individual	objects	per	
well	from	each	channel,	and	enhance	noise	suppression	to	balance	sensitivity	of	
analysis.	Relevant	masks	were	then	used	to	acquire	approximately	700	quantifiable	
morphological	features	per	structure,	including	data	relating	to	fluorescence	
intensities	per	channel.	Measurements	of	individual	features	per	organoid	were	
pooled	to	generate	measurements	on	a	well-by-well	basis.	Data	were	then	
normalised	to	negative	controls,	per	phenotypic	measurement,	to	account	for	
potential	variability	in	plating	conditions	and	staining	procedures	per	experiment.	
	
In	order	to	condense	phenotypic	measurements	to	key	principal	components,	PCA	
was	performed	upon	the	700	morphological	variables.	PCA	was	carried	out	on	each	
feature	acquired	from	experimental	drug	conditions	per	organoid	line,	across	a	dose	
response.	PCA	enabled	a	reduction	in	the	dimensionality	of	each	dataset	by	
facilitating	the	conversion	of	data	from	multiple	variables	(individual	phenotypic	
features	in	this	case)	into	a	new	coordinate.	This	conversion,	whereby	each	
coordinate	is	recognised	as	a	principal	component	,enables	the	greatest	variances	
across	data	(between	control	and	treatment	conditions)	to	lie	on	one	co-ordinate.	
The	greatest	variance	in	the	principal	components	therefore	lies	on	the	first	principal	
component,	with	the	next	greatest	variance	on	the	second	principal	component,	and	
so	forth.			Figure	4.11	demonstrates	a	typical	scree	plot	of	percentage	(%)	variation	
obtained	in	each	component,	as	represented	from	Iso	72	treatment	with	aspirin.		
The	variation	within	the	first	principal	component	in	this	instance	was	28%.		
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To	identify	drug-induced	effects	from	condensed	data,a	multidimensional	
Mahalanobis	Distance	metric	was	used	to	calculate	the	similarity	of	a	data	point	to	
the	negative	control,	based	upon	the	correlation	between	variables	contained	within	
the	first	5	principal	components.	The	Mahalanobis	distance	metric	facilitates	the	
measurement	of	distances	in	3D	space.	Here,	this	calculation	was	used	to	measure	
distances	between	each	dose	and	control	DMSO-treated	samples	per	organoid	line,	
per	treatment.		Theoretically,	the	Mahalanobis	distance	would	enable	a	calculation	
of	the	similarity	of	a	data	vector	to	negative	control	conditions.	Therefore,	a	larger	
Mahalanobis	distance	between	DMSO	control	and	treatment	would	equate	to	a	
greater	difference	in	phenotype	between	both	conditions.	Alternatively,	if	the	
treatment	induced	a	phenotype	that	was	similar	to	DMSO	control	conditions,	the	
distance	would	be	small.	This	enabled	extraction	of	the	greatest	variance	between	
DMSO	control	and	dose	of	compound	from	multiple	features.		Any	outliers	within	
the	data	analysis	were	confirmed	by	visual	inspection	of	the	image	of	the	whole	well	
(Appendix	i-1)	and	were	usually	a	result	of	either	empty	wells	as	a	result	of	shipping	
conditions,	or	poor	segmentation	due	to	over-seeding	in	the	well.	Following	
identification	and	removal	of	this	from	data,	a	minimum	of	6	wells	were	used	per	
condition.	Distances	measured	(Appendix	I-2)	from	each	treatment	dose	were	then	
used	to	generate	drug	dose	response	curves,	as	represented	in	Figure	4.11,	to	
determine	EC50	values	(dose	response	curves	obtained	from	Mahalanobis	distance	
measurements	were	plotted	for	each	organoid	line,	as	shown	in	Appendix	I-2).		
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Figure	4.11	Multi-parametric	analysis	output	from	Iso	72	organoids	
Freshly	digested	organoids	were	seeded	within	matrigel	in	384	well	plates	and	overlaid	with	optimal	
media	for	growth.	Following	3	days	of	recovery,	a	dose	titration	of	compounds	within	the	FOCUS	4	
trial	were	administered	versus	a	DMSO	negative	control.	Following	4	days	of	treatment,	organoids	
were	fixed	and	stained	simultaneously	for	Hoechst	and	F-actin.	Subsequent	z-stack	images	were	
collected	and	inputted	within	OMiner™	software	to	generate	multiple	phenotypic	measurements	
acquired	from	Hoechst	and	TRITC	channel	information.	Data	was	inputted	into	R	to	generate	
Prinicipal	Component	Analysis	(PCA)	of	features.	(A)	Screen	plot	from	Principal	component	analysis	
demonstrates	variables	contributing	to	most	variance	within	the	data	(B)	Features	within	the	first	5	
components	were	used	to	measure	Mahalanobis	distance	from	treatment	and	control	conditions.	
This	measurement	enabled	a	discrimination	between	each	treatment	dose	compared	to	control,	
based	on	multiple	measured	features.	
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Overall,	it	was	observed	in	some	instances	that	clustering	of	multiple	correlated	
phenotypic	parameters	identified	drug-induced	effects	at	lower	concentrations	of	
drug	compared	to	preceding	readouts	of	responses.		
	
Multiparametric	readouts	identified	Iso	34	and	Iso	78	as	aspirin-sensitive	organoid	
lines,	generating	EC50	values	of	5	µM	and	1	µM	(Figure	4.12).	Whilst	this	data	
corresponded	to	previous	observations	from	ATP	readouts,	the	overall	sensitivity	of	
the	multiparametric	assay	did	not	necessarily	further	discriminate	aspirin-dependent	
responses	within	the	organoid	cohort.	It	is	possible	that	a	number	of	factors	could	
contribute	to	this.	Firstly,	the	magnitude	of	difference	between	the	experimental	
groups	was	not	large	enough	for	distances	to	be	varied	within	increasing	doses.	It	is	
also	possible	that	only	a	few	features,	such	as	nuclear	morphologies,	were	altered	in	
response	to	aspirin.	In	this	case,	it	is	possible	that	a	large	number	of	readouts	that	
are	not	perturbed	as	a	result	of	treatment	represent	assay	noise	and	could	therefore	
interfere	with	the	accuracy	obtained	by	a	smaller	collection	of	parameters	(Hutz	et	
al.	2012).An	optimized	set	of	key	morphological	signatures	could	more	accurately	
identify	the	separation	between	treatment	and	control	conditions,	enabling	fewer	
variables	to	capture	more	biological	variation.			
	
Multi-parametric	analysis	of	compounds	that	targeted	DDRs	were	also	shown	to	
corroborate	previous	findings	from	ATP	assays.	EC50	values	of	Iso	50	exposed	to	AZ20	
treatment	were	found	to	be	closer	to	an	expected	IC50	value	when	multiple	variables	
were	measured	(1	nM).	Analysis	of	phenotypes	also	demonstrated	that	MK1775	
induced	a	number	of	alterations	on	phenotypes	in	all	organoids	assessed,	further	
corroborating	ATP	readouts	of	dose	range	response.	Collectively,	organoid	responses	
to	5-FU	were	varied	in	sensitivity	following	assessment	of	collective	phenotypic	
responses.	Iso	78	was	shown	to	be	the	most	resistant	organoid	line	to	5-FU	
treatment.		
	
Administration	of	the	Her1-3	inhibitor,	Sapitinib,	also	demonstrated	that	organoids	
overall	showed	limited	sensitivity	to	compound	inhibition.	Iso	72,	similarly	to	CTG	
measurements,	generated	a	high	EC50	value,	further	confirming	that	observations	
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were	likely	due	to	off	target	effects.	Interestingly,	Iso	75,	having	shown	no	response	
to	Sapitinib	in	ATP	readouts,	showed	sensitivity	to	Sapitinib	treatment	based	on	
multi-parametric	data,	yielding	EC50	values	of	approximately	30	nM.	It	is	possible	that	
morphological	readouts	were	able	to	detect	subtle	changes	in	Iso	75	in	response	to	
Sapitinib	that	could	not	be	measured	by	ATP	viability	readouts.		
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Figure	4.12	Organoids	reveal	differential	sensitivities	to	inhibitors		
A	cohort	of	8	Organoids	were	seeded	as	single	cells	and	following	3	days	of	recovery,	were	subject	to	
a	dose	titration	range	of	compounds	within	the	FOCUS	4	trial.	Following	phenotypic	screening,	PCA	
was	performed	in	order	to	project	the	features	obtained	within	each	treatment	to	independent	
principle	component	space.	The	5	principle	components	that	retained	the	largest	proportion	of	data	
variation	were	then	subject	to	Mahalanobis	distance	analysis,	to	calculate	the	similarities	of	data	
point	to	the	negative	control	based	on	correlation	between	the	variables.	These	were	then	plotted	as	
dose	response	curves	(Appendix	I-2)	to	generate	Log	EC50	values	per	compound.	(A)	Plot	of	Log	EC50	of	
each	compound	administered	within	FOCUS	4	against	organoids.	Each	dot	represents	an	organoid	
line.	
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4.3 Summary	
	
The	work	described	here	has	shown	a	possible	utility	of	patient	colorectal	tumour	
organoids	towards	mirroring	a	clinical	trial	in	vitro.	Using	assay	formats	previously	
described	in	Chapter	2,	in	combination	with	specific	optimised	culture	conditions	per	
line,	enables	the	investigation	of	multiple	pathways	relevant	to	clinical	trials.	This	
format	has	facilitated	the	measurement	and	assessments	of	effects	of	many	
different	groups	of	inhibitors.			
	
Using	such	systems,	this	work	has	particularly	highlighted	the	utility	of	organoids	to	
investigate	the	combination	therapies	of	3	compounds,	which	have	yet	to	be	studied	
in	vivo.	As	combination	therapies	become	increasingly	popular	within	the	clinic,	this	
shows	a	direct	future	application	of	organoids	to	study	complex	interactions	
between	multiple	targeted	therapies.		
	
This	work	further	demonstrates	the	need	for	relevant	pre-clinical	models	to	
accompany	biomarker	driven	strategies	for	CRC.	Through	this	system,	the	differential	
responses	of	organoids	to	hypothesis-driven	therapies	regardless	of	mutational	
status	was	apparent.		Overall,	whilst	the	use	of	phenotypic	screening	to	identify	
more	subtle	responses	could	also	be	used	to	guide	effects	that	would	otherwise	be	
ignored	for	lack	of	cytotoxic	effects,	it	was	found	that	monitoring	viability	of	
organoids	was	a	useful	readout	for	treatment	versus	phenotype.	This	affirms	that	
such	assay	set-ups	could	be	suitably	incorporated	within	the	design	of	parallel	
patient-organoid	clinical	trials.		
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5 Characterisation	of	the	effects	of	novel	Wnt	inhibitors	on	
human	CRC	organoids	using	3D	image-based	multi-
parametric	phenotypic	profiling	
	
5.1 Introduction	
	
Aberrant	Wnt	signalling,	as	a	result	of	activating	mutations	within	the	pathway,	has	a	
prominent	role	in	tumour	cell	proliferation	and	survival	in	CRCs.	As	such,	an	array	of	
components	within	the	Wnt	signalling	pathway	have	been	postulated	as	viable	
molecular	targets	to	limit	the	enrichment	of	CSCs	and	thus	improve	clinical	
outcomes.	Attenuation	of	Wnt	signalling	through	the	use	of	Tankyrase	inhibitors	
(TNKSi)	have	been	characterised	within	the	literature,	and	have	previously	been	
linked	to	prevent	the	growth	of	Apc-deficient	tumours	within	mice	(Waaler,	Machon,	
Tumova,	Dinh,	Korinek,	Wilson,	Paulsen,	Pedersen,	Tor	J	Eide,	et	al.	2012;	Lau	et	al.	
2013;	Wu	et	al.	2016).	However,	overall,	pre-clinical	drug	discovery	for	Wnt	pathway	
modulators	have	thus	far	proven	difficult,	with	few	small	molecule	inhibitors	having	
entered	clinical	trial	and	thus	remaining	within	the	drug	discovery	pipeline	
(Novellasdemunt	et	al.	2015;	Waaler,	Machon,	Tumova,	Dinh,	Korinek,	Wilson,	
Paulsen,	Pedersen,	Tor	J	Eide,	et	al.	2012)	despite	encouraging	evaluations	in	vitro	
and	in	vivo.	This	may	be	a	result	of	a	number	of	factors;	firstly	in	vivo	studies	often	
administer	treatments	at	maximum	tolerated	doses	of	compounds	to	test	for	
efficacy	based	on	in	vitro	studies	within	2D	cell	lines,	resulting	in	potentially	
unnecessary	toxicity.	Secondly,	given	the	variation	of	Wnt	dependency	from	one	
tumour	to	the	next,	and	the	complexity	of	targeting	cancer	stem	cell	dynamics,	it	is	
unsurprising	that	2D	cell	lines	fail	to	reflect	results	in	vivo,	and	raises	questions	as	to	
their	capacity	as	sufficient	surrogate	tumour	models.	The	need	for	translatable	
model	systems	within	drug	discovery	pipeline,	capable	of	demonstrating	on-target	
effects	of	a	compound,	whilst	retaining	patho-physiological	tumour	dynamics	could	
prove	invaluable	to	show	the	effects	of	such	novel	therapeutics.		
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Given	the	capacity	of	3D	primary	organoids	to	retain	stem/differentiated	cells	it	is	
possible	that	they	could	become	useful	model	systems	to	study	stem	cell	dynamics.	
However,	complex	3D	models	provide	a	challenging	platform	to	quantify	
reproducible	drug	sensitivity,	particularly	to	compounds	possessing	equally	complex	
effects	upon	cell	dynamics.	Analysis	platforms	therefore	need	to	be	compatible	with	
counterpart	models	to	yield	quantitative	data.	
	
Whilst	 previous	 chapters	 have	 described	 the	 utility	 of	 organoids	 as	 a	 medium-
throughput	system	to	assess	clinically	 relevant	compounds,	 this	 thesis	also	aims	to	
establish	organoids	as	a	useful	 tool	 in	a	drug	discovery	setting.	 In	order	 to	explore	
this,	 multi-parametric	 phenotypic	 screening	 (OcellO)	 of	 organoids	 were	 used	 to	
assess	 the	 impact	 of	 novel	 cancer	 stem	 cell-targeting	 tankyrase	 inhibitors	 (Merck	
Serono).	
	
	
	
	
	
	
	
	
	
	
	
	
	
Some	data	analysis	presented	in	this	chapter	was	performed	by	Bram	Herpers,	
Kuan	Yan,	and	Leo	Price	(OcellO),	as	specified	within	figure	legends.	In	vivo	data	
was	carried	out	by	Kenneth	Ewan	(Dale	lab).	Data	presented	within	this	chapter	is	
currently	being	formatted	for	submission	as	a	literature	article.		
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5.2 Results	
	
To	 fully	 investigate	 the	 capacity	 of	 organoids	 to	 demonstrate	 on-target	 effects	 of	
novel	 compounds,	 three	 compounds	 in	 development	 with	Merck	 Serono	 with	 log	
fold	 changes	 in	 EC50	 values	 (i.e	 effective	 concentration	 to	 limit	 growth	 of	 50%	 of	
cells)	were	tested	within	the	established	organoid	cohort	previously	described.		EC50	
values	 of	 each	 compound	 (MSC2501490A,	 MSC2572070A,	 MSC2524070)	 were	
provided	by	Merck	Serono,	as	detected	by	a	luminex	assay	against	AXIN2,	indicating	
EC50	values	of	300	nM,	36nM	and	3nM,	respectively.	This	2D	cell-based	assay	utilises	
AXIN2	 stabilisation	 as	 a	 readout,	 as	 AXIN2	 is	 a	 target	 of	 TNKS1/2.	 Upon	
administration	 of	 the	 compound,	 the	 TNKS-dependent	 degradation	 of	 AXIN2	 is	
inhibited,	promoting	the	stabilisation	of	the	protein,	as	detected	by	an	immunobead	
assay.		
	
5.2.1 Tankyrase	inhibitors	induce	a	dose	dependent	response	within	sensitive	
organoids	in	a	functional	ATP	readout	
	
Given	that	TNKSi	have	previously	been	implicated	in	the	literature	as	potential	
compounds	to	target	stem	cell	niches	within	tumour	populations	(Zhong	et	al.	2015;	
Arqués	et	al.	2016)	,	it	was	investigated	here	whether	organoid	formation	and	
subsequent	growth	in	culture	would	be	affected	by	treatment.	3	organoid	lines	were	
therefore	administered	with	a	dose	titration	range	(0.19	nM	–	50nM)	of	a	tool	TNKSi	
developed	by	Merck	Serono	(MSC2524070),	which	will	be	made	available	to	the	
wider	research	community	for	testing.	
	
Organoids	previously	established	in	culture	were	suspended	to	single	cells	within	
matrigel	and	treated	with	a	nine-point,	two-fold	dilution	of	compound	or	DMSO	
control	(0.1%)	in	triplicate	wells	per	condition,	for	a	total	of	six	days.	
Morphologically,	both	Iso	72	and	Iso	75	organoids	displayed	sensitivity	to	TNKS	
inhibition,	as	indicated	in	Figure	5.1.	Iso	72	structures	treated	with	TNKSi	were	
shown	to	be	overall	reduced	in	size	compared	to	control	conditions,	whereas	Iso	75	
organoids	were	also	arranged	more	sparsely	indicating	a	lower	density	of	organoids	
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formed.	It	appeared	however,	that	TNKSi	did	not	appear	to	induce	typical	cytotoxic	
effects,	frequently	characterised	by	an	increased	level	of	cellular	debris	and	dense	
structures.			
	
Following	6	days	of	treatment,	Cell	Titer	Glo	3D	reagent	was	administered	to	wells	
and	luminescent	readouts,	as	a	representation	of	ATP	levels	were	acquired.	A	dose-
dependent	response	was	generated	in	both	Iso	72	and	Iso	75,	as	shown	in	Figure	5.1,	
eliciting	mean	EC50	values	of	2±0.7nM	and	14±8	nM,	respectively	from	three	
independent	experiments.	Iso	50	appeared	to	have	a	less	prominent	response	to	
increasing	concentrations	of	TNKSi	according	to	ATP	readouts,	with	EC50	values	of	
1043.9±621.2nM	obtained.	An	overall	reduction	in	ATP	levels	(Relative	
Luminescence	Units)	were	observed	at	the	highest	concentrations	of	TNKSi	
administered	(50	nM),	indicative	of	off-target	effects	in	comparison	with	sensitive	
lines.	
	
To	further	corroborate	qualitative	findings	as	well	as	ATP	quantification,	images	of	
wells	of	organoids	were	acquired	and	quantified	for	basic	morphometric	
measurements	using	GelCount™	CHARM	settings,	at	day	3	and	day	6	in	culture,	
whilst	exposed	to	a	dilution	of	treatment	conditions.	Measurements	of	total	
organoid	volume,	as	shown	in	Figure	5.2	were	shown	to	be	consistent	between	
control	and	treatment	conditions	within	all	organoid	lines	at	day	3.	Following	6	days	
of	treatment,	a	reduction	in	overall	volume	was	observed	in	Iso	72	organoids	in	
particular	between	control	and	MSC2524070	treatment	(1.56	nM	–	50	nM),	
indicating	that	overall	growth	was	minimized	following	treatment.		Iso	75,	despite	
showing	some	reduction	in	an	endpoint	ATP	assay	readout	at	day	6,	showed	little	
variation	between	average	organoid	volumes	in	control	and	treatment	conditions.	
This	could	be	the	result	of	partial	TNKS	inhibition,	stimulating	organoid	growth	to	
reach	similar	volumes	as	observed	by	control	organoids,	highlighting	the	complexity	
of	signaling	events	when	using	such	compounds.	However,	it	is	more	likely	that	this	
is	a	result	of	a	lack	of	sensitivity	from	basic	morphometric	readouts	obtained	using	
GelCount	charm	settings;	data	acquired	from	inherently	small	structures,	
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such	as	Iso	75	in	routine	culture,	could	harbor	sensitivity	of	detection	in	differences	
in	overall	sizes.		
	
A	count	of	average	number	of	organoids	formed	per	well	(n=3	wells)	by	day	6	in	
culture	were	generated	from	established	CHARM	settings	and	used	to	calculate	
organoid	formation	efficiency	from	a	known	number	of	single	cells	seeded	(Figure	
5.3).	Organoid	formation	efficiency	(%)	was	significantly	reduced	in	50	nM	of	TNKSi	
treatment	conditions	compared	to	control	DMSO	(0.1%)	conditions	in	Iso	75	
organoids	(n=3,	one	way	ANOVA	with	Dunnett’s	post	hoc	test).	Interestingly,	Iso	72,	
showed	no	treatment	dependent	effect	on	organoid	formation	efficiencies	(%)	
despite	overall	changes	in	growth.	This	could	be	as	a	result	of	TNKS	inhibition	
eliciting	affects	upon	this	line	at	a	later	point	in	treatment	compared	with	Iso	75.	Iso	
50,	a	non	responder	line,	as	expected,	showed	no	overall	alteration	in	organoid	
formation	efficiency	(%)	in	treatment	conditions.	
	
Taken	together,	this	data	indicates	that	TNKSi	induces	marked	effects	on	overall	
organoids	formation	or	subsequent	growth	in	culture.	It	was	notable	that	even	at	
highest	concentrations	of	treatment,	TNKSi	did	not	appear	to	induce	obvious	signs	of	
cell	death,	such	as	an	increased	number	of	debris	in	wells.		
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Figure	5.1:	Analysis	of	the	effects	of	the	Tankyrase	inhibitor	MSC2524070	on	the	viability	of	three	
tumour	organoids.	
Iso	50,	Iso	72	and	Iso	75	organoids	were	seeded	at	400	cells/µl	Matrigel	and	overlaid	with	previously	
specified	growth	media,	supplemented	with	MSC2524070	at	a	two-fold	dilution	(0.195	nM	–	50	nM),	
and	a	matched	DMSO	control	(0.1%	in	media).	(A)	Representative	images	at	day	6	in	culture.	(B)ATP	
endpoint	assay	readouts	across	a	dilution	of	drug	doses	in	Iso	50	(i),	Iso	72	(ii),	Iso	75	(iii)	were	
performed	following	6	days	of	exposure	to	TNKS	inhibitor.	EC50	best	fit	curve	were	plotted	using	XLFit	
plug-in	for	Microsoft	Excel,	and	are	shown	from	one	representative	experiment.	Each	plot	represents	
data	obtained	from	a	single	well	within	an	assay.	(C)	Organoid	volumes	calculated	on	day	6	of	culture	
with	each	treatment	of	compound,	measured	using	GelCountTM	analysis	software	for	Iso	50	(i),		Iso	
72	(ii)	and	Iso	75	(iii).	Data	generated	by	Jennifer	Shone	under	my	supervision.	Dose	response	curves	
generated	by	Jennifer	Shone,	referenced	in	report	‘Maniuplating	the	Wnt	signaling	pathway’,	PTY	
report	(2015-2016)	
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Figure	5.2	Analysis	of	the	effects	of	the	Tankyrase	inhibitor	MSC2524070	on	overall	organoid	
volume	
Iso	50,	Iso	72	and	Iso	75	organoids	were	seeded	at	400	cells/µl	Matrigel	and	overlaid	with	previously	
specified	growth	media,	supplemented	with		MSC2524070	at	a	two	fold	dilution	(0.195	nM	–	50	nM),	
and	a	matched	DMSO	control	(0.1%	in	media).	(A)Organoid	volumes	of	(i)	Iso	50,	(ii)	Iso	72,	(iii)	Iso	75	
calculated	on	day	6	of	culture	with	each	treatment	of	compound,	measured	using	GelCountTM	
analysis	software.	Data	generated	by	Jennifer	Shone	under	my	supervision.	
	
(Ai) 
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Figure	5.3	Analysis	of	the	effects	of	the	Tankyrase	inhibitor	MSC2524070	on	organoid	formation	
efficiency.	
Freshly	trypsinised	organoids	were	seeded	at	400	cells/µl	Matrigel	and	overlaid	with	previously	
specified	growth	media	supplemented	with	concentrations	of	each	of	the	MSC2524070	at	a	two	fold	
dilution	(0.195	nM	–	50	nM),	and	a	matched	DMSO	control	(0.1%	in	media)	for	6	days	in	culture.	(A)	
Bar	charts	depicting	organoid	formations	efficiencies	calculated	following	3	days	in	culture	for	(i)	Iso	
50;	(ii)	Iso	72;(iii)	Iso	75.	Data	are	shown	as	mean±s.e.m,	whereby	n=3.	Statistical	significance	as	
compared	to	control	as	indicated	by	*	(p≤0.05)	**	(p≤0.01),	calculated	by	a	one	way	ANOVA,	followed	
by	Dunnett’s	multiple	comparison	post-hoc	testing.	Data	generated	by	Jennifer	Shone	under	my	
supervision.	
(Ai) 
(Aii) 
(Aiii) 
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5.2.2 Tankyrase	inhibition	significantly	reduces	proliferation		
	
Prompted	by	indications	that	TNKSi	induced	differential	levels	of	growth	responses	
in	a	subset	of	organoids,	it	was	further	explored	whether	treatment	with	
MSC2524070	impacted	cell	proliferation.		
	
Following	6	days	of	treatment	with	25nM	MSC2524070A	or	0.1%	DMSO	untreated	
control,	Iso	50	and	Iso	72	structures	(a	non-responder	and	responder	organoid	line,	
respectively)	were	fixed	by	addition	of	4%	PFA	to	each	well	at	room	temperature	for	
15	minutes.	Organoids	were	washed	and	stained	within	black,	clear-bottomed	96	
well	plates	and	stained	with	a	nuclear	stain	(Hoechst)	and	proliferation	marker	
(Ki67),	prior	to	acquisition	of	z-stack	images	on	a	confocal	microscope.	To	detect	and	
quantify	positively	stained	cells	within	organoids,	an	automated	counting	tool	was	
established	using	IMARIS	software	(BITPLANE).	A	number	of	thresholds	were	
generated	to	assess	staining	intensity	and	morphology	to	ensure	that	counted	
objects	were	not	duplicated.	For	counting	purposes,	a	mask	was	generated	to	
quantify	the	number	of	Hoechst-stained	nuclei	present,	and	Ki67	positive	cells	on	an	
organoid-by-organoid	basis.	The	number	of	ki67-positive	cells	were	then	calculated	
as	a	percentage	per	whole	organoid	(%).		
	
Using	the	established	settings	for	automated	cell	counts,	it	was	possible	to	score	the	
number	of	cells	per	organoid	structure	from	Hoechst	stained	nuclei	as	a	further	
measurement	of	organoid	growth.	As	shown	in	Figure	5.4,	Iso	72	organoids	
contained	an	average	of	108±12	cells	per	organoid	in	untreated	control	conditions,	
as	opposed	to	47±11	in	the	presence	of	TNKSi	MSC2524070.	On	the	contrary,	Iso	50	
showed	no	significant	alteration	in	the	number	of	nuclei	per	organoid	following	a	six-
day	exposure	to	compound,	with	no	significant	difference	in	number	of	nuclei	in	
control	and	treated	conditions.		
	
Quantification	of	ki67	positive	cells	revealed	a	significant	reduction	in	the	
percentage	of	proliferating	cells	per	organoid	following	6	days	of	TNKSi	treatment	
compared	to	control	conditions	in	Iso	72	organoids	(0.33%	±	0.2562%	versus	34.38%	
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±	8.510%,	p=0.005,	unpaired	t-test	with	Welch’s	correction).	In	contrast,	a	non-
TNKSi-sensitive	organoid	line,	Iso	50,	showed	no	significant	difference	in	the	overall	
ratio	of	ki67	positive	cells	per	organoid	in	both	conditions,	indicating	that	
proliferation	was	unaffected	despite	treatment.		
	
Despite	organoids	assessed	showing	a	TNKSi-dependent	decrease	upon	proliferation	
in	sensitive	organoids	(Iso	72),	it	is	worth	noting	that	such	counts	have	technical	
limitations	upon	what	can	be	interpreted	biologically;	such	a	low-throughput	system	
restricts	the	number	of	organoids	which	can	be	quantified,	and	in	this	case	were	
limited	to	a	maximum	of	12	organoids	per	condition.	
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5.2.3 Phenotypic	screening	of	TNKSi-treated	organoids			
Given	the	limitations	of	quantifiable	readouts	used	thus	far,	it	was	necessary	to	
further	interrogate	the	functional	effects	of	TNKSi	upon	organoids	beyond	such	basic	
measures,	to	facilitate	a	clearer	discrimination	between	dose-dependent	effects	of	
treatment.	As	such,	a	high-throughput	multi-parametric	phenotypic	analysis	screen	
was	performed,	in	collaboration	with	OcellO	(Leiden	University).	Phenotypic	
screening	has	been	implicated	as	a	successful	way	to	identify	drug	responses	relying	
on	functional	effects	of	cell	behaviour	as	opposed	to	focusing	purely	on	molecular	
targets	(Moffat	et	al.	2014;	Sandercock	et	al.	2015).	Within	the	literature,	OcellO	
have	established	a	refined	system	whereby	images	z-stacks	can	be	interrogated	to	
identify	certain	treatment-dependent	feature	responses	which	can	take	place	
(Sandercock	et	al.	2015;	Di,	Klop,	Rogkoti,	Devedec,	Water	van	de,	et	al.	2014).	Here,	
the	high-throughput	format	of	such	an	assay	system	was	used	to	investigate	the	
impact	of	three	novel	TNKSi	with	log-fold	changes	in	known	EC50	values	(previously	
established	by	Merck	Serono)	upon	8	organoid	lines.	
5.2.3.1 Multi-parametric	quantification	of	morphological	and	fluorescence	
intensity	reveals	TNKSi-dependent	effects	within	an	organoid	cohort	
	
8	organoid	lines	(Iso	34,	38,	48,	49,	50	,	72,	75,	78)	were	seeded	as	single	cells	at	a	
density	of	400	cells/µl	matrigel	per	well	of	a	384	plate,	to	a	total	volume	of	12µl	
within	a	matrigel	meniscus.	Upon	matrigel	polymerisation,	tailored	media,	as	
previously	established	per	line	(Chapter	3)	was	added	to	each	well	with	a	titration	of	
compounds	(MSC2524070A	0.39	nM	-100nM;	MSC2572070A	0.8	nM	–	250	nM;	
MSC2521490A	4nM	–	1250	nM)	at	a	ten-point,	two-fold	dilution,	with	DMSO	(0.1%)	
as	a	negative	control.	A	total	of	8	replicate	wells	were	used	per	condition.	Organoids	
were	subject	to	treatment	for	a	total	of	6	days	prior	to	simultaneous	fixation	and	
staining	with	F-actin	(TRITC	phalloidin)	and	nuclear	stains	(Hoechst	3568)	(as	
described	by	Di	et	al	2014).			
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Individual	z-stack	images	of	whole	384	well	plates	were	collected	on	a	MetaXpress®	
high-content	microscope	at	OcellO.	Images	were	then	inputted	into	the	OMiner	
analysis	software	developed	by	OcellO,	as	detailed	previously	in	Chapter	2	(section	
2.6.3).	Briefly,	projections	of	the	F-actin	and	nuclei-derived	image	stacks	were	used	
to	extrapolate	masks	of	individual	organoids,	internal	lumen	structures	and	nuclei.	
Image	segmentation	and	filters	were	applied	to	distinguish	individual	objects	per	
well,	and	enhance	noise	suppression	to	balance	sensitivity	of	analysis.	Relevant	
masks	were	then	used	to	acquire	approximately	700	quantifiable	morphological	
features,	including	data	relating	to	fluorescence	intensities	acquired	per	channel.		
	
Data	from	individual	organoids	were	then	pooled	on	a	well-by-well	basis,	with	data	
from	individual	wells	then	gathered	to	yield	average	parameter	readings	per	
treatment	condition.	Variation	in	specific	measured	parameters	across	a	plate	were	
assessed	by	heat	mapping,	as	shown	in	Figure	5.5,	to	ensure	that	technical	replicates	
were	valid	for	analysis;	any	outliers	were	removed	from	analysis,	resulting	in	a	
minimum	of	6	replicate	wells	used	for	subsequent	data	accumulation.	Any	outliers	
from	analysis	were	usually	a	result	of	matrigel	disruption	within	the	well	(as	a	
consequence	of	plating	or	shipping	conditions).	
	
Images	and	corresponding	masks	obtained	from	nuclei	and	F-actin	channels	
demonstrated	that	within	control	conditions,	organoids	formed	distinct	structures	
with	intense	f-actin	staining	within	organoid	lumens.	F-actin	integrity	has	previously	
been	implicated	as	a	critical	factor	for	overall	cell	viability	and	structural	support,	as	
well	as	nuclear	division	(Caie	et	al.	2010).	Measurement	of	individual	parameters,	
such	as	overall	organoid	size,	showed	clear	TNKSi-induced	effects	in	Iso	72,	as	
indicated	by	heat	mapping	across	the	plate	,	as	depicted	in	Figure	5.5,	further	
corroborating	previous	data.	Consistent	with	previous	findings	using	GelCount	
measurements,	morphometric	analysis	highlighted	a	dose-dependent	difference	in	
overall	organoid	sizes	of	Iso	72	treated	MSC2524070	compared	to	negative	control	
conditions	(DMSO,	0.1%).	In	concordance	with	this,	using	measurements	generated	
from	masks	of	Hoechst	channel	information,	it	was	also	observed	that	there	was	an	
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overall	decrease	in	the	number	of	nuclei	per	organoid	compared	to	control	
conditions.		
	
Morphometric	analysis	also	revealed	that	iso	72	demonstrated	a	change	in	overall	
lumen	size	as	a	result	of	tankyrase	inhibition.		Interestingly,	in	the	lowest	
concentrations	of	compound	administered,	it	was	found	that	an	overall	increase	in	
lumen	size	occurred,	which	did	not	seem	to	equate	to	overall	increase	in	organoid	
size.	In	a	recent	study	by	Lau	et	al	(2013),	it	was	also	found	that	TNKSI	G007-LK	and	
G244-LM,	mediated	a	similar	effects	in	organoids	cultured	from	Apcmin	small	
intestine	adenomas.	A	similar	effect	could	be	taking	place	in	organoids	cultured	
here,	whereby	an	increase	in	size	with	tankyrase	inhibitor	could	be	coupled	with	the	
induction	of	differentiation	whereby	cells	are	shed	into	the	central	lumen.	This	might	
also	occur	if	epithelial	cell	to	cell	junction	integrity	were	disrupted,	whereby	
polarised	lumens	are	no	longer	formed	in	response	to	TNKS	inhibition.
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Figure	5.5	TNKSi	mediate	morphological	changes	in	Iso	72	organoids.	
Iso	72	organoids	were	seeded	in	384	well	format	within	growth	factor-reduced	matrigel	and	
administered	with	a	titration	of	MSC2524070A	compound	at	a	range	of	concentrations	(19nM	–	
50nM).	Organoids	were	subject	to	treatment	for	6	days	prior	to	simultaneous	fix	and	stain,	then	
analysed	by	OcellO	Ominer	software.	(A)	Heat	map	based	on	total	organoid	area	within	a	384	well	
plate	between	DMSO	(0.1	%)	and	MSC2522070A	conditions	(Heat	map	generated	by	OcellO	readout,	
raw	data	obtained	by	Ominer	software,	OcellO).	(B)	Fold	change	in	average	lumen	size	in	response	to	
tankyrase	inhibition	(C)	Counts	of	changes	in	average	number	of	nuclei	per	organoid	in	response	to	
treatment;	p<0.05*;p<0.01**;	p<0/001***,	ANOVA	with	Dunnett’s	multiple	comparison	test.
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5.2.3.2 Feature-space	training	of	phenotypic	screening	reveals	targeted	
effects	of	TNKSi	treatments	within	organoids	
	
To	assess	whether	on-target	effects	of	compounds	could	be	measured	by	phenotypic	
screening,	multi-parametric	feature	space	training	analysis	was	implemented	to	
facilitate	further	discrimination	of	phenotypes	observed	between	administered	
doses	and	negative	control	conditions.		Previous	studies	within	the	literature	have	
utilised	such	methods	of	analysis	to	enable	a	selection	of	optimum	features	to	
classify	responses	to	a	particular	compound	(Sandercock	et	al.	2015;	Di,	Klop,	
Rogkoti,	Devedec,	Water	van	de,	et	al.	2014;	Caie	et	al.	2010).		
	
Firstly,	following	morphometric	and	fluorescent	measurements	of	individual	
organoid	components,	all	data	were	normalised	per	feature	by	robust	z-score	
(Described	in	(Di,	Klop,	Rogkoti,	Devedec,	Water	van	de,	et	al.	2014),	supplementary	
information),	to	account	for	variability	between	plates	(such	as	potential	differences	
in	staining	intensities).	The	highest	doses	of	each	compound	were	then	used	to	
select	features	that	maximally	separated	high	dose	treatment	from	negative	
controls,	based	on	robust	z-scores.		Principal	component	analysis	(PCA)	was	then	
performed	on	each	data	set	for	compound	and	control	DMSO-treated	samples,	per	
organoid	line,	to	reduce	phenotypic	measurements	to	key	principal	components	(PC)	
only,	as	opposed	to	assessing	individual	parameters.	By	reducing	data	into	key	
components	of	variation,	it	was	possible	to	visualise	responses	across	a	titration	
range	of	doses,	to	clearly	discriminate	between	the	highest	doses	and	negative	
control	(DMSO,	0.1%)	conditions.	The	distances	between	the	primary	principal	
components	(PC0)	in	phenotypic	space	were	then	measured	using	an	Euclidean	
distance	metric	(	equivalent	to	Mahalanobis	distance	metric	utilised	in	chapter	4)	
between	control	and	treatment	conditions	of	organoids.	It	would	be	expected	that	a	
maximal	separation	of	Euclidean	distances	would	be	observed	in	wells	whereby	
phenotypes	are	most	dissimilar.	Based	on	this	assumption,	TNKSi	sensitivity	would	
therefore	result	in	larger	segregation	of	Euclidean	distances	in	measured	principal	
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components	between	DMSO	conditions	and	increasing	concentrations	of	an	
inhibitor.		
	
Euclidean	distance	analyses	of	three	compounds	measured	against	DMSO	control	
conditions	in	a	cohort	of	8	organoids	were	plotted	with	a	log	EC50	(µM).	As	shown	in		
Figure	5.6	(B)	the	organoid	lines	Iso	72,	Iso	75	and	Iso	78	were	shown	to	have	a	clear	
dose-dependent	response	upon	phenotypic	parameters	induced	by	compounds.	
Figure	5.6	(A)	further	highlights	the	morphometric	output	of	sensitive	organoid	line	
Iso	75	treated	with	the	highest	concentration	of	each	compound,	compared	to	Iso	
50,	showing	visually	little	alteration	in	the	presence	of	compounds	administered.	
Interestingly,	both	Iso	75	and	Iso	78	were	dependent	on	Full	media	containing	Wnt	
and	R-spondin	to	facilitate	normal	growth	in	culture,	indicative	of	high	levels	of	Wnt	
dependency.	However,	Iso	72	was	shown	to	sustain	growth	independent	of	Wnt	in	
the	media,	suggesting	that	response	if	not	necessarily	correlated	of	external	growth	
factor	dependence.	Iso	38	and	34	appeared	to	have	a	strong	response	to	two	of	the	
inhibitors;	MSC2501490A	and	MSC2572070A,	but	we	were	unable	to	detect	such	a	
clear	EC50	for	the	most	potent	tested	TNKSi,	MSC2524070A.	It	was	observed	that	
TNKSi	appeared	to	have	a	minimal	effect	across	the	range	of	phenotypes	measured	
in	the	remaining	lines,	with	little	changes	in	Euclidean	distance	measurements	
between	DMSO	control	conditions	and	an	increasing	dose	range	of	TNKSi	.	Iso	50	
responses	corroborated	previous	data	collected	on	a	lack	of	impact	upon	overall	
organoid	size	as	an	indication	of	growth,	as	well	as	no	impact	upon	overall	
proliferation.		
	
Plotting	principal	components	of	a	number	of	phenotypes	in	a	multidimensional	plot	
enabled	a	higher	level	of	discrimination	between	highest	and	lowest	dose	of	
treatment,	enabling	the	measurement	of	a	clear	dose-response	curves	whose	
aggregate	quality	far	exceeded	that	of	individual	parameters.	Importantly,	such	
responses	correlated	with	expected	EC50s	over	3	log	fold	changes,	indicating	that	
collective	data	obtained	from	multiple	phenotypic	profiles	were	able	to	represent	
targeted	effects	of	compounds.		
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Figure	5.6	3D	image	analysis	demonstrates	on-target	effects	of	TNKSi	within	organoid	cultures	
Tumor	organoids	were	seeded	within	384	well	plates	and	overlaid	with	optimal	growth	media	
supplemented	with	MSC2501490A,MSC2524070A,	MSC2572070A	in	a	nine-point,	two-fold	drug	
titration,	or	a	DMSO	(0.1%)	negative	control.	Cultures	were	treated	for	six	days,	prior	to	fixing	and	
staining	simultaneously	with	DAPI	(nuclei;	blue)	and	phalloidin	(F-actin;	red).	(A)	Representative	
images	of	individual	wells	of	a	384	well	plate,	demonstrating	slight	morphological	effects	of	highest	
tankyrase	inhibitor	doses	in	a	sensitive	and	non-sensitive	organoid	line	(Iso	72,	Iso	50)		(B)	Principal	
component	analysis	was	used	to	select	the	top	10	most	discriminating	features	to	separate	
compound-induced	phenotypes	between	high	and	low	doses	of	tankyrase	inhibitors.	Selected	
parameters	were	used	for	feature	space	training,	whereby	Euclidean	distance	metrics	were	calculated	
between	high	and	low	doses	of	each	compound	for	each	organoid	line.	Highest	doses	of	each	
compound	were	used	to	select	the	most	discriminating	features	that	best	separated	treatments	from	
negative	controls.	Euclidean	distance	between	the	treated	and	non-treated	conditions	was	plotted	for	
each	treated	organoid.	Data	are	presented	as	mean	Euclidean	distance	from	8	replicate	wells	±	
standard	deviation.	Images	captured	and	analysed	by	OcellO.	
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5.2.4 Assessing	changes	in	organoid	gene	expression	as	a	result	of	TNKSi	
treatment	
5.2.4.1 TNKSi	treatment	simultaneously	attenuates	stem-cell	marker	
expression	and	increases	expression	of	differentiated	intestinal	cell	
markers	in	TNKSi-sensitive	organoid	lines	
	
As	previously	discussed,	activation	of	Wnt	signalling	specifically	induces	the	
expansion	of	stem	cell	populations	in	the	intestine,	as	well	as	an	active	role	in	the	
maintenance	of	cancer	stem	cells.	To	determine	whether	inhibition	of	Wnt	
dependent	growth	by	TNKSi	induced	an	overall	change	in	the	stem	cell	signature	of	
tumour	organoids,	quantitative	RT-PCR	analysis	was	used	to	examine	the	relative	
expression	levels	of	a	range	of	epithelial	markers	of	stem	and	differentiated	cell	
activity	relevant	to	the	large	intestine.	It	was	hypothesised	that	TNKSi	would	induce	
a	downregulation	of	stem	cell	markers	in	sensitive	organoid	lines,	impacting	
differentiation	and	subsequent	organoid	growth.	Previous	studies	have	highlighted	
the	impact	of	gene	expression	as	a	response	to	TNKS	inhibitors	in	culture	(Lau	et	al.	
2013).To	determine	whether	TNKSi	treatment	impact	the	overall	stem	cell	signature	
of	organoids,	quantitative	RT-PCR	analysis	examining	the	expression	of	published	ISC	
markers	Lgr5,	Ascl2	as	well	as	the	differentiation	markers	KRT20	and	DKK1.	
	
Organoids	previously	established	in	culture	were	dissociated	to	single	cells	by	
administration	of	TrypLE,	washed,	then	embedded	at	a	density	of	400	cells/	µl	within	
growth	factor-reduced	matrigel.	Iso	72	and	Iso	50	were	overlaid	with	7+	media	
conditions,	whilst	that	Iso	75	required	exogenously	supplied	Wnt,	R-spondin	and	
other	growth	factors	within	‘Full’	media,	as	indicated	by	previous	experiments.		
Treatment	was	administered	within	media	upon	seeding	(0.1%	DMSO	control,	15nM	
MSC22524070A).	Following	6	days	of	treatment,	organoids	were	dissociated	to	
extract	RNA	to	be	utilised	for	subsequent	gene	expression	analysis.	Overall,	as	
shown	in	Figure	5.7,	a	significant	reduction	was	found	in	the	expression	of	both	Lgr5	
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and	Ascl2	following	6	days	of	treatment,	with	the	most	enhanced	effects	on	Lgr5	and	
Ascl2	gene	expression	observed	in	sensitive	lines	Iso	72	and	Iso	75.	Interestingly,	
Ascl2	expression	was	also	diminished	in	a	resistant	organoid	line,	Iso	50	whereas	
Lgr5	expression	was	unaffected.	This	could	potentially	suggest	that	Iso	50	is	
inherently	reliant	on	different	stem	cell	populations	that	were	not	assessed	here,	
such	as	Olfm4,	or	that	TNKSi	treatment	induces	an	effect	to	up-regulate	different	
stem	cell	populations	to	compensate	and	facilitate	organoid	growth.		
	
To	further	corroborate	this	data,	TNKSi-treated	organoids	were	immunostained	with	
an	Lgr5	antibody.	Following	treatment	with	MSC2524070A	or	DMSO	(control	
conditions,	0.1	%)	for	6	days,	organoid	lines	were	stained	phalloidin	to	mark	F-actin	
to	highlight	overall	cellular	architecture.	Lgr5	staining	was	found	prominently	on	the	
basal	edges	of	all	organoids	in	control	conditions,	with	some	variability	in	degree	of	
Lgr5	positive	cells.	Lgr5	expression	of	TNKSi-sensitive	lines	was	abrogated	in	both	Iso	
72	and	Iso	75,	as	shown	in	Figure	5.8	with	no	staining	visible	in	organoids	per	well	
(n=3	technical	replicates)	as	depicted	by	representative	images.	Morphologically,	the	
number	of	nuclei	per	organoid	was	generally	diminished	per	structure,	within	
sensitive	organoid	lines.	Iso	72	structures	in	particular	were	composed	of	few	cells,	
as	indicated	by	Hoechst	staining	and	a	generally	poor	cellular	organisation.	
Interestingly,	F-actin	staining	intensity	was	also	somewhat	diminished.	Overall,	these	
observations	support	qRT-PCR	data;	however,	given	that	counts	could	not	be	
obtained	from	Lgr5	positive	cells	due	to	the	nature	of	the	immunostain,	the	
corroborating	conclusions	are	purely	qualitative.		
	
An	enhanced	expression	of	an	intestinal	differentiation	marker	cytokeratin	20,	
KRT20,	was	also	observed	in	two	TNKSi-sensitive	organoid	lines	(Iso	72,	Iso	75)	
following	treatment	with	MSC2524070	(8.9±1.8	and	13.3±4.58	fold	change	
compared	to	DMSO	control,	respectively).	Iso	50,	a	previously	identified	non-
responder	line	was	however	was	shown	to	have	a	non-significant	increase	in	KRT20	
expression	(1.7±0.67	fold	increase	in	KRT20	gene	expression	normalised	to	control	
conditions)	indicative	that	differentiation	was	not	substantially	enhanced.	However,	
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it	is	worth	noting	that	KRT20	is	not	the	only	possible	marker	that	could	have	been	
used	as	an	indication	of	differentiation	within	intestinal	stem	cells.	
	
Consistent	with	these	findings,	immunostaining	three	organoid	lines	for	KRT20	
expression	also	revealed	an	increased	expression	of	cytokeratin	20	upon	treatment,	
compared	to	control	conditions	(Appendix	II-1,	Figure	7.3),	in	TNKSi	sensitive	lines,	
particularly	in	the	lumen	compartments	of	each	organoid.	However,	given	that	
TNKSi-sensitive	organoids	lines	(Iso	72,	Iso	75)	were	generally	smaller	structures	as	a	
result	of	treatment,	this	could	be	a	staining	artefact	whereby	antibody	penetration	is	
vastly	improved.	As	this	method	is	not	quantifiable	it	is	not	possible	to	comment	on	
levels	of	significance	these	results	at	present.	This	is	particularly	important	to	note	
for	Iso	72	treated	with	MSC2504070A	as	the	organoids	were	more	readily	washed	
away	in	the	preparation	for	staining	as	they	were	so	small,	which	lowers	confidence	
in	numbers.		
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Figure	5.7	Organoid	gene	expression	in	response	to	tankyrase	inhibitor.	
Organoids	were	dissociated	to	near	single	cells	using	TrypLE,	and	seeded	at	a	density	of	400	cells/	µl	
of	Matrigel.	Cells	were	administered	with	appropriate	media	conditions	supplemented	with	control	
(DMSO,	0.1%)	or	treatment	conditions	(MSC2524070)	for	a	total	of	six	days	in	culture.	Following	
treatment	or	control	conditions,	gene	expression	was	evaluated	by	quantitative	RT-PCR.	Data	are	
expressed	as	fold	change	(vs.	untreated	DMSO	control,	means	±	standard	error	of	the	mean,	n=3	
independent	experiments).	Statistical	analysis	was	performed	using	paired	Student	T	Test	whereby	
*indicates	p≤0.05,	**	indicates		p≤0.01,	***	indicates	p	≤0.001.		
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Figure	5.8	Analysis	of	the	effects	of	the	Tankyrase	inhibitor	M
SC2524070A	on	Lgr5	expression.	
Freshly	trypsinised	organoids	(Iso	50,	Iso	72,	Iso	75)	w
ere	seeded	at	400	cells/µl	M
atrigel	and	overlaid	w
ith	previously	specified	grow
th	m
edia	supplem
ented	w
ith	
M
SC2524070A	(15nM
,	6	days),	and	a	m
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SO
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5.2.4.2 TNKSi	impact	on	Wnt/	ß-catenin	targets	
	
In	order	to	further	investigate	the	downstream	impacts	of	tankyrase	inhibitors,	gene	
expression	profiles	of	Wnt	target	genes,	including	AXIN	2,	TNKS	1/2,	were	obtained	
in	3	organoid	lines	(Iso	50,	Iso	72,	and	Iso	75).	Iso	72,	a	TNKSi	sensitive	line,	exhibited	
stabilisation	of	AXIN	2	as	a	result	of	treatment.	AXIN1	was	unaffected	in	all	lines	
measured,	as	shown	in	Figure	5.7.		
	
DKK1,	a	direct	Wnt/ß-catenin	signalling	antagonist		(Lau	et	al.	2013)	demonstrated	a	
marked	reduction	in	expression	of	Iso50	organoids	treated	with	MSC2424070	
normalised	to	control,	but	a	significant	increase	in	a	sensitive	organoid	line	Iso	72.	
This	difference	could	be	essential	in	their	converse	responses	to	TNKS	inhibition	as	
DKK1	may	increase	Wnt	negative	regulation,	leading	to	an	overall	reduction	in	
Wnt/ß-catenin	signalling	and	a	reduction	in	proliferation.	Increase	gene	expression	
of	DKK1,	observed	in	the	TNKSi	sensitive	line	Iso	72,	may	further	increase	Wnt	
negative	regulation,	resulting	in	an	overall	reduction	of	Wnt/	ß-catenin	signalling.	It	
is	clear	that	responses	and	feedback	outcomes	are	therefore	highly	dynamic,	further	
highlighting	the	complexity	of	Wnt	signalling.	
	
In	order	to	further	investigate	the	downstream	impacts	of	tankyrase	inhibitors,	the	
cellular	distribution	of	ß-catenin	was	also	assessed	by	immunofluorescence	in	
organoids	treated	with	MSC2524070	(15nM,	6	days)	as	depicted	in	Figure	5.9.		In	a	
population	of	DMSO	(0.1%)	–	treated	organoids,	all	three	lines	expressed	ß-catenin	
in	both	cytoplasmic	and	nuclear	compartments.	However,	MSC2524070	treatment	
induced	a	general	reduction	in	total	ß-catenin	levels	in	both	sensitive	and	non-
sensitive	lines.	Iso	72,	in	particular	demonstrated	no	levels	of	ß-catenin	stain	within	
structures.		
	
Overall,	this	data	would	suggest	that	TNKS	inhibition	elicits	a	downstream	effect	
upon	Wnt	signalling	gene	targets	in	both	sensitive	and	non-sensitive	organoid	lines,	
which	may	or	may	not	subsequently	impact	growth	and	proliferation	in	the	different	
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cellular	contexts	in	each	line.	Given	that	the	stem	cell	markers	were	somewhat	
downregulated,	and	differentiated	markers	upregulated	compared	to	control	and	
treatment	conditions,	this	would	suggest	that	the	stem	cell	signature	becomes	
reduced	in	organoids.	However,	given	that	the	stem	and	differentiated	markers	
explored	here	were	by	no	means	exhaustive,	further	work	would	need	to	be	in	place	
to	identify	whether	some	organoids	lines	were	better	adapted	to	compensate	for	
loss	of	stem	cell	activity,	potential	that	compensatory	mechanisms	could	be	induced	
in	some	lines	to	overcome	effects	of	TNKS	inhibition.
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5.2.5 TNKS	inhibition	significantly	delays	tumour	growth	in	an	organoid-derived	
xenograft	model	
 
To	assess	whether	functional	and	phenotypic	effects	of	TNKSi-sensitive	organoids	
would	translate	to	tumour	growth	inhibition	in	vivo,	a	novel	organoid-derived	
xenograft	model	was	generated	within	the	Dale	Lab.		
	
To	investigate	the	therapeutic	potential	of	TNKSi	to	target	stem	cell	capacity	of	CRC,	
organoids	pre-treated	with	TNKSi	were	transplanted	into	mice	to	assess	whether	this	
would	alter	the	capacity	of	tumours	to	form,	as	well	as	an	indication	of	proliferative	
status	of	cells.		Given	that	Iso	75	had	shown	reliance	upon	Wnt	and	R-spondin	within	
media,	as	well	as	other	growth	factors,	and	was	shown	to	be	sensitive	to	TNKSi	
within	in	vitro	assays,	experiments	were	performed	with	this	line	since	it	was	
expected	to	show	maximal	effects.	Freshly	trypsinised	Iso	75	organoids	were	
embedded	in	Matrigel	and	overlaid	with	Full	media	containing	MSC2524070A	at	a	
concentration	of	30	nM	(EC50,	10	X	concentration)	or	DMSO	(0.1%)	as	a	negative	
control.	Following	growth	for	24	hours,	which	was	estimated	to	be	long	enough	to	
induce	biochemical	changes	without	being	long	enough	to	alter	the	total	number	of	
cells	in	the	organoids,	samples	from	each	condition	were	injected	into	the	flanks	of	
of	16	γ-irradiated	Non-	Obese	Diabetic	(NOD/SCID)	mice,	using	one	injection	site	per	
mouse,	per	condition.		
	
It	was	observed	that	tumour	formation	occurred	in	100%	of	sites	injected,	showing	
promise	for	this	method	to	generate	organoid-derived	xenograft	models.	
Furthermore,	it	was	noted	that	organoids	pre-treated	with	MSC2524070A	resulted	in	
a	significant	delay	in	tumour	formation	compared	to	control	organoids,	resulting	in	
an	increase	in	overall	median	survival	of	mice	(Figure	5.10).	This	would	suggest	that	
MSC2524070A	was	sufficient	to	limit	proliferative	capacity	of	injected	organoids.	
Given	the	complexity	of	stem	cell	dynamics	within	tumours,	further	experiments,	
including	analysis	of	tumours	formed,	would	need	to	take	place	to	determine	the	
mechanisms	in	place.	It	is	possible	that	whilst	tankyrase	inhibition	depleted	Lgr5+	
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stem	cells,	that	Lgr5-	cells	could	have	maintained	proliferation	formed	enabling	
tumours	to	eventually	form.	This	is	in	line	with	previous	studies	that	have	
demonstrated	pharmacological	inhibition	of	Lgr5+	cells	result	in	tumour	regrowth	
after	cessation	of	treatment	(Junttila	et	al.	2015).	Furthermore,	a	recent	study	has	
demonstrated	that	in	the	absence	of	Lgr5+	CSCs,	Lgr5-	cells	are	capable	of	
maintaining	proliferation,	to	a	lesser	degree	of	function	(Shimokawa	et	al.	2017).	In	
this	context,	it	would	appear	that	pre-treatment	of	organoids	with	TNKSi	limited	
initial	CSCs	population	within	the	tumour,	that	was	able	to	recover	following	lack	of	
treatment.		
	
Despite	this,	the	data	give	initial	promise	for	potential	therapies,	which	could	
possibly	be	used	in	combination	with	agents	to	treat	bulk	tumour	cells	following	
ablation	of	a	pool	of	certain	cancer	stem	cells.	Furthermore,	our	observations	
confirm	that	in	vitro	work	described	here	is	translatable	to	in	vivo	studies,	
highlighting	the	possibilities	of	further	work	for	the	organoid	model	system.		
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Figure	5.10	Kaplan-Meier	survival	analysis	of	NOD/SCID/	γ-irradiated	mice	injected	with	control	or	
TNKSi	treated	organoids.	
Mice	were	randomised	to	be	injected	with	organoid	treated	for	24	hours.	Organoids	were	exposed	to	
either	DMSO	(0.1%)	or	4070	(15nM).	TNKSi	treatment	was	found	to	delay	the	formation	of	tumours	
compared	to	control	conditions	(p	value=0.032*,	n=16	mice	per	cohort,	Log-rank	Mantel-cox	test).		
Experimental	procedures	and	Kaplan-Meier	survival	analysis	carried	out	by	Dr.	Kenneth	Ewan	(Dale	
lab)		
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5.3 Summary	
	
The	work	described	in	this	chapter	has	shown	a	potential	utility	of	colorectal	
organoids	within	drug	discovery.	Here,	a	cohort	of	primary	CRC	organoids	were	used	
to	investigate	novel	inhibitors	of	the	Wnt	signalling	pathway.	
	
Through	the	use	of	phenotypic	screening	in	collaboration	with	OcellO,	it	was	shown	
that	clear	organoid	responses	could	be	obtained	from	readouts	of	overall	organoid	
morphology	in	response	to	compounds.	Given	the	complexity	of	Wnt	signalling	
inhibitors	and	their	potential	subtle	effects	upon	cells,	demonstrating	clear	efficacy	
over	3	log	EC50	values	has	emphasised	organoids	as	a	valuable	asset	for	future	drug	
discovery	programmes.		The	results	also	indicated	that	TNKSi	successfully	limited	the	
number	of	Lgr5+	cells	within	organoids,	as	well	as	limiting	ß-catenin	levels,	
suggesting	an	overall	inhibitory	effect	upon	Wnt	signalling.	Functionally,	this	was	
shown	to	have	differential	effects	dependent	on	the	organoid	line,	further	
highlighting	the	complexity	of	Wnt	responses	and	the	need	for	a	range	of	phenotypic	
readouts.	
	
Encouragingly,	this	work	also	demonstrated	a	concordance	between	effects	of	Wnt	
signalling	inhibitors	observed	in	vitro	and	in	a	comparative	in	vivo	model.	Whilst	this	
was	performed	on	a	select	cohort	with	limited	follow-up	analysis	on	in	vivo	effects,		
this	was	a	particularly	encouraging	result	to	form	the	basis	of	future	studies	to	assess	
whether	organoids	be	used	as	an	initial	readout	for	compounds	in	drug	discovery,	
thus	limiting	the	overall	number	of	mouse	models	required.		
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6 Discussion	
	
The	prospective	modelling	of	CRC	mutations	in	a	patient-derived	organoid	system	to	
generate	functional	predictive	readouts	for	stratified	medicine	and	the	drug	
discovery	pipeline	is	a	promising	avenue	for	cancer	precision	medicine.	Despite	the	
increasing	evidence	in	the	literature	to	support	the	notion	that	organoids	provide	a	
more	sufficient	model	system	than	preceding	2D	in	vitro	cell	lines,	their	overall	
validation	in	terms	of	providing	a	robust	screening	tool	in	the	context	of	biomarker-
driven	therapeutics	in	the	clinic	requires	further	proof-of-concept	studies.	In	order	to	
ultimately	measure	concordance	between	organoids	and	respective	patient	
counterparts,	a	number	of	challenges	associated	with	complex	3D	culture	need	to	be	
addressed,	enabling	the	employment	of	organoids	as	a	pre-clinical	model	system.	
	
The	overarching	aim	of	this	thesis	was	thus	to	validate	the	utility	of	organoids	
derived	from	CRC	patient	material	as	a	relevant	pre-clinical	platform,	in	order	to	
ascertain	their	application	within	stratified	medicine	and	drug	discovery.	To	address	
this,	this	thesis	aimed	to:	
	
1. Develop	suitable	methodologies	to	transfer	patient-derived	organoids	
towards	functional	readouts.	
2. Establish	the	capacity	of	organoids	to	provide	functional	readouts	for	
biomarker-driven	therapies	by	mirroring	the	FOCUS	4	clinical	trial,	towards	
assessing	their	predictive	power.	
3. Validate	the	potential	utility	of	organoids	in	the	drug	discovery	pipeline	using	
novel	Wnt-signalling	inhibitors.	
	
As	a	result,	many	interesting	findings	were	raised	and	will	be	discussed	in	turn	in	this	
chapter,	to	explore	the	extent	to	which	the	aims	have	been	addressed,	and	the	
overall	contribution	of	this	thesis.		
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6.1 Niche	requirements	facilitate	organoid	culture	from	patient	derived	samples	
	
The	isolation	of	human	crypts	and	consecutive	culture	conditions	to	propagate	
organoid	development,	previously	published	by	Sato	et	al	(2011)	and	further	
adapted	for	our	primary	human	samples,	were	shown	to	support	robust	long-term	
culture	of	patient	derived	organoids	that	can	be	adapted	towards	more	high-
throughput	screenings.		
	
Here,	it	was	shown	that	parallel	processing	of	samples	within	two	media	conditions	
was	sufficient	to	generate	tumour	organoids	in	the	first	instance	from	approximately	
80%	of	all	samples	processed.	The	generation	of	an	organoid	biobank	from	CRC	
material	has	previously	been	established	(Wetering,	Francies,	Garnett,	Wetering,	et	
al.	2015)	to	generate	22	primary	organoid	lines,	however	failed	to	encompass	rectal	
cancers.	Within	our	collection	stream	at	the	Dale	lab,	a	total	of	78	samples	have	
been	isolated	thus	far,	with	8	of	these	extensively	characterised	for	the	purpose	of	
this	study,	inclusive	of	rectal	cancer.	From	our	processed	samples,	a	clear	divide	was	
found	in	terms	of	reliance	of	some	of	our	subset	on	‘Full’	growth-factor	and	Wnt/R-
spondin-	containing	media,	as	opposed	to	Basal	‘7+’	media	conditions.	Both	Iso	75	
and	Iso	78	were	dependent	on	Full	media	to	sustain	growth;	Iso	75	harboured	no	
truncating	APC	mutations,	therefore	it	is	possible	that	the	exogenous	Wnt	and	R-
spondin	were	essential	to	maintain	cells	in	culture.	CRISPR-mediated	engineering	of	
intestinal	organoids	have	previously	shown	that	APC	wild	type	cells	require	the	
presence	of	Wnt	and	R-spondin	within	the	media	to	continue	in	culture	(Matano	et	
al.	2015).	However,	without	fully	characterising	the	effects	of	titrating	various	
components	within	the	media,	these	observations	are	purely	speculative.	It	is	
possible	that	the	tumour	grades	may	have	a	role	in	determining	reliance	upon	
multiple	growth	factors;	previous	studies	have	demonstrated	the	importance	of	the	
organoid	niche	as	maintained	by	Wnt,	Notch	and	Bone-morphogenetic	protein	
(BMP),	to	determine	differentiation	of	epithelial	cell	lineages	(Sato	et	al.	2009;	Yin	et	
al.	2013).		It	is	plausible	that	advanced	tumours	are	so	far	adapted	to	this	
environment	they	have	a	requirement	for	multiple	growth	factors	(Sachs	et	al	2013),	
or	even	hypoxic	conditions	(Fujii	et	al.	2016b).	
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The	importance	of	the	niche	environment	for	optimal	tumour	organoid	growth	as	
noted	here	has	been	further	explored	by	Fujii	et	al.,	(2016),	where	they	describe	the	
formation	of	a	tumour	organoid	biobank,	established	from	eight	various	growth	
conditions	containing	different	combinations	of	EGF,	Noggin	Wnt	and	R-spondin	
within	the	base	medium.	Within	this	study,	the	authors	established	niche	factor	
dependencies	by	withdrawing	each	factor	from	the	media	and	investigating	the	
impact	upon	colony	formation,	until	the	minimal	essential	niche	factor	combinations	
for	growth	were	deduced.	However,	a	limiting	factor	of	adopting	this	approach	to	
establish	conditions	to	favour	organoid	growth	for	a	range	of	clinical	subtypes	is	the	
quality	of	the	surgically	resected	tissue	in	the	first	instance;	if	samples	were	necrotic,	
few	viable	cells	were	capable	of	survival.	This	would	limit	the	number	of	growth	
conditions	that	could	be	tested	in	the	crucial	first	hours-days	of	culture.		
	
A	key	consideration	for	evaluating	the	potential	of	organoids	as	an	effective	pre-
clinical	model	is	reliant	upon	their	capacity	to	represent	molecular	and	biological	
components	of	parental	tumours.	Collaborative	efforts	with	the	WCB	have	enabled	
us	to	mostly	integrate	our	data	with	patient	data	to	generate	a	full	cohort	of	degree	
stages	corresponding	to	development	of	organoids.	Organoids	grown	under	optimal	
conditions	were	shown	to	recapitulate	histologically	relevant	architectures	to	
corresponding	parent	tumours	(Figure	3.7),	as	well	as	functional	differentiation,	
matching	those	from	mirrored	patient	histology	(Figure	3.8).	Further	exploration	of	
specific	markers	to	characterise	tumours	suggested	that	not	only	were	organoids	
representative	of	particular	tumours	subtypes	but,	to	a	degree,	were	able	to	
recapitulate	expression	of	differentiated	cell	markers	such	as	Mucin,	as	marked	by	
Muc2,	indicating	that	tumour	characteristics	were	retained	in	culture.			
	
A	subset	of	organoids	that	were	characterised	by	next	generation	sequencing	were	
further	shown	to	harbour	a	diverse	pattern	of	genetic	mutations,	consistent	with	
those	reported	within	the	Cancer	Genome	Atlas	study	(Cancer	Genome	Atlas	
Network	2012)	whereby	a	collection	of	clinical	CRC	samples	demonstrated	the	most	
commonly	mutated	genes	in	CRC.		Similarly,	the	most	frequent	mutations	within	our	
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organoid	cohort	were	genes	such	as	APC,	PIK3CA	and	TP53.	As	well	as	showing	
clinical	relevance,	our	cohort	were	shown	to	have	successfully	established	in	culture,	
irrespective	of	mutational	background.	The	organoid	cohort	here	further	
demonstrates	a	similar	distribution	of	specific	genotypes	as	described	in	a	recent	
generation	of	a	CRC	tumour	organoid	biobank	(Wetering,	Francies,	Garnett,	
Wetering,	et	al.	2015).	The	comparative	genomic	profiles	between	CRC	organoids	
and	parental	tumours	are	yet	to	be	determined	due	to	limited	access	to	patient	
genotype	data	during	the	timeline	of	this	study.	Previous	studies	have	demonstrated	
that	overall,	organoids	capture	the	overall	genetic	landscape	of	their	parental	
tumour,	which	translates	through	to	organoid-xenograft	models,	and	further	
maintaining	stability	over	subsequent	passage	(Schütte	et	al.	2017)	with	some	
discrepancies	arising	as	a	result	of	intratumour	heterogeneity.		It	is	plausible	that	
different	tumour	regions	may	have	variable	responses	to	targeted	therapies.	Tumour	
heterogeneity	can	occur	on	a	regional	basis	within	a	tumour	(Weeber	et	al.	2015)	
and	thus	organoid	culture	from	multiple	tumour	sites	could	potentially	give	a	more	
rounded	overview	of	heterogeneity	and	therefore	overall	drug	responses.	However,	
broadly	speaking,	biomarkers	such	those	relevant	to	the	FOCUS	4	clinical	trial,	were	
shown	to	be	retained	across	tumour	sites	(Weeber	et	al.	2015),	which	was	sufficient	
for	our	particular	studies.	
	
6.2 Functional	testing	in	a	relevant	model	system	is	necessary	to	support	genetic	
data;	biomarkers	do	not	always	predict	drug	responses.		
	
Despite	the	understanding	of	critical	components	that	form	the	basis	of	tumour	
progression	and	malignancy,	the	ability	to	effectively	treat	tumours	based	on	their	
biomarker	profile	has	proved	challenging.	Stratification	of	patients	based	on	the	
genomic	imprint	of	their	tumour	ideally	requires	functional	readouts	to	assess	
therapeutic	effects	of	compounds.		Chapter	4	described	the	application	of	organoids	
as	a	predictive	model	for	biomarker-driven	therapies,	by	mimicking	compounds	
utilised	within	the	FOCUS	4	clinical	trial.	The	findings	gathered	from	this	thesis	
therefore	hold	some	clinical	implications,	in	particular	to	the	molecularly	stratified	
phase	II	MRC	FOCUS	4	clinical	trial	for	metastatic	CRC	patients.		The	design	of	an	in	
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vitro	clinical	trial	discussed	here	was	sought	to	establish	the	potential	efficacy	of	
biomarker	driven	therapeutics	in	a	relevant	pre-clinical	system,	which	could	
ultimately	be	compared	with	patient	responses	harbouring	similar	mutations.	Unlike	
the	FOCUS	4	clinical	trial,	it	was	possible	to	test	all	treatments	upon	organoids	to	
establish	optimal	treatments.	Interestingly,	it	was	noted	that	the	overall	genotypic	
profile	of	organoids	did	not	necessarily	equate	to	growth	inhibition	by	the	treatment	
assigned	to	each	arm,	further	highlighting	the	requirement	of	functionally	relevant	
models.	The	most	relevant	findings	will	be	discussed	in	turn	here.	
	
6.2.1 Aspirin	metabolite	induces	growth	inhibition	within	a	subgroup	of	
organoids,	irrespective	of	PIK3CA	mutation	status.		
	
An	apparent	observation	within	this	work	was	the	varied	level	of	responses	of	
organoids	to	aspirin	metabolite	treatment	in	order	to	mirror	treatments	that	will	be	
administered	to	patients	within	PIK3CA	mutant	arm	of	FOCUS	4.	Within	responsive	
organoids	it	was	found	that	aspirin	induced	partial	growth	inhibition,	and	ultimately	
increased	the	number	of	apoptotic	cells	per	organoid,	in	agreement	with	studies	in	
aspirin-sensitive	CRC	cell	lines	(Goel	et	al.	2003).	In	a	retrospective	study	by	(Liao	et	
al.	2012),	it	was	shown	that	regular	aspirin	use	following	a	diagnosis	of	colon	cancer	
has	been	associated	with	an	improved	clinical	outcome	in	patients	with	mutated	
PIK3CA	as	opposed	to	wild	type,	further	corroborated	in	studies	by	(Domingo	et	al.	
2013).	However,	no	such	correlation	was	observed	in	this	organoid	cohort	treated	
with	aspirin;	organoids	responsive	to	aspirin	metabolite	were	not	necessarily	PIK3CA	
mutant,	and	not	all	PIK3CA	mutant	organoids	were	responsive	to	aspirin.			
	
The	lack	of	response	in	PIK3CA	mutant	organoids	could	be	as	a	result	of	the	assay	
format	itself;	previous	studies	have	indicated	that	Aspirin	has	also	been	shown	to	be	
more	effective	in	rapidly	dividing	cells	only;	as	cell	doubling	rates	in	were	not	
deduced	for	all	organoid	lines	in	this	assay	format,	it	is	possible	that	the	assay	
window	to	detect	responses	could	vary	(Zumwalt	et	al.	2017).	The	discordance	in	our	
findings	is	arguably,	most	likely,	a	result	of	the	plethora	of	different	mechanisms	that	
could	be	induced	by	aspirin	treatment,	regardless	of	PIK3CA	mutation	status	in	cells,	
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and	the	few	sample	numbers	of	organoids	tested.	PIK3CA	mutations	leads	to	an	
upregulation	of	PI3K-AKT	activation,	which	have	an	array	of	interactions	upon	the	
cell	and	can	also	be	activated	by	receptor	tyrosine	kinases	or	activated	RAS	
(Engelman	2009b).	Despite	the	overall	survival	benefit	for	regular	aspirin	
administration	in	PIK3CA-mutated	CRC,	the	mechanistic	understanding	of	this	
association	is	yet	to	be	established.	The	molecular	mechanisms	of	aspirin	are	
strongly	debated	as	to	their	effect	upon	tumour	formation	and/or	growth;	aside	
from	their	effects	upon	the	immune	system,	studies	have	investigated	the	role	of	
aspirin	metabolites	upon	glycolytic	metabolism	in	tumour	cells,	disruption	of	
multiple	signalling	pathways,	and	inhibition	on	the	basis	of	DNA	MMR	proficiency.	
Studies	have	also	proposed	that	the	use	of	NSAIDs	such	as	aspirin	mediates	a	
reduction	in	Lgr5	expression	within	carcinoma	cell	lines	(DLD1	cells)	in	a	PGE2-
dependent	manner	(Al-kharusi	et	al.	2013).	Theoretically,	a	reduced	Lgr5+	cell	
population	would	thus	result	in	a	reduced	clonogenic	growth	of	CSCs,	thus	
preventing	tumour	formation.	Given	that	organoids	are	capable	of	retaining	a	stem	
cell	population,	this	mechanism	could	be	further	investigated	in	future	studies.		
Aspirin	has	multiple	targets	and	thus	PI3KCA	is	not	necessarily	the	best	as	a	
predisposed	biomarker	and	may	have	numerous	influences	that	determine	overall	
tumour	responses.	The	variable	responses	to	aspirin	from	organoid	could	indicate	a	
major	mechanism	is	on	the	immune	cells	and/or	stroma,	which	are	absent	in	
organoids.		
	
The	major	caveat	of	this	work	described	in	chapter	4	is	that	the	organoids	described	
were	not	necessarily	obtained	from	patients	recruited	to	the	FOCUS	4	clinical	trial.	
However,	the	organoids	described	were	representative	of	relevant	biomarkers	and	
thus	hold	some	basis	to	mirror	biomarker-targeted	drug	responses	administered	
within	the	trial.	Given	that	a	subset	of	8	organoids	were	used	for	this	study	also,	
further	analysis	would	be	required	to	assess	the	true	predictive	power	of	organoids.	
Taken	together,	the	data	presented	herein	would	suggest	that	PIK3CA	mutations	
were	not	the	only	apparent	biomarker	to	indicate	aspirin	response,	which	could	have	
important	clinical	implications	within	the	FOCUS	4	clinical	trial.	
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6.2.2 Compounds	targeting	DNA	damage	responses	impose	anti-
proliferative	and	pro-apoptotic	effects	within	organoids	harbouring	
TP53	mutations.	
	
The	therapeutic	potential	of	compounds	targeting	Wee1	and	ATR,	both	crucial	
components	within	the	DNA	damage	responses	was	assessed	in	our	organoid	cohort	
to	ultimately	assess	whether	similar	treatment	outputs	would	be	observed	in	
patients.	Ultimately,	this	data	may	hold	some	clinical	value	on	the	overall	efficacy	of	
reducing	tumour	growth.	It	would	be	hypothesised	that	synthetic	lethality	by	
administration	of	Wee1	and	ATR	inhibitor,	would	prevent	cell	cycle	progression,	and	
thus	inhibit	growth	in	the	organoid	model.		
	
Administration	of	MK1775	(Wee1	inhibitor)	and	AZ20	(ATR	inhibitor)	resulted	in	an	
inhibition	of	overall	organoid	growth,	as	indicated	by	measurements	of	viability	and	
basic	morphometric	measurements	following	4	days	of	exposure	with	the	
compound.	As	described	previously,	Wee1	has	a	major	role	in	mediating	the	G2/M	
checkpoint	in	the	cell	cycle,	enabling	time	to	repair	any	remaining	double	strand	
breaks	before	cell	division	(Weisberg	et	al.	2015).	Administration	of	Wee1	inhibitor	
upon	organoids	was	also	shown	to	potentiate	apoptotic	effects,	as	evident	by	
phenotypic	readouts.	This	is	in	accordance	with	previous	studies	that	have	
elucidated	the	cytotoxic	effects	of	this	compound	in	an	array	of	cell	lines,	and	further	
shown	to	be	effective	in	mouse	models	(Guertin	et	al.	2013).	Mechanistically,	studies	
have	shown	that	p53	loss	in	cells	result	in	mitotic	catastrophe	in	cell	lines	and	thus	
the	main	cause	of	synthetic	lethality	(Aarts	et	al.	2012).		However,	recent	studies	
have	identified	further	epigenetic	biomarkers	such	as	trimethylation	of	histone	
H3K36me3	(Pfister	et	al.	2015)	and	shown	that	Wee1	can	also	induce	synthetic	
lethality	in	p53	wild-type	cells.	This	further	highlights	the	need	for	functional	systems	
which	can	encompass	potentially	multiple	biomarkers	for	identification	of	
therapeutic	responses.	Studies	have	also	demonstrated	that	gastric	cell	lines	lacking	
ATM,	or	contain	TP53	defects,	are	vulnerable	to	inhibition	of	ATR	by	AZD6738	
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(analogue	of	AZ20),	inducing	replication	initiation	and	fork	stalling,	ultimately	
resulting	in	DNA	damage	and	an	overall	cytotoxic	effects	upon	cells	(Min	et	al.	2017).		
The	data	presented	here	suggests	that	targets	of	the	DNA	damage	response	may	
provide	a	suitable	target	for	CRC	therapy	in	ATM	or	Tp53	mutant	patients.	However,	
the	overall	relevance	of	the	model	system	must	be	considered.		Whilst	readouts	of	
toxicity	upon	organoids	derived	from	patients	provides	encouraging	support	for	the	
relevance	of	such	compounds,	the	lack	of	readout	on	toxicity	upon	normal	cells	
restricts	the	utility	of	organoids	to	confidently	predict	patient	responses	to	therapy.	
Whilst	the	culture	of	healthy	colorectal	material	was	attempted	during	this	study,	
growth	was	restricted	to	a	month	in	culture,	preventing	the	possibility	of	generating	
sufficient	material	as	a	control	for	subsequent	drug	readouts.	A	biobank	of	CRC	
organoids	have	recently	presented	the	comparison	of	CRC-relevant	compounds	
upon	both	normal	and	tumour	tissue	to	achieve	a	basic	readout	of	toxicity	
(Wetering,	Francies,	Garnett,	Wetering,	et	al.	2015).	Such	systems	could	be	
employed	for	future	studies	whereby	organoids	are	generated	and	treated	in	parallel	
with	such	clinical	trials.	An	important	consideration	for	this	work	is	also	the	lack	of	
suitable	organoid	based	controls	that	were	available	for	this	study;	given	that	all	
organoids	generated	were	both	ATM	and	tP53	mutant	a	clear	distinction	of	the	
effects	between	ATM	wild	type	and	tp53	wild	type	were	not	able	to	take	place.	This	
would	be	hugely	important	to	collect	population-based	data	that	is	required	for	
stratification	studies.		
	
6.2.3 Combination	therapy	targeting	RAF-ERK	signalling	potentiates	
organoid	growth	inhibition	
	
Despite	the	initial	promise	of	BRAF	and	EGFR	targeting	therapies,	clinical	studies	
have	demonstrated	an	overall	limited	success	for	treatment	of	CRC	due	to	a	lack	of	
therapeutic	effect.	Both	in	vitro	and	in	vivo	studies	support	the	notion	that	this	lack	
of	effect	is	mediated	by	the	up-regulation	of	mechanisms	to	compensate	for	
pathway	inhibition	(Corcoran	et	al.	2015;	Corcoran	2015),	as	well	as	pre-existing	
mutations	that	predict	non-response.	Whole-exome	sequencing	of	paired	
pretreatment	and	post-progression	biopsies	from	BRAF	mutant	CRC	samples	from	
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patients	have	identified	significant	alteration	in	MAPK	pathway	such	as	BRAF	and	
MEK	amplifications.	(Ahronian	et	al.	2015).	As	such,	drug	development	strategies	
and	pre-clinical	investigations	have	justifiably	focused	efforts	to	target	components	
of	BRAF-mediated	signalling.	Within	the	MRC	FOCUS	4	clinical	trial	it	is	hypothesised	
that	targeting	three	components	of	BRAF-mediated	signaling	will	improve	tumour	
free	progression	within	CRC	patients	(Figure	6.1).	Here,	to	address	whether	such	
hypotheses	could	be	tested	in	a	relevant	preclinical	model,	organoids	propagated	
from	BRAF	mutant	patients	were	assessed	for	their	sensitivity	to	BRAF,	EGFR	and	
MEK	inhibition,	mirroring	treatments	administered	to	patients	within	the	FOCUS	4	
trial.	
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Figure	6.1	Inhibition	of	RAS-ERK	signaling	;	targeting	adaptive	feedback	mechanisms	
EGFR	activates	RAS-ERK	signalling	pathway	to	induce	gene	expression	of	components	involved	in	cell	proliferation	and	growth.	Combination	therapies,	targeting	multiple	
components	within	the	pathway	is	theorized	to	overcome	adaptive	feedback	reactivation	induced	by	single	agent	therapies.	
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The	therapeutic	effects	of	each	compound	in	turn	were	assessed	to	determine	
whether	as	hypothesised,	BRAF	mutations	would	incur	sensitivity.	Trametinib	(MEK	
inhibitor)	administration	upon	organoids	resulted	in	a	pro-apoptotic	effect	within	
cells,	as	opposed	to	Dabrafenib	(BRAF	inhibitor)	and	Panitumumab	(EGFR	inhibitor),	
compounds	that	showed	little	effect	as	single	agents.	Trametinib	was	further	shown	
to	potentiate	the	growth	inhibition	potential	of	both	Dabrafenib	and	Panitumumab	
within	combination	drug	screens.	Previously,	assessment	of	Trametinib	and	
Dabrafenib	in	combination	has	shown	favourable	effects	in	BRAF	mutant	PDX	
models,	as	well	as	within	CRC	patients	setting,	improving	overall	prognosis	(Corcoran	
et	al.	2015).	Some	data	has	also	shown	the	improvement	of	dual	BRAF	and	MEK	
inhibition	to	treat	metastatic	colorectal	adenocarcinomas	(Williams	et	al.	2015).		
Importantly,	sub-optimal	inhibition	of	MAPK	pathway	has	been	shown	to	play	a	role	
in	limited	efficacy	in	patients,	further	highlighting	the	need	for	relevant	model	
systems	to	test	target	affinity.		Our	studies	also	demonstrated	a	dose	reduction	
index	could	be	applied	to	both	compounds,	further	corroborating	findings	that	co-
administration	of	BRAF	and	MEK	inhibitor	Dabrafenib	and	Trametinib	improve	
overall	safety	profiles	of	compounds	(King	et	al.	2013).	In	a	recent	study	
administration	of	Trametinib	and	an	ERK	inhibitor	within	organoids	were	able	to	
induce	cell	cycle	arrest,	further	affirming	the	application	of	Trametinib	as	an	
effective	compound	(Verissimo	and	et	al.	2016).	However,	as	well	as	demonstrating	
the	effects	of	given	compounds,	the	dose	reduction	effects	were	not	established	in	
this	study,	and	are	of	equal	importance	to	consider	to	ensure	full	tumour	regression.		
	
A	BRAF-mutant	organoid	was	further	exposed	to	3	compounds	in	combination	and	
were	found	to	impact	growth,	and	limit	the	dosage	of	drug	required	of	each	
compound	to	induce	an	IC50	effect.	These	findings	suggest	that	targeting	multiple	
components	of	EGFR-RAS-RAF	signalling	may	succeed	in	preventing	compensatory	
mechanisms	to	induce	proliferation.	Given	the	increasing	number	of	combination	
strategies	that	require	multiple	targets	for	tumour	growth	inhibition,	the	capacity	of	
organoids	to	be	used	within	such	a	pre-clinical	setting	could	be	invaluable	to	
generate	data	on	the	most	appropriate	combinations.	A	recent	study	demonstrated	
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the	use	of	basic	readouts	of	toxicity	upon	normal	organoids	to	establish	the	effects	
of	combination	therapies	upon	the	stem	cell	capacity	in	the	colon	(Verissimo	and	et	
al.	2016).	It	was	found	that	EGFR	inhibition	induced	similar	effects	in	normal	colonic	
organoids	as	to	RAS	Wild	type	organoids.	Here,	by	utilising	Chou-Talalay	methods	of	
analysis	it	was	further	possible	to	determine	a	fold	change	in	compound	treatment	
that	could	be	effective	in	organoids	at	a	much	lower	dose	comparative	to	single	
agent	administration.		
	
In	order	to	increase	confidence	in	this	analysis	and	drug	regime,	further	studies	upon	
multiple	organoid	lines	would	be	required	to	fully	establish	the	effects	of	BRAF	
inhibition.	Ideally,	findings	would	require	some	corroboration	to	determine	the	
effects	in	vivo.		A	recent	study	within	our	group	aiming	to	establish	the	in	vivo	
activity	of	MEK	and	PI3K	inhibitors	within	GEMMs	as	a	pre-clinical	evaluation	for		
FOCUS4	(a	preceding	FOCUS	4	outline)	found	that	not	only	were	favourable	
compound	combinations	essential	for	anti-tumour	effects,	but	also	the	dosage	
regime	and	order	of	treatment	(Raja	et	al.,	2015).	As	such	studies	can	be	time	
consuming,	the	promise	of	carrying	out	preliminary	dose	scheduling	combination	in	
organoids,	prior	to	translating	within	in	vivo	systems	could	be	invaluable	for	
acquisition	of	preclinical	data.	Organoid-derived	xenografts	based	on	the	lines	used	
here	may	be	useful	in	this	respect.	
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Taken	together,	this	work	would	suggest	that	biomarkers	do	not	necessarily	
predispose	effective	responses	in	an	organoid-based	system,	supporting	
observations	in	the	literature	that	biomarker-led	analyses	alone	are	not	sufficient	to	
predict	patient	responses	to	therapies	(Voest	and	Bernards	2016).	Despite	the	
promise	of	genetic	biomarkers	alone	to	guide	precision	medicine,	it	is	becoming	
increasingly	apparent	that	multiple	factors	influence	and	somewhat	obscure	
genotype-phenotype	drug	response	outcomes.	A	number	of	reasons	would	account	
for	this,	some,	some	of	which	are	noted	herein.	
	
Firstly,	preclinical	biomarker-driven	therapeutic	studies	have	classically	relied	upon	
in	vitro	studies	within	a	uniform	cellular	context.	The	representation	of	tumour	
heterogeneity	to	explore	genotype-phenotype	interactions	has	therefore	been	
limited	due	to	clonal	nature	of	2D	cell	lines,	resulting	in	some	failures	between	the	
translations	of	targeted	therapy	to	patients	(Weeber	et	al.	2017;	Barretina	et	al.	
2012).	Whilst	pharmacogenomics	interactions	between	genotypes	and	cellular	
phenotypes	with	the	intention	of	targeting	select	tumour	cell	subpopulations	have	
therefore	improved	clinical	outcomes	for	a	number	of	patients	(Iorio	et	al.	2016),	it	is	
widely	accepted	that	such	studies	do	not	necessarily	capture	the	biology	of	the	
whole	tumour	(Pauli	et	al.	2017)	.Furthermore,	biomarkers	alone	do	not	sufficiently	
account	for	gene	expression	profiles	in	CRC;		recent	transcriptomic	analyses	of	CRC	
have	further	emphasized	the	complexity	of	predicting	drug	responses	based	solely	
on	genetic	biomarkers	(Guinney	et	al.	2015;	Sadanandam	et	al.	2013)	and	the	need	
for	further	subclassification	of	CRC	types.	A	lack	of	biomarker-dependent	responses	
in	the	clinic	could	also	by	accounted	for	by	the	use	of	pharmacological	agents	with	
uncharacterized	mechanisms	of	action	that	do	not	necessarily	correspond	to	a	single	
pathway	biomarker	thus	making	it	more	complex	to	elucidate	outcomes.		
	
Most	notably,	the	lack	of	translation	between	targeted	genotypes	and	phenotypic	
outcomes	are	likely	to	be	obscured	by	the	cross-talk	between	a	complex	network	of	
signalling	pathways,	which	can	ultimately	overcome	therapeutic	efficacy	(Voest	and	
Bernards	2016).	Pathway	activation	or	inactivation	within	the	tumour	is	therefore	
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entirely	context	dependent,	relying	on	multiple	feedback	loops,	therefore	cannot	
necessarily	be	defined	on	the	basis	of	static	genomic	and	transcriptomic	profiling.		
	
Organoids,	having	shown	the	capacity	to	reflect	overall	tumour	phenotypic	
heterogeneity,	could	provide	further	information	as	a	context	dependent	model	to	
assess	therapeutic	efficacies	of	targeted	therapies,	as	well	as	explore	further	
mechanisms	of	action	to	elicit	responses	to	readily	available	compounds.	
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6.3 Sophisticated	phenotypic	assays	measure	drug-induced	effects	of	complex	
3D	models		
	
In	order	to	establish	organoids	as	a	model	suitable	to	the	drug	discovery	pipeline,	
assay	validation	is	of	fundamental	importance;	robustness,	sensitivity	and	
reproducibility	are	critical	to	determine	the	suitable	application	of	organoids.		
Furthermore,	the	successful	incorporation	of	3D	ex	vivo	organoids	into	drug	
discovery	requires	the	confirmation	that	increased	physiological	relevance	and	
complexity	is	not	compromised	by	a	lack	of	ability	to	extract	accurate	measurements	
of	drug	sensitivity.	Part	of	this	thesis	has	aimed	to	overcome	such	challenges	by	
addressing	the	need	to	expand	organoids	from	relatively	low	yield	of	starting	
material	and	adaption	to	suitable	assay	formats,	as	well	as	investigating	whether	
sophisticated	phenotypic	readouts	are	sufficient	to	encompass	complexity	of	3D	
structures.		
	
Experiments	conducted	demonstrated	the	application	of	organoids	towards	higher-
throughput	assay	formats,	in	96-	or	384-well	plates,	having	expanded	successfully	
from	relatively	small	amounts	of	viable	patient	material,	as	described	in	Chapter	3.	
Organoids	were	able	to	proliferate	functionally	following	digestion	to	single	cells,	
consistent	with	previous	findings	showing	that	single	cells	derived	from	CRC	
material,	when	suspended	into	a	matrix	and	appropriate	growth	conditions,	self-
organise	into	individual	organoid	structures	(Sato	et	al.	2009;	Boehnke	et	al.	2016).	It	
was	shown	that	regulation	of	organoid	size	using	enzymatic	digestion	was	critical	to	
obtain	relatively	consistent	numbers	of	structures	within	replicate	wells	and	across	
replicate	plates	for	drug	screening	studies.	The	adaptation	of	organoids	to	such	
formats	was	shown	to	improve	overall	assay	noise.	Supporting	data	in	the	literature	
has	further	emphasised	the	importance	of	organoid	uniformity	in	terms	of	sizes	per	
structure	to	obtain	statistically	data	(Boehnke	et	al.	2016),	a	crucial	requirement	of	
the	drug	discovery	pipeline	in	order	to	obtain	robust	and	reproducible	data	.	
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Further	to	the	above	observations,	this	work	also	highlighted	the	importance	of	
suitable	assay	readouts	to	generate	quantifiable	data	from	3D	structures	for	drug	
screening	purposes.	Overall,	optimisation	of	ATP	readouts	within	96	well	assay	
formats	were	sufficient	to	determine	IC50	values	of	compounds	that	induced	clear	
cytotoxic	effects	within	organoids,	such	as	those	shown	in	Figure	3.13.	However,	in	
instances	whereby	effects	of	compounds	were	limited	on	the	overall	organoid	
population,	sensitivity	of	detection	of	responses	was	also	limited	.	In	the	studies	of	
Wnt	inhibition	using	TNKSi,	whilst	a	reduction	in	overall	ATP	in	a	dose	response	
titration	of	doses	was	considered	as	a	positive	outcome	on	reduction	of	overall	
growth,	such	assay	formats	suffered	from	small	assay	windows	that	prevented	the	
production	of	definite	cellular	EC50	values	that	are	required	to	drive	compound	
development	pipelines	during	drug	development.	By	providing	readouts	that	are	
relevant	to	the	effect	of	compounds	on	prospective	populations	of	CSCs,	the	
organoid	assays,	when	combined	with	appropriate	morphometric	readouts	
constitute	a	suitable	system	for	next-generation	drug	discovery	efforts.	
	
	A	recent	proof-of-concept	study	incorporated	ATP	assay	readouts	to	assess	the	
effects	of	a	multiple	compounds	relevant	for	CRC	therapies	upon	a	biobank	of	20	
patient-derived	CRC	organoids	(Wetering,	Francies,	Garnett,	Francis,	et	al.	2015).	In	
some	instances,	a	clear	correlation	was	observed	between	mutations	in	organoids	
and	sensitivity	to	compounds.	However,	it	was	also	noted	that	IC50		values	obtained	
from	treated	organoids	were	variable	between	experiments,	potentially	as	a	result	
of	the	organoid	suitability	within	assays,	or,	most	likely,	a	relatively	limited	dose	
response	range	of	compounds	administered,	resulting	in	a	poorer	assay	sensitivity,	
potentially	resulting	in	observation	of	off-target	effects	of	compounds.	Given	the	
complexity	of	pathways	targeted	for	therapeutic	intervention,	targeted	pathways	in	
these	culture	systems,	capturing	exact	mechanism	of	compounds	is	important	if	
organoids	are	going	to	become	clinically-relevant	models.	
	
As	described	in	both	Chapters	4	and	5,	it	was	found	that	phenotypic	assays	were	
able	to	successfully	quantify	organoid	responses	to	compounds	on	the	basis	of	
multiple	morphometric	parameters.	Importantly,	such	sophisticated	assay	formats	
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had	the	capacity	to	detect	effects	of	compounds	otherwise	missed	by	basic	
metabolic	readouts,	classifying	organoid	responses	to	both	clinically	relevant,	and	
novel	cancer-stem-cell	targeting	compounds.	The	data	acquired	using	novel	software	
by	OcellO	(Leiden,	Netherlands)	selected	over	500	features	for	organoid	
characterisation	in	responses	to	treatment,	including	intensity	information	gathered	
from	nuclear	and	F-actin	staining,	as	well	as	morphological	measurements	of	whole	
organoid	structures	and	nuclei.	Whilst	the	number	of	features	investigated	may	
seem	redundant	for	each	system,	it	enabled	the	analysis	of	multiple	features	that	
contributed	most	to	separation	between	negative	control	and	treatment	data	to	
assess	multiple	biological	effects	of	organoids.	Testing	a	novel	TNKSi	within	
organoids	over	a	three-log	fold	changes	in	IC50,	increased	confidence	that	this	is	a	
result	of	on	target	effects.		Such	analysis	methods	has	previously	been	used	in	the	
literature	to	facilitate	an	unbiased	method	to	relate	the	effects	of	particular	groups	
of	compounds	upon	biological	function	of	immortal	cell	lines	cultured	in	3D	(Di,	Klop,	
Rogkoti,	Devedec,	van	de,	et	al.	2014;	Sandercock	et	al.	2015).		
	
	Given	the	biological	complexity	of	3D	organoids,	it	is	likely	that	a	number	of	
organoid-specific	characteristics	contribute	to	treatment-induced	changes	in	
phenotypic	responses.	An	alteration	that	could	be	detected	by	phenotypic	screening	
is	overall	organoid	structure;	one	of	the	main	advantages	of	organoid	culture	
compared	to	preceding	in	vitro	culture	systems	is	their	overall	capacity	to	retain	a	
hierarchy	of	cell	lineages	within	a	self-directed	spatial	organisation.	Both	histological	
and	basic	morphometric	analysis	of	patient	derived	organoids	demonstrated	a	
variety	of	overall	structures	dependent	upon	tumour	subtypes,	as	demonstrated	in	
Figure	3.5.	This	is	in	line	with	preceding	studies	of	organoid	heterogeneity	across	
CRC	tumour	samples	(Fujii	et	al.	2016b).	Iso	75,	in	particular	was	shown	to	retain	
glandular	structures	found	in	matching	patient	material	(Figure	3.7)	as	multiple	
lumen	structures	within	an	organoid.	
	
Analysis	of	F-actin,	a	critical	factor	for	overall	cell	viability	and	structural	support,	as	
well	as	nuclear	division	(Caie	et	al.	2010),	facilitated	a	detailed	analytical	approach	to	
organoid	response	to	treatment.	Interestingly,	TNKS	inhibition	resulted	in	an	overall	
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diminished	F-actin	staining	intensity	within	structures,	suggesting	a	compromised	
integrity	of	cell-to-cell	connections.	Furthermore,	F-actin	staining	also	facilitated	the	
detection	of	lumen	structures,	which	were	altered	by	low	concentrations	of	TNKS	
inhibitors,	with	cystic	structures	morphologies	induced	as	a	result	in	Iso	72	
organoids.	This	was	further	observed	by	a	study	published	by	Lau,	using	the	TNKSi	
GL007-LK,	they	found	induced	cystic	morphologies	at	low	concentrations	of	
compound	(Lau	et	al.	2013).		Such	a	change	induced	by	overall	cell	organisation	
would	be	lacking	in	2D	structures,	further	supporting	the	notion	that	organoid	
models	have	the	potential	to	reveal	more	complex	characteristics	of	tumours	of	
origin,	making	them	a	more	suitable	model	for	drug	discovery	purposes.			
	
A	unique	characteristic	of	organoids	is	their	ability	to	retain	different	cell	types	
within	individual	structures,	likely	to	be	composed	of	cells	at	various	stages	of	the	
cell	cycle	such	as	proliferating,	quiescent,	apoptotic	and	necrotic.	As	a	result,	
changes	in	cell	signalling	as	a	result	of	environmental	or	mutational	background	
could	alter	organoid	responses	to	treatment	that	would	translate	through	to	multi-
parametric	screening.	Organoids	described	in	this	study	were	shown	to	harbour	APC	
and	ß-catenin	mutations,	which	have	been	previously	associated	with	increased	Wnt	
signalling	activation	in	the	intestine,	resulting	in	a	loss	of	polarity	and	cellular	
organisation	(Barker	2014b;	Sansom	et	al.	2004).	Iso	75,	a	multi-lumen	structure	
could	be	resultant	of	such	a	loss	of	cellular	polarity.	The	importance	of	phenotype	as	
a	representation	of	potential	cell	signalling	has	been	somewhat	identified	in	other	
organoid	model	systems.	Organoids	generated	from	a	mouse	model	of	APC	
inactivation	demonstrated	that	a	loss	of	APC	resulted	in	a	loss	of	epithelial	cell	
organisation,	as	confirmed	further	in	vivo	(Fatehullah	et	al.	2013)	A	recent	study	by	
Riemer	et	al	(2017)	further	demonstrated	the	relationship	between	cancer	
phenotypes	and	signalling	in	organoids,	whereby	the	authors	generated	transgenic	
mice	to	create	stabilized	ß-catenin	and	PIK3CA-mutant	organoids.	ß-catenin	
upregulation	was	found	to	induce	cystic	organoids	in	culture,	enriched	for	Lgr5	and	
myc	dependent	stem-cell	activity	(Riemer	et	al.	2017).	It	was	found	that	changes	in	
cell	signalling	initiated	by	compound	activity	resulted	in	changes	in	overall	
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phenotypes,	further	highlighting	the	possibility	of	phenotypic	screening	as	a	drug	
discovery	approach	for	organoids.		
	
6.4 Organoids	provide	a	platform	to	assess	stem	and	differentiation	of	cell	
populations	
	
The	role	of	Wnt	signalling	at	tumour	initiation	and	progression	in	the	intestine	has	
been	well	documented	in	the	literature,	with	many	studies	indicating	that	a	
continued	dependency	on	ß-catenin	mediated	Wnt	signalling	is	required	for	tumour	
growth,	which	varies	from	one	tumour	to	the	next.	Studies	have	emphasised	the	
reliance	of	tumour	progression	on	a	‘just-right’	level	of	Wnt	signalling;	according	to	
this	hypothesis,	there	is	a	gradient	of	Wnt	signalling	which	is	sufficient	for	tumour	
formation,	whereby	impairment	of	APC	function	is	within	a	finite	window	to	enable	
sufficient	accumulation	of	nuclear	ß-catenin.	Conversely,	over	accumulation	of	
nuclear	ß-catenin	also	results	in	cell	death	leading	to	inhibition	of	tumour	
development	(Albuquerque	et	al.	2002)	,	further	highlighting	the	need	for	precise	
levels	of	Wnt	signalling	in	the	intestine.	Reliable	in	vitro	models,	capable	of	
encompassing	the	complexity	of	the	Wnt	signalling	pathway,	relatable	to	tumours,	
have	proved	challenging	so	far,	most	likely	due	to	a	lack	of	all	tumour	cell	types	
within	2D	cell	lines	which	fail	to	encompass	all	relevant	cell	types	and	signalling	
networks.  
	
The	investigation	of	Wnt	signalling	inhibition	was	therefore	of	interest	here	in	a	
relevant	model;	predominantly,	the	effect	of	Wnt	inhibition	upon	stem-cell	
containing	organoid	phenotypes,	as	described	in	the	previous	section,	as	well	as	
further	assessment	of	effects	upon	CSC	compartments.	It	would	be	hypothesised	
that	Wnt	inhibition	would	prevent	the	CSC	activity	and	thus	reduce	the	likelihood	of	
tumour	growth,	or	in	this	case	organoid	growth.	Assay	formats	were	designed	to	
simulate	similar	conditions,	by	assessing	the	effects	of	TNKSi	inhibition	upon	overall	
organoid	formation	and	downstream	signalling,	in	an	attempt	to	manipulate	the	CSC	
population.		
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Phenotypic	screening	of	three	novel	TNKS	inhibitors	against	a	panel	of	8	organoids	
highlighted	TNKSi-sensitive	organoids,	representing	known,	on	-target	EC50	values.	
Iso	75	and	Iso	78	(APC	and	CTNNB1	mutant)	were	two	lines	of	the	cohort	that	relied	
on	a	growth-factor	rich	media,	including	exogenous	Wnt	and	R-spondin	and	both	
showed	responses	to	TNKS	inhibition.	However,	Iso	72	(APC	mutant),	having	showed	
sufficient	growth	in	7+	media	was	also	responsive,	suggesting	that	this	is	not	only	a	
readout	for	the	growth	factor	conditions	in	which	organoids	are	maintained.	
Previous	work	in	the	literature	has	shown	that	the	inhibition	of	Wnt/ß-catenin	
signalling	by	TNKSi	is	complete	within	cell	lines	harbouring	wild-type	APC,	simulated	
with	exogenous	Wnt.	Similarly,	complete	inhibition	of	ß-catenin-driven	Wnt	
signalling	has	previously	been	implicated	in	cell	lines	containing	wild-type	APC	and	
are	stimulated	with	exogenous	Wnt	(Huang	et	al.	2009;	Waaler,	Machon,	Tumova,	
Dinh,	Korinek,	Wilson,	Paulsen,	Pedersen,	Tor	J	Eide,	et	al.	2012).		
	
	Further	gene	expression	analysis	of	two	responders,	Iso	72	and	Iso	75,	showed	a	
downregulation	in	stem	cell	markers	Ascl2	and	Lgr5	following	TNKSi	treatment,	
coupled	with	an	upregulation	in	the	differentiation	markers	Krt20	and	Dkk1	and	
corresponding	diminished	ß-catenin	levels.	Both	Ascl2	and	Lgr5	have	been	previously	
implicated	as	identifiers	of	ISCs	with	functional	roles	in	the	intestine.	Several	studies	
have	reported	that	LGR5	functions	as	a	receptor	of	R-spondins	within	SCs,	and	thus	is	
an	activator	of	Wnt	signalling	(de	Lau	et	al.	2011b).	Ascl2	has	also	been	implicated	as	
a	marker	of	stem	cells,	is	a	Wnt	target	gene,	and	has	been	reported	to	govern	the	
identity	of	Lgr5+	stem	cells	in	the	normal	intestine	(van	der	Flier	et	al.	2009)	and	can	
be	upregulated	as	a	result	of	a	feedback	loop	dependent	on	Wnt	signalling	(Schuijers	
et	al.	2015).	Taken	together,	this	would	indicate	that	TNKS	inhibition	mediates	
diminished	Wnt	signalling	within	organoids,	and	as	a	result	reduces	the	overall	stem	
cell	population,	inducing	differentiation	and	mediating	phenotypic	changes	in	
organoids.	
	
Interestingly,	Iso	50,	having	shown	little	change	in	overall	proliferation	in	response	to	
TNKSi	treatment,	was	shown	to	retain	a	baseline	level	of	Lgr5+	expression,	and	a	
decreased	expression	of	another	stem	cell	marker	Ascl2.	Furthermore,	
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immunohistochemical	staining	demonstrated	a	complete	loss	of	ß-catenin	markers,	
indicating	diminished	Wnt	signalling	activity.	On	one	hand,	results	may	suggest	that	
Iso	50	organoids	harbour	a	TNKSi-resistant	population,	or	partial	inhibition	by	Wnt	
signalling,	so	that	CSCs	continue	to	divide,	producing	more	CSCs.	Given	that	an	
exhaustive	list	of	stem	cell	markers	were	not	assessed	here	it	is	possible	that	Iso50	is	
either	inherently	reliant	on	different	stem	cell	populations,	or	becomes	reliant	as	a	
result	of	TNKS	inhibition.	Furthermore,	it	is	possible	that	co-operating	mutations	
may	result	in	an	alternative	driver	of	growth,	leading	to	independence	from	Wnt	
signalling	for	overall	proliferation.		An	alternative	assay	system	would	be	required	to	
pinpoint	specific	mechanisms	highlighted	from	this	organoid	cohort	in	response	to	
TNKS	inhibition.	
	
Importantly,	this	work	demonstrated	a	concordance	between	in	vitro	and	a	
respective	organoid-derived	xenograft	model.	The	gold	standard	method	for	the	
identification	of	cancer	stem	cells	is	often	obtained	by	transplantation	of	tumour	
cells	within	immune	deficient	animal	models	and	assessing	subsequent	formation	of	
structures.	There	is	some	controversy	as	to	the	accuracy	of	this	statement,	as	
xenotransplantation	does	not	necessarily	model	an	environment	of	relevance	to	
tumour	growth	and	could	thus	be	measuring	an	overall	selective	pressure	for	cell	
survival	as	opposed	to	CSC	activity.	However,	for	the	purposes	of	this	study	it	was	
deemed	a	sufficient	assay	format	to	assess	the	capacity	of	organoids	to	form	
tumours,	and	to	secondly	assess	the	effects	of	Wnt	signalling	inhibition	upon	tumour	
formation.	It	was	hypothesised	that	the	pre-treatment	of	organoid	cells	with	TNKSi	
would	result	in	a	transcriptional	effect	following	diminished	Wnt	signalling,	thus	
affecting	the	capacity	of	stem	cell	-directed	formation	of	a	tumour.		
	
A	100%	take	rate	was	observed	from	mice	implanted	with	control	and	TNKSi	pre-
treated	Iso	75	organoids.	However,	organoids	pre-treated	with	TNKSi	were	found	to	
significantly	delay	tumour	formation	in	mice	compared	to	control	conditions.	Taken	
together	with	gene	expression	data	it	would	seem	that	a	reduced	Wnt	signalling	
signature	following	TNKSi	administration	resulted	in	a	decreased	number	of	stem	
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cells,	resulting	in	a	reduction	in	the	capacity	to	form	tumours	compared	to	control	
conditions,	as	illustrated	by	Figure	6.2.	
	
Given	that	treatment	did	not	entirely	prevent	tumour	outgrowth	in	the	mouse,	
further	detailed	assessments	would	be	required	to	identify	mechanisms	involved.	It	
is	possible	that	whilst	transcriptional	events	were	able	to	occur	within	24	hours	of	
treatment,	that	some	stem	cells	remained	active	and	were	not	completely	ablated	
by	exposure	to	TNKSi.	Alternatively,	a	lack	of	continual	TNKSi	treatment	within	the	
mouse	resulted	in	eventual	recovery	of	cells;	studies	within	organoids	had	
demonstrated	that	the	effects	of	TNKSi	were	not	completely	cytotoxic,	resulting	in	a	
lower	tumour	formation	capacity.	It	is	also	possible	that	alternative	stem	cell	pools,	
not	necessarily	marked	by	Lgr5	or	Ascl2,	were	also	able	to	compensate	for	effects	of	
Wnt	signalling	inhibition.	Studies	have	identified	that	Wnt	inhibitors	have	the	
capacity	to	convers	stem	cells	to	a	transit	amplifying	fate	in	a	mouse	model	
expressing	oncogenic	ß-catenin	(Clarke	et	al.	2016)	.An	alternative	explanation	could	
be	inferred	by	recent	studies	that	have	investigated	plasticity	of	CSCs	in	the	mouse	
intestine.	Increasing	data	in	the	literature	supports	the	notion	that	Lgr5+	cell	
populations	are	not	strict	lineages	and	are	in	fact	heterogeneous,	capable	of	
expressing	a	distinct	subset	of	Wnt	target	genes	(Shiokawa	et	al.	2017).	In	the	
instance	of	Lgr5+	cell	ablation,	Lgr5-	cells	are	able	to	compensate	these	effects	by	
replenishing	the	Lgr5+	cell	population	(Shimokawa	et	al.	2017;	Cortina	et	al.	2017).	
Further	lineage	tracing	experiments	have	also	shown	that	differentiated	cells	marked	
by	Krt20	can	reverse	into	Lgr5	cells	following	Lgr5+	cell	ablation,	thus	driving	tumour	
re-growth.	It	is	possible	herein	that	stem	cell	plasticity	enabled	the	upregulation	of	
Lgr5+	cells	from	a	differentiated	cell	population	stem	cell	pools	as	described	in	
previous	studies	following	ablation	of	some,	or	all	CSCs	(Shimokawa	et	al.	2017)	to	
eventually	re-populate	the	tumour.	Further	studies	would	be	required	to	elucidate	
this	in	context	to	work	carried	out	here.		
	
The	validation	of	an	organoid-derived	xenograft	model	that	demonstrates	
concordance	between	comparative	organoid	line	studies	is	encouraging	for	the	drug	
discovery	pipeline.	To	further	explore	this,	histological	analysis	of	mouse	tumours	
	 210	
would	be	beneficial,	as	well	as	studies	in	a	larger	organoid-xenograft	cohort.	From	a	
clinical	perspective,	further	detailed	investigation	of	a	Wnt	signalling	inhibitor	as	a	
potential	therapeutic	would	be	required.	Given	that	treatment	did	not	entirely	
ablate	tumour	organoids,	or	subsequent	tumours	developed	in	vivo	it	is	difficult	to	
estimate	the	clinical	benefit	TNKSi	would	hold,	particularly	with	increasing	evidence	
that	CSC	trans	-differentiation	can	facilitate	tumour	growth.	Furthermore,	the	assay	
formats	used	here	were	in	relation	to	looking	at	the	cancer	stem	cell	signature	as	
opposed	to	a	therapeutic	effect,	and	would	thus	require	care	in	their	interpretation	
given	that	established	tumours	would	potentially	hold	completely	different	cell	
dynamics.	Nevertheless,	cancer	stem	cell-targeting	therapies	are	not	currently	in	
clinical	trial	and	would	therefore	benefit	study	in	a	relevant	model	system	that	can	
represent	true	on-target	doses.		 	
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Figure	6.1	Schematic	representation	of	a	potential	mechanism	for	the	effects	of	TNKS	inhibition	upon	tumour	forming	capacity	of	organoids	
This	hypothesis	would	propose	that	TNKS	inhibition	reduces	levels	of	Wnt-signalling	within	organoids	,	thus	reducing	the	number	of	active	cycling	cancer	stem	cells,	as	cells	
are	promoted	to	undergo	differentiation,	as	suggested	by	increased	levels	of	Krt20.	The	remaining	cells	have	the	capacity	to	form	tumours,	with	a	significant	delay	
compared	to	DMSO-treated	organoids.		
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6.5 Further	work	in	the	organoid	model	
	
Whilst	data	generated	here	supports	the	expansion	of	patient-derived	CRC	organoids	
from	relatively	little	material,	with	relevant	histological	representation	of	patient	
subtypes,	the	concordance	of	organoids	between	patient	counterparts	would	need	
to	be	ascertained	to	successfully	recapitulate	human	tumours,	and	thus	responses	to	
therapy.		
6.5.1 Towards	a	clinical	trial	in	vitro		
	
The	work	presented	in	this	thesis	forms	the	basis	towards	suitable	assay	formats	to	
enable	organoids	to	be	transitioned	to	be	run	in	parallel	alongside	clinical	trials	to	
provide	“live	cell	biomarkers”	as	a	functional	readout	of	patient	responses.	
Collection	of	patient-derived	material	and	their	expansion	in	culture	could	provide	a	
mirrored	response	between	organoid	treatment	and	patient	responses	to	therapies.		
Early	work	in	the	Dale	lab	has	established	the	successful	culture	of	CRC	tumour	
organoids	from	punctured	tumour	resections	to	recapitulate	a	thin	needle	biopsy	
collection.	This	would	therefore	be	amenable	to	collection	from	patients	recruited	
for	the	FOCUS	4	clinical	trial,	as	well	as	other	future	clinical	trials.	By	comparing	
organoid	responses	directly	to	those	of	patients	this	would	enable	us	to	answer	
whether	organoids	recapitulate	tumour	biology.		Given	the	take	rate	and	successful	
protocols	for	relatively	rapid	expansion	in	culture,	organoids	could	even	be	used	to	
test	multiple	compounds	in	combination	to	direct	improved	therapeutic	options.	
Ideally,	with	patient	consent,	biopsies	collected	prior	and	after	treatment	would	help	
delineate	any	mechanisms	of	resistance	to	therapy.		
	
Collection	of	normal	colorectal	tissue	could	also	improve	drug	response	readouts	by	
generating	an	additional	control	for	responses	to	therapy.	This	would	be	of	
particular	importance	for	compounds	such	as	MK1775	and	AZ20,	both	of	which	
demonstrated	substantial	effects	to	inhibit	overall	organoid	growth	from	the	cohort	
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tested.	By	generating	organoids	from	normal	corresponding	tissue	as	previously	
published	(Wetering,	Francies,	Garnett,	Wetering,	et	al.	2015;	Sato	et	al.	2011a),	this	
would	provide	an	opportunity	to	test	standard	of	care	chemotherapeutics	against	
biomarker-driven	therapies.	If	an	improved	level	of	toxicity	was	obtained	from	
normal	organoids,	it	would	provide	some	premise	that	compounds	were	more	
selective	for	tumour	cells	than	current	chemotherapeutics	used	for	the	treatment	of	
CRC.		
	
An	important	future	direction	for	work	described	in	this	thesis	is	the	optimisation	of	
assay	methods	that	would	enable	the	co-culture	of	an	immune	component	alongside	
organoids	to	facilitate	the	study	of	immune-based	therapies.	Immune	based	
therapies	have	shown	promising	pre-clinical	data	for	CRC	treatment	and	would	thus	
require	a	representative	model	system	for	testing.		The	understanding	between	
tumour	and	immune	system	has	important	implications	for	the	design	and	
development	of	novel	cancer	immunotherapies	(Weeber	et	al.	2017).	The	role	of	the	
tumour	environment	should	not	be	ignored	in	establishing	such	methods.		
	
Whilst	work	described	here	provides	some	evidence	as	to	the	utility	of	organoids	as	
a	model	system,	the	ultimate	comparison	between	concordance	between	organoids	
and	patients	will	come	from	large-scale	clinical	trials	whereby	organoids	can	be	used	
as	a	functional	test	alongside	acquisition	of	patient	data.	The	aggregation	of	both	
genomic,	patient-derived	organoid	responses	and	clinical	responses	could	then	be	
used	to	provide	justification	of	the	suitability	of	organoids	as	a	predictive	clinical	
model	(Picco	and	Garnett	2017).		
	
6.6 Future	directions	for	organoid	technology	
	
Whilst	data	generated	here	has	shown	the	amenability	of	organoids	towards	higher	
throughput	assay	formats	for	supporting	clinical	data,	as	well	as	the	discovery	
pipeline,	there	are	some	limitations	to	consider,	as	with	any	other	model	system.	
Broadly	speaking,	organoid	culture	is	still	in	infancy	as	a	successful	tumour	model;	a	
relatively	reductionist	approach	has	thus	far	been	employed	to	select	for	epithelial	
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cells,	deprived	of	a	surrounding	stroma,	vasculature	and	immune	component.	This	
has	some	restrictive	effects	upon	studies	that	wish	to	explore	the	interaction	
between	organoids	and	their	surrounding	niche.	It	is	certain	that	the	field	is	moving	
towards	including	some	of	these	components	in	co-culture	systems	to	further	utilise	
this	model,	with	some	systems	having	included	fibroblasts	in	co-culture	with	murine	
organoids	(Pastula	et	al.	2016).	Furthermore,	whilst	PDO	models	have	the	capacity	to	
move	towards	high	throughput	screening,	the	use	of	Matrigel	can	provide	issues	in	
terms	of	batch-to-batch	inconsistency,	which	can	result	in	discrepancies	between	
experiments	(Gjorevski	et	al.	2016).	The	influence	of	the	micro-environment	of	
organoids	should	not	be	underestimated	in	terms	of	their	effects	upon	organoid	
growth.		
	
A	promising	avenue	that	is	becoming	increasingly	prominent	in	the	organoid-based	
literature	is	the	implementation	of	genetic	modifications	in	vitro	using	CRISPR/Cas9	
systems	to	assess	the	effects	of	particular	disease-causing	genes	and	their	
downstream	effects	(Fujii	et	al.	2016b;	Matano	et	al.	2015).	This	technology	could	
facilitate	the	assessment	of	tumourigenesis	at	early	stages,	for	indications	as	to	
consequences	of	mutations	prior	to	tumour	development.	Further	to	this,	genetic	
manipulation	could	generate	organoids	that	carry	tailored	mutations	as	a	model	to	
test	relevant	biomarker-driven	therapies.		
	
The	generation	of	3D	stem	cell-containing	organoid	culture	systems	has	enabled	the	
long-term	expansion	of	an	array	of	adult	tissue	types,	and	has	resulted	in	a	paradigm	
shift	in	their	application	towards	accurately	modelling	tumours	for	precision	
oncology	and	drug	discovery.	The	findings	in	this	thesis,	collectively,	have	shown	the	
potential	of	organoids	within	both	stratified	medicine	and	drug	discovery	alike,	
whilst	raising	potential	enquiries	for	furthering	the	understanding	of	tumour	
dynamics	in	a	relevant	model	system.			
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7.1 Appendix	I	:	Image	analysis	output	images	and	FOCUS	4	compound	titration	
studies		
	
Appendix	I-1	Representative	image	masks	of	compound-treated	organoid	lines	for	phenotypic	
screening.	
Organoid	lines	Iso	49,	Iso	75,	and	Iso	72	were	cultured	in	384	well	plates	and	treated	with	a	dose	
response	range	of	5FU,	Salicylic	acid	and	ATR	inhibitor,	following	3	days	of	recovery.	After	4	days	of	
treatment,	organoids	were	fixed	with	Hoechst	and	TRITC-phalloidin.	Images	were	captured	on	a	high	
content	confocal	microscope	and	subject	to	analysis.	Masks	of	organoids	were	generated	for	
subsequent	downstream	image	analysis	applications	(OcellO).		
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Appendix	I-2	Schematic	of	Mahalanobis	Distance	Calculation	
Data	output	from	OMiner	software	was	inputted	to	generate	Principal	Component	Analysis	(PCA)	of	
extracted	features.	After	performing	normalisation,	multidimensional	data	subsets	were	created	for	
each	organoid,	per	treatment,	containing	technical	replicates	for	each	treatment	and	control	(DMSO,	
0.1	%).	PCA	was	performed	,		and	components	are	scaled	by	the	proportion	of	variance	that	they	
explain.	Features	within	the	first	5	components	were	then	used	to	measure	Mahalanobis	distance	
between	each	dose	and	control	condition.	This	measurement	facilitates	a	quantifiable	separation	
between	the	principal	components.	A	larger	degree	of	separation	correlates	with	an	increasing	
phenotypic	effect	between	treatment	and	control	conditions.	Image	adapted	from	Hutz	et	al.,	(2012).	
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Appendix	I-3	Mahalanobis	distance	analysis	from	phenotypic	screening	of	each	organoid	line	with	
compounds	relevant	to	the	FOCUS	4	clinical	trial.	
Freshly	digested	organoids	were	seeded	within	matrigel	in	384	well	plates	and	overlaid	with	optimal	
media	for	growth.	Following	3	days	of	recovery,	a	dose	titration	of	compounds	within	the	FOCUS	4	
trial	were	administered	versus	a	DMSO	negative	control.	Following	4	days	of	treatment,	organoids	
were	fixed	and	stained	simultaneously	for	Hoechst	and	F-actin.	Subsequent	z-stack	images	were	
collected	and	inputted	within	OMiner™	software	to	generate	multiple	phenotypic	measurements	
acquired	from	Hoechst	and	TRITC	channel	information.	Data	was	inputted	into	R	to	generate	
Prinicipal	Component	Analysis	(PCA)	of	features.	Features	within	the	first	5	components	were	used	to	
measure	Mahalanobis	distance	from	treatment	and	control	conditions.	This	measurement	enabled	a	
discrimination	between	each	treatment	dose	compared	to	control,	based	on	multiple	measured	
features.	
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7.2 Appendix	II:	Analysis	of	Tankyrase	inhibition	effects	upon	Lgr5	and	
Cytokeratin	20	expression.	
	
	
	
Appendix	II-1	Analysis	of	the	effects	of	the	Tankyrase	inhibitor	MSC2524070	on	Lgr5	and	
cytokeratin	20	expression.	
Freshly	trypsinised	organoids	(Iso	50,	Iso	72,	Iso	75)	were	seeded	at	400	cells/µl	Matrigel	and	overlaid	
with	previously	specified	growth	media	supplemented	with	MSC2524070	(15nM,	6	days),	and	a	
matched	DMSO	control	(0.1%	in	media).	Organoids	were	then	fixed	and	immunostained	for	Lgr5	and	
cytokeratin	20	within	treatment	and	control	conditions.	Scale	bar	=	50µm.		
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7.3 Appendix	III:	Media	Components	
	
Appendix	III-1	Table	of	media	components	and	sources.	
	
	
Component	 Target/	
purpose	
Source	 Catalogue	
Number	
7+	
Media	
Full	Media	
ADV-DMEM/F12	 	 Invitrogen	 12634-028	 1X	 1X	
Penicillin/	
Streptocymcin		
	 Invitrogen	 15140-122	 100	U/ml	 100	U/ml	
HEPES	(1M)	 	 Invitrogen	 15630-056	 10mM	 10mM	
GlutaMAX	(100X)	 	 Invitrogen	 35050-079	 2mM	 2mM	
N2	(100X)	 	 Invitrogen	 17502-048	 1X	 1X	
B27	(50X)	 	 Invitrogen	 17504-044	 1X	 1X	
N-acetylcysteine	 Anti-
oxidant	
Sigma-
Aldrich	
A9165-5G	 1mM	 1mM	
Epidermal	
Growth	Factor	
(EGF)	
	 Sigma-
Aldrich	
E4127	 	 50ng/ml	
Mouse	
recombinant	
Noggin	
	 Peprotech	 250-38	 	 100ng/ml	
A-83-01	 Alk4/5/7	
inhibitor	
Tocris	 2939	 	 500µM	
SB202190	 P38		MAP	
kinase	
inhibitor	
Sigma-
Aldrich	
57067	 	 10µM	
Wnt3A	
conditioned	
medium	
	 	 	 	 40%	(v/v)	
R-spondin	
conditioned	
medium	
	 	 	 	 10%	(v/v)	
Fungizone*	 	 Invitrogen	 	 2µl/ml	 2µl/ml	
Y-27632*	 ROCK	
inhibitor	
R&D	 129830-38-2	 10µM	 10µM		
